APTARGROUP, INC., 10-K filed on 2/6/2026
Annual Report
v3.25.4
Cover - USD ($)
12 Months Ended
Dec. 31, 2025
Feb. 02, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2025    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-11846    
Entity Registrant Name AptarGroup, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 36-3853103    
Entity Address, Address Line One 265 EXCHANGE DRIVE    
Entity Address, Address Line Two SUITE 301    
Entity Address, City or Town CRYSTAL LAKE    
Entity Address, State or Province IL    
Entity Address, Postal Zip Code 60014    
City Area Code 815    
Local Phone Number 477-0424    
Title of 12(b) Security Common Stock, $.01 par value    
Trading Symbol ATR    
Security Exchange Name NYSE    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction Flag false    
Entity Shell Company false    
Entity Public Float     $ 10,345,798,465
Entity Common Stock, Shares Outstanding   64,379,735  
Documents Incorporated by Reference
Portions of the definitive Proxy Statement to be delivered to stockholders in connection with the Annual Meeting of Stockholders to be held May 6, 2026 are incorporated by reference into Part III of this report.
   
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000896622    
Amendment Flag false    
v3.25.4
Audit Information
12 Months Ended
Dec. 31, 2025
Auditor Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Chicago, Illinois
Auditor Firm ID 238
v3.25.4
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]      
Net Sales $ 3,777,181 $ 3,582,890 $ 3,487,450
Operating Expenses:      
Cost of Sales (exclusive of depreciation and amortization): 2,372,446 2,227,381 2,224,051
Selling, Research & Development and Administrative: 606,497 582,226 565,783
Depreciation and amortization 287,363 263,784 248,593
Restructuring initiatives 9,837 13,002 45,004
Total Operating Expenses 3,276,143 3,086,393 3,083,431
Operating Income 501,038 496,497 404,019
Other (Expense) Income:      
Interest expense (52,737) (43,898) (40,418)
Interest income 11,676 12,101 4,373
Net investment (loss) gain (483) 1,713 1,413
Equity in results of affiliates 7,393 87 2,226
Gain from remeasurement of equity method investment 26,518 0 0
Miscellaneous (expense) income, net (2,027) 3,265 3,212
Total Other Expense (9,660) (26,732) (29,194)
Income before Income Taxes 491,378 469,765 374,825
Provision for Income Taxes 98,881 95,587 90,649
Net Income 392,497 374,178 284,176
Net Loss Attributable to Noncontrolling Interests 206 363 311
Net Loss Attributable to Redeemable Noncontrolling Interests 86 0 0
Net Income Attributable to AptarGroup, Inc. $ 392,789 $ 374,541 $ 284,487
Net Income Attributable to AptarGroup, Inc. per Common Share:      
Basic (in dollars per share) $ 5.97 $ 5.65 $ 4.34
Diluted (in dollars per share) 5.89 5.53 4.25
Dividends per Common Share (in dollars per share) $ 1.83 $ 1.72 $ 1.58
v3.25.4
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]      
Net Income Attributable to AptarGroup, Inc. and Noncontrolling Interests $ 392,583 $ 374,178 $ 284,176
Other Comprehensive Income (Loss):      
Foreign currency translation adjustments 246,710 (145,807) 48,946
Changes in derivative (losses) gains, net of tax (15,621) 7,813 (10,086)
Defined benefit pension plan, net of tax      
Actuarial gain (loss), net of tax 11,960 17,043 (6,711)
Amortization of prior service cost included in net income, net of tax 73 258 130
Amortization of net loss included in net income, net of tax 523 112 641
Total defined benefit pension plan, net of tax 12,556 17,413 (5,940)
Total other comprehensive income (loss) 243,645 (120,581) 32,920
Comprehensive Income 636,228 253,597 317,096
Comprehensive (Income) Loss Attributable to Noncontrolling Interests (336) 438 (205)
Comprehensive Income Attributable to AptarGroup, Inc. $ 635,892 $ 254,035 $ 316,891
v3.25.4
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Assets    
Cash and equivalents $ 402,424 $ 223,844
Short-term investments 7,109 2,337
Accounts and notes receivable, less current expected credit loss ("CECL") of $17,732 in 2025 and $15,785 in 2024 803,830 658,057
Inventories 537,845 461,807
Prepaid and other 142,354 132,338
Total Current Assets 1,893,562 1,478,383
Land 31,503 28,172
Buildings and improvements 885,936 751,813
Machinery and equipment 3,658,289 3,143,236
Property, Plant and Equipment, Gross 4,575,728 3,923,221
Less: Accumulated depreciation (2,899,249) (2,476,071)
​Property, Plant and Equipment, Net 1,676,479 1,447,150
Investments in equity securities 131,030 146,269
Goodwill 1,077,898 936,256
Intangible assets, net 255,339 254,769
Operating lease right-of-use assets 65,698 64,213
Miscellaneous 152,713 105,238
Total Other Assets 1,682,678 1,506,745
Total Assets 5,252,719 4,432,278
Liabilities, Mezzanine Equity and Stockholders’ Equity    
Short-term obligations 183,947 176,035
Current maturities of long-term obligations, net of unamortized debt issuance costs 159,584 162,250
Accounts payable, accrued and other liabilities 822,913 729,996
Total Current Liabilities 1,166,444 1,068,281
Long-Term Obligations, net of unamortized debt issuance costs 1,139,433 688,066
Deferred income taxes 19,649 14,259
Retirement and deferred compensation plans 67,596 62,210
Operating lease liabilities 47,940 49,716
Deferred and other non-current liabilities 99,432 63,822
Commitments and contingencies - (See Note 13) 0 0
​Total Deferred Liabilities and Other 234,617 190,007
Mezzanine Equity:    
Redeemable noncontrolling interests 26,244 0
Total Mezzanine Equity 26,244 0
AptarGroup, Inc. stockholders’ equity    
Common stock, $.01 par value, 199 million shares authorized, 72.8 and 72.5 million shares issued as of December 31, 2025 and 2024, respectively 728 725
Capital in excess of par value 1,165,518 1,125,882
Retained earnings 2,642,552 2,370,537
Accumulated other comprehensive loss (186,382) (429,475)
Less: Treasury stock at cost, 8.6 and 6.0 million shares as of December 31, 2025 and 2024, respectively (954,320) (595,781)
Total AptarGroup, Inc. Stockholders’ Equity 2,668,096 2,471,888
Noncontrolling interests in subsidiaries 17,885 14,036
Total Stockholders’ Equity 2,685,981 2,485,924
Total Liabilities, Mezzanine Equity and Stockholders’ Equity $ 5,252,719 $ 4,432,278
v3.25.4
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Statement of Financial Position [Abstract]    
Accounts and notes receivable, less current expected credit loss $ 17,732 $ 15,785
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 199,000,000 199,000,000
Common stock, shares issued (in shares) 72,800,000 72,500,000
Treasury stock, shares (in shares) 8,600,000 6,000,000.0
v3.25.4
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Total
Retained Earnings
Accumulated Other Comprehensive (Loss)Income
Common Stock Par Value
Treasury Stock
Capital in Excess of Par Value
Non- Controlling Interest
Balance at beginning of period at Dec. 31, 2022 $ 2,068,204 $ 1,929,240 $ (341,366) $ 709 $ (503,266) $ 968,618 $ 14,269
Increase (Decrease) in Stockholders' Equity              
Net income (loss) 284,176 284,487         (311)
Foreign currency translation adjustments 48,946 (228) 48,658       516
Changes in unrecognized pension gains (losses) and related amortization, net of tax (5,940)   (5,940)        
Changes in derivative gains (losses), net of tax (10,086)   (10,086)        
Stock awards and option exercises 87,233     8 11,414 75,811  
Cash dividends declared on common stock (103,683) (103,683)          
Treasury stock purchased (47,552)       (47,552)    
Balance at end of period at Dec. 31, 2023 2,321,298 2,109,816 (308,734) 717 (539,404) 1,044,429 14,474
Increase (Decrease) in Stockholders' Equity              
Net income (loss) 374,178 374,541         (363)
Foreign currency translation adjustments (145,807) 235 (145,967)       (75)
Changes in unrecognized pension gains (losses) and related amortization, net of tax 17,413   17,413        
Changes in derivative gains (losses), net of tax 7,813   7,813        
Stock awards and option exercises 93,722     8 12,261 81,453  
Cash dividends declared on common stock (114,055) (114,055)          
Treasury stock purchased (68,638)       (68,638)    
Balance at end of period at Dec. 31, 2024 2,485,924 2,370,537 (429,475) 725 (595,781) 1,125,882 14,036
Increase (Decrease) in Stockholders' Equity              
Net income (loss) 392,583 392,789         (206)
Acquisitions of non-controlling interest 3,513           3,513
Foreign currency translation adjustments 246,710 10 246,158       542
Changes in unrecognized pension gains (losses) and related amortization, net of tax 12,556   12,556        
Changes in derivative gains (losses), net of tax (15,621)   (15,621)        
Stock awards and option exercises 48,848     3 9,209 39,636  
Cash dividends declared on common stock (120,784) (120,784)          
Treasury stock purchased (365,005)       (365,005)    
Excise tax on treasury shares (2,743)       (2,743)    
Balance at end of period at Dec. 31, 2025 $ 2,685,981 $ 2,642,552 $ (186,382) $ 728 $ (954,320) $ 1,165,518 $ 17,885
v3.25.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash Flows from Operating Activities:      
Net income $ 392,497 $ 374,178 $ 284,176
Adjustments to reconcile net income to net cash provided by operations:      
Depreciation 242,312 219,667 203,873
Amortization 45,051 44,117 44,720
Stock-based compensation 43,941 47,650 41,293
Provision for CECL 1,301 1,016 8,077
Loss (gain) on disposition of fixed assets 712 (52) (3,584)
Net loss (gain) on remeasurement of equity securities 483 (1,713) (1,413)
Deferred income taxes (11,689) (21,406) (19,883)
Defined benefit plan expense 12,554 12,049 14,198
Equity in results of affiliates (7,393) (87) (2,226)
Gain on remeasurement of equity method investment 26,518 0 0
Impairment loss 2,197 254 257
Changes in balance sheet items, excluding effects from foreign currency adjustments and acquisitions:      
Accounts and other receivables (73,888) (18,079) 15,431
Inventories (10,646) 21,901 (10,641)
Prepaid and other current assets 4,956 (2,368) (3,900)
Accounts payable, accrued and other liabilities (18,274) (23,705) 14,596
Income taxes payable (9,073) 4,064 (8,301)
Retirement and deferred compensation plan liabilities (6,477) (14,259) 2,984
Retirement and deferred compensation plan assets (12,582) 0 (1,134)
Other changes, net 535 186 (3,284)
Net Cash Provided by Operations 569,999 643,413 575,239
Cash Flows from Investing Activities:      
Capital expenditures (270,419) (276,481) (312,342)
Proceeds from government grants 3,308 0 0
Proceeds from sale of property, plant and equipment 3,547 1,506 5,348
Maturities and (purchases) of short-term investments 3,369 (2,242) 0
Acquisition of business, net of cash acquired and release of escrow (60,204) 0 (16,570)
Acquisition of intangible assets, net (5,020) (17,709) (6,061)
Investment in equity securities (8,664) (99,055) 0
Proceeds from sale of investment in equity securities 2,401 0 5,604
Notes receivable, net 256 (2,740) (442)
Net Cash Used by Investing Activities (331,426) (396,721) (324,463)
Cash Flows from Financing Activities:      
Proceeds from notes payable and overdrafts 31,015 22,302 25,531
Repayments of notes payable and overdrafts (28,218) (23,344) (28,643)
(Repayments) and proceeds of short term revolving credit facility, net (42,380) 108,848 76,966
Proceeds from long-term obligations 600,206 168,581 403
Repayments of long-term obligations (166,562) (373,847) (125,809)
Payment of contingent consideration obligation 0 0 (22,750)
Dividends paid (120,784) (114,055) (103,683)
Bond issuance costs (5,424) 0 0
Proceeds from stock option exercises 18,891 54,809 53,983
Purchase of treasury stock (365,005) (68,638) (47,552)
Redeemable noncontrolling interest 790 0 0
Net Cash Used by Financing Activities (77,471) (225,344) (171,554)
Effect of Exchange Rate Changes on Cash 19,403 (21,147) 2,189
Net Increase in Cash and Equivalents and Restricted Cash 180,505 201 81,411
Cash and Equivalents and Restricted Cash at Beginning of Period 224,344 224,143 142,732
Cash and Equivalents and Restricted Cash at End of Period 404,849 224,344 224,143
Supplemental Cash Flow Disclosure:      
Interest paid 49,972 43,520 39,599
Restricted cash included in the line item prepaid and other on the Consolidated Balance Sheets as shown below represents amounts held in escrow      
Cash and equivalents 402,424 223,844 223,643
Restricted cash included in prepaid and other 606 500 500
Restricted cash included in miscellaneous 1,819 0 0
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows $ 404,849 $ 224,344 $ 224,143
v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.
AptarGroup’s organizational structure consists of three market-focused business segments which are Pharma, Beauty and Closures. This is a strategic structure which allows us to better serve our customers and position us for long-term profitable growth.
Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentine peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. Our Argentinian operations contributed less than 0.4% and 1.1% of consolidated net assets and revenues, respectively, at and for the year ended December 31, 2025.
ACCOUNTING ESTIMATES
The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS
We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents.
ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES
At December 31, 2025, we reported $803.8 million of accounts receivable, net of CECL of $17.7 million. The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Changes in CECL were not material for the year ended December 31, 2025.
INVENTORIES
Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead.
ACQUISITIONS
We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes estimates and significant assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment.
INVESTMENTS IN EQUITY SECURITIES
We account for our 20% to 50% owned investments using the equity method. Under the equity method, we initially record our investment at cost and our interest in the net assets of the investee is included in the equity method investment on the Consolidated Balance Sheets. We recognize our equity in earnings in our equity method affiliates on a one-month lag basis and record our proportionate share of each investee's net income or loss into earnings after the date of investment, the adjustment of basis difference initially recognized and the other comprehensive income allocated to us from the investee. We evaluate the equity method investments for impairment under ASC 323. An impairment loss on the equity method investments is recognized in earnings when the decline in value is determined to be other-than-temporary.
Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception. There were no dividends received from affiliated companies in 2025, 2024 or 2023.
REDEEMABLE NONCONTROLLING INTEREST
During the third quarter of 2025, we entered into an agreement with the shareholder of three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”), which provides them with redemption rights (i.e., a put option) that could require Aptar to purchase the shareholder's remaining 20% noncontrolling interests in BTY upon the passage of time. As these redemption rights are not solely within the control of Aptar, such interests are classified as redeemable noncontrolling interest outside of permanent equity, in mezzanine equity, on the Consolidated Balance Sheets.
At initial recognition, redeemable noncontrolling interests are recorded at their issuance-date or acquisition date, fair value. The fair value is estimated by applying an income approach and is based on significant inputs that are not observable in the market and is therefore a Level 3 model. Key assumptions in the valuation of the redeemable noncontrolling interest include a discount rate, a terminal value based on a range of long-term sustainable growth rates and adjustments because of the lack of control that market participants would consider when measuring the fair value of the noncontrolling interests. Subsequently, redeemable noncontrolling interests that are currently redeemable, or probable of becoming redeemable, are adjusted to the greater of (i) current redemption value or (ii) carrying amount. Adjustments to redemption value are recorded through retained earnings. Upward adjustments are considered a deemed dividend, and would result in a reduction to earnings available to common shareholders for the calculation of earnings per common share. For additional information, see Note 22 - Redeemable Noncontrolling Interests.
PROPERTY AND DEPRECIATION
Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment.
FINITE-LIVED INTANGIBLE ASSETS
Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years.
IMPAIRMENT OF LONG-LIVED ASSETS
Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In those circumstances, we perform undiscounted operating cash flow analyses for asset groups at the lowest level for which cash flows are separately identifiable to determine if an impairment exists. Any impairment loss is calculated as the excess of the asset group’s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset group less costs of disposal.
GOODWILL
The Company evaluates the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arise in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires judgment and the use of estimates and significant assumptions related to projected revenue growth rates, projected EBITDA margins, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate.
Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management performed this qualitative assessment as of October 1, 2025 over all reporting units with the exception of Beauty and October 1, 2024 over all reporting units with the exception of Injectables and Other Pharma. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for the Beauty segment, management determined it appropriate to calculate the Step 1 fair value of the Beauty reporting unit and compare with its associated carrying amount as of October 1, 2025.
Based on our qualitative and quantitative analysis performed over the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required.
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction.
PURCHASE OF TREASURY STOCK
During 2025, 2024 and 2023, we repurchased 2.7 million, 433 thousand and 399 thousand shares, respectively, all of which were returned to treasury stock. If retired, common stock is reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings.
RESEARCH & DEVELOPMENT EXPENSES
Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred. These costs amounted to $105.1 million, $96.1 million and $92.8 million in 2025, 2024 and 2023, respectively.
INCOME TAXES
We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made.
We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: $160.0 million of 2025 earnings in France, all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding tax, local income taxes, and U.S. federal and state income tax when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals.
We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information.
We are subject to taxation and file income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements.
We have elected to include amounts paid for transferable, non-refundable U.S. energy credits as income taxes paid in our table of income taxes paid. Refer to Note 6 - Income Taxes for further details.
TRANSLATION OF FOREIGN CURRENCIES
The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity. Realized and unrealized foreign currency transaction gains and losses are reflected in income, as a component of miscellaneous income and expense, and represented losses of $2.9 million, $2.0 million and $7.3 million in 2025, 2024 and 2023, respectively.
STOCK-BASED COMPENSATION
Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur. See Note 16 – Stock-Based Compensation for more information.
REVENUE RECOGNITION
At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results. See specific discussions about methods of accounting for control transfers of product, tooling and service contract sales in Note 2 – Revenue.
LEASES
We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in accounts payable, accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.
We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise).
Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability.
GOVERNMENT GRANTS
We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost.
SUPPLY CHAIN FINANCE PROGRAM
We regularly renegotiate our supplier contracts and as a result have been successful in securing extended payment terms with many of our suppliers to be in line with local and regional trends. We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions.
All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows. As of December 31, 2025 and 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $32.0 million and $34.4 million, respectively.
20252024
SCF obligations outstanding at the beginning of the year$34,401 $36,309 
Additions161,090 160,847 
Settlements(163,535)(162,755)
SCF obligations outstanding at the end of the year$31,956 $34,401 
To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS
Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("DISE"), which requires the disaggregation of certain expenses in the notes to the financial statements, to provide enhanced transparency into the expense captions presented on the face of the income statement. In January 2025, the FASB issued ASU 2025-01 clarifying the effective date. This standard will be effective for fiscal years beginning after December 15, 2026 and interim reporting periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective adoption. We are evaluating the impact of the standard on our disclosures in the Consolidated Financial Statements.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and is required to be applied prospectively with the option of retrospective application. We adopted this guidance in the fourth quarter of 2025 on a prospective basis. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 6 - Income Taxes for further discussion.
In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We adopted this guidance in the fourth quarter of 2024. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 18 - Segment Information for further discussion.
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We adopted this guidance in the fourth quarter of 2024.
Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.
v3.25.4
REVENUE
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
In prior years, our geographic revenue disclosure was based on shipped from location. Beginning in 2024, we have started to report our geographic sales based on shipped to locations to give the reader a better understanding of the geographies we serve. Revenue by segment and geography based on shipped to locations for the years ended December 31, 2025, 2024 and 2023 were as follows:
For the Year Ended December 31, 2025
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$833,146 $601,861 $48,752 $253,722 $1,737,481 
Beauty795,903 230,049 163,880 119,605 1,309,437 
Closures233,510 342,392 83,773 70,588 730,263 
Total$1,862,559 $1,174,302 $296,405 $443,915 $3,777,181 
For the Year Ended December 31, 2024
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$806,606 $556,642 $47,124 $232,780 $1,643,152 
Beauty745,198 241,115 155,692 83,725 1,225,730 
Closures218,064 347,733 83,376 64,835 714,008 
Total$1,769,868 $1,145,490 $286,192 $381,340 $3,582,890 
For the Year Ended December 31, 2023
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$779,929 $495,057 $52,074 $193,933 $1,520,993 
Beauty806,963 219,760 152,963 88,011 1,267,697 
Closures218,833 336,315 84,146 59,466 698,760 
Total$1,805,725 $1,051,132 $289,183 $341,410 $3,487,450 
We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.
The opening and closing balances of our contract asset and contract liabilities are as follows:
Balance as of December 31, 2025Balance as of December 31, 2024Increase/
(Decrease)
Contract asset (current)$11,600 $12,571 $(971)
Contract liability (current)74,827 64,425 10,402 
Contract liability (long-term)49,901 40,551 9,350 
The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during 2025 against contract liabilities is $162.1 million, including $60.9 million relating to contract liabilities at the beginning of the year. Current contract assets are included within prepaid and other, while current contract liabilities and long-term contract liabilities are included within accounts payable, accrued and other liabilities and deferred and other non-current liabilities, respectively, within our Consolidated Balance Sheets.
Determining the Transaction Price
In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identifies reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which it will be entitled.
Product Sales
We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of shipment, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.
To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.
There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress toward completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced.
As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.
Tooling Sales
We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress toward completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion.
In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of December 31, 2025 or December 31, 2024.
Service Sales
We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation.
Royalty Revenue
We determine the amount and timing of royalty revenue based on our contractual agreements with customers. These contracts contain variable consideration which primarily relate to sales- or usage-based royalties related to the license of intellectual property and license contracts. For sales- and usage-based royalties, ASC 606 provides an exception to estimating variable consideration. Under this exception, we recognize revenues from sales- or usage-based royalty revenue at the later of when the sales or usage occurs or the satisfaction (or partial satisfaction) of the performance obligation to which the royalty has been allocated.
Contract Costs
We do not incur significant costs to obtain or fulfill revenue contracts.
Credit Risk
We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.
We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
Practical Expedients
Significant financing component: We elected not to adjust the promised consideration for the time value of money for contracts where the difference between the time of payment and performance is one year or less.
Remaining performance obligations: We elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for our contracts that are one year or less, as the revenue is expected to be recognized within the next year. In addition, we have elected not to disclose the expected consideration related to performance obligations where we recognize revenue in the amount it has a right to invoice (e.g., usage-based pricing terms).
v3.25.4
INVENTORIES
12 Months Ended
Dec. 31, 2025
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories, by component net of reserves, consisted of:
20252024
Raw materials$152,574 $133,885 
Work in process194,176 161,350 
Finished goods191,095 166,572 
Total$537,845 $461,807 
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS
12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for the year ended December 31, 2025 by reporting segment are as follows:
PharmaBeautyClosuresTotal
Balance as of December 31, 2023$508,447 $287,097 $167,874 $963,418 
Foreign currency exchange effects(20,213)(5,811)(1,138)(27,162)
Balance as of December 31, 2024$488,234 $281,286 $166,736 $936,256 
Acquisitions9,397 76,183 — 85,580 
Foreign currency exchange effects41,072 13,379 1,611 56,062 
Balance as of December 31, 2025$538,703 $370,848 $168,347 $1,077,898 
We have completed the annual impairment analysis of our reporting units as of October 1, 2025. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for the Beauty segment, management determined it appropriate to calculate the fair value of the Beauty reporting unit and compare with its associated carrying amount as of October 1, 2025.
We estimated the fair value of the reporting unit based upon the present value of their estimated future cash flows. Our determination of fair value involved judgment and the use of estimates and significant assumptions related to projected revenue growth rates, projected EBITDA margins, as well as the discount rate to calculate estimated future cash flows. We believe that our assumptions used in discounting future cash flows are appropriate.
Based on our review of macroeconomic, industry, and market events and circumstances of the reporting units, as well as the overall financial performance including the discounted cash flow analysis for the Beauty reporting unit, we determined that it was more likely than not that the fair values of the reporting units were greater than their carrying amounts. No impairment was recognized during the years ended December 31, 2025, 2024 or 2023.
The table below shows a summary of intangible assets for the years ended December 31, 2025 and 2024.
20252024
Weighted Average
Amortization Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Value
Gross
Carrying
Amount
Accumulated
Amortization
Net
Value
Amortized intangible assets:
Patents13.0$19,032 $(4,016)$15,016 $18,333 $(2,343)$15,990 
Acquired technology10.7157,350 (99,551)57,799 137,444 (80,171)57,273 
Customer relationships13.9332,088 (177,686)154,402 303,502 (145,772)157,730 
Trademarks and trade names7.146,885 (41,726)5,159 42,882 (36,450)6,432 
License agreements and other25.232,927 (9,964)22,963 26,318 (8,974)17,344 
Total intangible assets14.0$588,282 $(332,943)$255,339 $528,479 $(273,710)$254,769 
During the year ended December 31, 2025, related to acquisitions made during the year, we purchased $31.2 million of intangibles primarily associated with the purchase of customer relationships of $17.4 million, acquired technology of $7.2 million, and other intangible assets of $6.6 million. Aggregate amortization expense for the intangible assets above for the years ended December 31, 2025, 2024 and 2023 was $45,051, $44,117 and $44,720, respectively.
Future estimated amortization expense for the years ending December 31 is as follows:
2026$45,384 
202738,615 
202833,964 
202933,018 
203029,568 
2031 and thereafter74,790 
Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of December 31, 2025.
v3.25.4
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES
12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES
At December 31, 2025 and 2024, accounts payable, accrued and other liabilities consisted of the following:
20252024
Accounts payable, principally trade$340,563 $295,967 
Accrued employee compensation costs232,595 211,441 
Customer deposits and other unearned income74,827 64,425 
Other accrued liabilities174,928 158,163 
Total$822,913 $729,996 
v3.25.4
INCOME TAXES
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Income before income taxes consists of:
Years Ended December 31,202520242023
United States$135,913 $99,573 $49,681 
International355,465 370,192 325,144 
Total$491,378 $469,765 $374,825 
The provision (benefit) for income taxes is composed of:
Years Ended December 31,202520242023
Current tax expense (benefit):
U.S. Federal$6,726 $10,933 $11,777 
U.S. State and Local3,735 2,744 1,300 
International100,109 103,316 97,455 
Total current tax expense (benefit)$110,570 $116,993 $110,532 
Deferred tax expense (benefit):
U.S. Federal$12,040 $(8,936)$(10,931)
U.S. State and Local889 (923)(675)
International(24,618)(11,547)(8,277)
Total deferred tax expense (benefit)$(11,689)$(21,406)$(19,883)
Total income tax expense (benefit):
U.S. Federal$18,766 $1,997 $846 
U.S. State and Local4,624 1,821 625 
International75,491 91,769 89,178 
Total income tax expense (benefit)$98,881 $95,587 $90,649 
As further described in Note 1 – Summary of Significant Accounting Policies, the Company has elected to prospectively adopt the guidance in ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, or ASU 2023-09. The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company’s effective tax rate for the year ended December 31, 2025 in accordance with the guidance in ASU No. 2023-09:
Years Ended December 31,2025
AmountPercent
Provision for Income taxes at U.S. federal statutory rate$103,189 21.0 %
Domestic Federal:
Tax credits(2,115)(0.4)%
Nontaxable and nondeductible items, net
Excess benefits from share-based compensation(2,804)(0.6)%
Other382 0.1 %
Cross border tax laws (1)(3,045)(0.6)%
Changes in valuation allowance(300)(0.1)%
Other313 0.1 %
Domestic state and local income taxes, net of federal effect (2)3,179 0.6 %
Foreign:
France
Rate differential8,114 1.7 %
Other2,256 0.5 %
Germany - Federal
Municipal taxes12,781 2.6 %
Other(7,380)(1.5)%
Brazil
Changes in valuation allowance(8,300)(1.7)%
Other262 0.1 %
China
Nontaxable and nondeductible items, net
Equity investment remeasurement gain(5,394)(1.1)%
Other(2,129)(0.4)%
Other Foreign Jurisdictions2,007 0.2 %
Worldwide changes in unrecognized tax benefits(2,135)(0.4)%
$98,881 20.1 %
(1)The Company has elected to include U.S. foreign tax credits in the Cross Border tax section.
(2)The states that contribute to the majority (greater than 50%) of the tax effect in this category include New Jersey, Illinois and California.
The Company’s effective tax rate of 20.1% for the year ended December 31, 2025 is due primarily to benefits from the release of valuation allowances as a result of our revised assessment of the realization of tax losses in Brazil and Luxembourg, excess tax benefits on deductible share-based compensation and a benefit related to the gain resulting from remeasurement of equity investments to fair value upon Aptar becoming the majority shareholder in the invested companies.
As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective tax rate differs from the statutory tax rate as follows:
Years Ended December 31,20242023
Income tax at statutory rate$98,651 $78,713 
State income taxes, net of federal tax effect1,439 362 
Excess tax benefits from share-based compensation(11,041)(5,935)
Deferred tax (benefits) charges, incl. tax rate changes2,691 (3,512)
Valuation allowance(14,625)158 
Legal entity reorganization— 3,630 
Rate differential on earnings of foreign operations21,357 18,917 
Other items, net(2,885)(1,684)
Actual income tax provision$95,587 $90,649 
Effective income tax rate20.3 %24.2 %
The provision for income taxes for 2023 includes a $3.6 million charge for taxes related to legal entity reorganizations to enhance our dividend and cash management capabilities. The provision for income tax is favorably impacted by excess tax benefits on deductible share-based compensation. The tax provision for 2024 reflects a $11.0 million benefit from this item compared with a $5.9 million tax benefit for 2023. During 2024, we were able to change our previous assessment on the realization of tax losses, and our need for a valuation allowance, in various jurisdictions due to sufficient positive evidence becoming available during the year. Our revised assessment of the realization of tax losses in Luxembourg resulted in a $11.0 million net tax benefit in 2024. Our mix of earnings has an unfavorable tax rate impact since a majority of our pretax income is earned in higher tax jurisdictions.
The amount of income taxes paid were as follows:
Years Ended December 31,2025
U.S. Federal (1)
$28,166 
U.S. State and Local5,407 
Foreign
France55,539 
Germany - Federal32,445 
Germany - Muni27,943 
Other29,851 
Total Foreign$145,778 
Total income taxes paid
$179,351 
(1)The Company has elected to include amounts paid for transferable, non-refundable U.S. energy credits of $17.5 million, as income taxes paid.
For the years ended December 31, 2024 and 2023, income taxes paid were $89.4 million and $112.0 million, respectively.
Significant deferred tax assets and liabilities as of December 31, 2025 and 2024 are composed of the following temporary differences:
20252024
Deferred Tax Assets:
Net operating loss carryforwards$82,593 $72,766 
Operating and finance leases22,077 21,712 
Share-based compensation11,061 3,747 
Vacation and bonus15,979 16,223 
U.S. capitalized research expenditures41,338 41,956 
Accrued liabilities and other reserves10,324 9,598 
Other35,589 33,931 
Total gross deferred tax assets$218,961 $199,933 
Less valuation allowance(56,465)(61,134)
Net deferred tax assets$162,496 $138,799 
Deferred Tax Liabilities:
Acquisition related intangibles$52,023 $51,155 
Depreciation and amortization26,489 21,325 
Operating and finance leases22,408 22,672 
Other7,169 8,059 
Total gross deferred tax liabilities$108,089 $103,211 
Net deferred tax assets
$54,407 $35,588 
We evaluate the deferred tax assets and record a valuation allowance when it is believed it is more likely than not that the benefit will not be realized. We have established a valuation allowance for $51.2 million of the $82.6 million of tax effected net operating loss carryforwards. These losses are generally in locations that have not produced cumulative three year operating profit. A valuation allowance of $5.0 million has also been established against the $7.0 million of U.S. state tax credit carryforwards.
There is no expiration date on $72.8 million of the tax-effected net operating loss carryforwards and $9.8 million (tax effected) will expire in the years 2026 to 2045. The U.S. state tax credit carryforwards of $7.0 million (tax effected) will expire in the years 2026 to 2039.
None of the earnings accumulated outside of the U.S. will be subject to U.S. taxation under the current U.S. federal income tax laws. We maintain our assertion that all other cash and distributable reserves at our non-U.S. affiliates will continue to be indefinitely reinvested, with the exception of $160.0 million of 2025 earnings in France, all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. We estimate the amount of additional local income tax and withholding tax that would be payable on distributions to be in the range of $20.0 million to $25.0 million if earnings accumulated outside the U.S. are repatriated to the U.S.
Income Tax Uncertainties
We provide a liability for the amount of tax benefits realized from uncertain tax positions. A reconciliation of the beginning and ending amount of income tax uncertainties is as follows:
202520242023
Balance at January 1$5,792 $5,942 $6,919 
Increases based on tax positions for the current year400 300 985 
Increases (Decreases) based on tax positions of prior years3,759 107 (997)
Settlements(301)(127)(901)
Lapse of statute of limitations(720)(430)(64)
Balance at December 31$8,930 $5,792 $5,942 
As of December 31, 2025, the total amount of unrecognized tax benefits was $8.9 million, which if recognized, would favorably impact our effective tax rate.
We recognize interest and penalties related to unrecognized tax benefits as a component of income taxes. As of December 31, 2025, 2024 and 2023, we had approximately $4.0 million, $3.6 million and $3.4 million, respectively, accrued for the payment of interest and penalties, of which approximately $0.4 million, $0.2 million and $0.2 million was recognized in income tax expense for the years ended December 31, 2025, 2024 and 2023, respectively.
Aptar or its subsidiaries file income tax returns in the U.S. Federal jurisdiction and various state and foreign jurisdictions. The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below:
Major Tax
Jurisdiction
Tax Years
Subject to
Examination
United States — Federal2022-2025
United States — State2021-2025
France2022-2025
Germany2023-2025
Italy2019-2025
China2015-2025
v3.25.4
DEBT
12 Months Ended
Dec. 31, 2025
Debt Disclosure [Abstract]  
DEBT DEBT
Short-term obligations
At December 31, 2025 and 2024, our short term obligations, revolving credit facility and overdrafts consisted of the following:
20252024
Short-term obligations 1.50% to 3.00%
$31,314 $— 
Revolving credit facility 2.96%
152,633 176,035 
$183,947 $176,035 
The short-term obligations of $31.3 million were acquired as part of the BTY acquisition and bear interest at rates ranging from 1.5% to 3.0%. These obligations have contractual maturities of less than one year and are therefore classified as short-term obligations within the Consolidated Balance Sheets.
We have a revolving credit facility (the "revolving credit facility") with a syndicate of banks that provides us with unsecured financing of up to $600.0 million, which may be increased by up to $300.0 million more, subject to the satisfaction of certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and could be drawn in various currencies including USD, EUR, GBP, and CHF. On July 2, 2024, we entered into a new amended and restated agreement (the "amended revolving credit facility") that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances. As of December 31, 2025, €130.0 million ($152.6 million) was utilized under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2024, we utilized €170.0 million ($176.0 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.
There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the amended revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. We incurred approximately $10.1 million and $9.5 million in interest and fees related to our credit facility and money market borrowing arrangement during 2025 and 2024, respectively.
Average borrowings under the amended revolving credit facility and money market borrowing arrangement were $237.7 million and $170.6 million for 2025 and 2024, respectively. The average annual interest rate on the amended revolving credit facility and money market borrowing arrangement was 3.9% and 5.1% for 2025 and 2024, respectively.
We also have an unsecured money market borrowing arrangement to provide short term financing of up to $30.0 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of December 31, 2025 or December 31, 2024.
Long-Term Obligations
On November 20, 2025, we issued $600.0 million aggregate principal amount of 4.75% Senior Notes due March 2031 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a Second Supplemental Indenture, dated as of November 20, 2025, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with all of our other existing and future senior, unsecured indebtedness.
On December 16, 2025, we repaid in full the $125.0 million 3.6% Senior Notes that were due in December 2025.
On February 26, 2024, we repaid in full the $100.0 million 3.49% Senior Unsecured Notes that were due in February 2024. On July 19, 2024, we repaid in full the €200.0 million 1.17% Senior Unsecured Notes that were due in July 2024. On September 5, 2024, we repaid in full the $50.0 million 3.4% Senior Unsecured Notes that were due in September 2024.
At December 31, 2025 and 2024, our long-term obligations consisted of the following:
December 31, 2025December 31, 2024
Notes payable 0.00% – 8.35%, due in monthly and annual installments through 2035
$17,051 $15,135 
Senior unsecured notes 3.6%, due in 2025
 125,000 
Senior unsecured notes 3.6%, due in 2026
125,000 125,000 
Term loan 4.9% floating, due in 2027
141,100 166,000 
Senior unsecured notes 4.8%, due in 2031, net of discount of $0.5 million
599,512 — 
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.6 million
399,361 399,258 
Finance Lease Liabilities25,339 23,753 
Unamortized debt issuance costs(8,346)(3,830)
$1,299,017 $850,316 
Current maturities of long-term obligations(159,584)(162,250)
Total long-term obligations$1,139,433 $688,066 
On July 2, 2024, we entered into a term loan with a syndicate of banks (the "Term Loan"). The Term Loan matures in July 2027. As of December 31, 2025 and 2024, $141.1 million and $166.0 million, respectively, was utilized under the Term Loan facility.
The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 8, due annually for the next five years and thereafter are:
2026$156,528 
2027116,565 
2028959 
2029109 
203055 
Thereafter1,007,808 
Covenants
Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:
RequirementLevel at December 31, 2025
Consolidated Leverage Ratio (1)
Maximum of 3.50 to 1.00
1.38 to 1.00
Consolidated Interest Coverage Ratio (1)
Minimum of 3.00 to 1.00
15.07 to 1.00
(1)Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.
v3.25.4
LEASE COMMITMENTS
12 Months Ended
Dec. 31, 2025
Leases [Abstract]  
LEASE COMMITMENTS LEASE COMMITMENTS
We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.
Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”).
The components of lease expense for the years ended December 31, 2025 and 2024 were as follows:
Year Ended December 31,20252024
Operating lease cost$22,714 $20,061 
Finance lease cost:
Amortization of right-of-use assets$7,778 $6,803 
Interest on lease liabilities1,226 1,192 
Total finance lease cost$9,004 $7,995 
Short-term lease and variable lease costs$21,938 $20,149 
Supplemental cash flow information related to leases was as follows:
Year Ended December 31,20252024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$22,387 $20,376 
Operating cash flows from finance leases1,367 1,289 
Financing cash flows from finance leases3,706 3,054 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$12,135 $33,726 
Finance leases4,791 1,705 
Supplemental balance sheet information related to leases was as follows:
December 31,
2025
December 31,
2024
Operating Leases
Operating lease right-of-use assets$65,698 $64,213 
Accounts payable, accrued and other liabilities$17,745 $17,015 
Operating lease liabilities47,940 49,716 
Total operating lease liabilities$65,685 $66,731 
Finance Leases
Property, plant and equipment, gross$57,610 $50,319 
Accumulated depreciation(28,588)(20,103)
Property, plant and equipment, net$29,022 $30,216 
Current maturities of long-term obligations, net of unamortized debt issuance cost$3,303 $3,563 
Long-term obligations, net of unamortized debt issuance cost22,036 20,190 
Total finance lease liabilities$25,339 $23,753 
Weighted Average Remaining Lease Term (in years)
Operating leases5.14.7
Finance leases4.84.9
Weighted Average Discount Rate
Operating leases5.69 %5.77 %
Finance leases4.95 %5.12 %
Maturities of lease liabilities as of December 31, 2025, were as follows:
Operating
Leases
Finance
Leases
Year 1$20,903 $4,532 
Year 217,176 7,727 
Year 311,020 2,994 
Year 47,750 8,015 
Year 55,510 1,098 
Thereafter17,000 4,532 
Total lease payments79,359 28,898 
Less imputed interest(13,674)(3,559)
Total$65,685 $25,339 
As of December 31, 2025, we have additional operating leases that have not yet commenced of $0.3 million and no finance leases that have not yet commenced. These operating leases will commence in 2026 with lease terms of 3 to 4 years.
LEASE COMMITMENTS LEASE COMMITMENTS
We lease certain warehouse, plant, and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.
Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”).
The components of lease expense for the years ended December 31, 2025 and 2024 were as follows:
Year Ended December 31,20252024
Operating lease cost$22,714 $20,061 
Finance lease cost:
Amortization of right-of-use assets$7,778 $6,803 
Interest on lease liabilities1,226 1,192 
Total finance lease cost$9,004 $7,995 
Short-term lease and variable lease costs$21,938 $20,149 
Supplemental cash flow information related to leases was as follows:
Year Ended December 31,20252024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$22,387 $20,376 
Operating cash flows from finance leases1,367 1,289 
Financing cash flows from finance leases3,706 3,054 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$12,135 $33,726 
Finance leases4,791 1,705 
Supplemental balance sheet information related to leases was as follows:
December 31,
2025
December 31,
2024
Operating Leases
Operating lease right-of-use assets$65,698 $64,213 
Accounts payable, accrued and other liabilities$17,745 $17,015 
Operating lease liabilities47,940 49,716 
Total operating lease liabilities$65,685 $66,731 
Finance Leases
Property, plant and equipment, gross$57,610 $50,319 
Accumulated depreciation(28,588)(20,103)
Property, plant and equipment, net$29,022 $30,216 
Current maturities of long-term obligations, net of unamortized debt issuance cost$3,303 $3,563 
Long-term obligations, net of unamortized debt issuance cost22,036 20,190 
Total finance lease liabilities$25,339 $23,753 
Weighted Average Remaining Lease Term (in years)
Operating leases5.14.7
Finance leases4.84.9
Weighted Average Discount Rate
Operating leases5.69 %5.77 %
Finance leases4.95 %5.12 %
Maturities of lease liabilities as of December 31, 2025, were as follows:
Operating
Leases
Finance
Leases
Year 1$20,903 $4,532 
Year 217,176 7,727 
Year 311,020 2,994 
Year 47,750 8,015 
Year 55,510 1,098 
Thereafter17,000 4,532 
Total lease payments79,359 28,898 
Less imputed interest(13,674)(3,559)
Total$65,685 $25,339 
As of December 31, 2025, we have additional operating leases that have not yet commenced of $0.3 million and no finance leases that have not yet commenced. These operating leases will commence in 2026 with lease terms of 3 to 4 years.
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS
12 Months Ended
Dec. 31, 2025
Retirement Benefits [Abstract]  
RETIREMENT AND DEFERRED COMPENSATION PLANS RETIREMENT AND DEFERRED COMPENSATION PLANS
We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion.
Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date.
The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans.
Domestic PlansForeign Plans
2025202420252024
Change in benefit obligation:
Benefit obligation at beginning of year$175,194 $186,013 $104,196 $104,757 
Service cost7,931 9,462 6,711 6,492 
Interest cost9,563 8,968 3,868 3,488 
Plan Amendment —  (17)
Curtailment/Settlement — (1,298)(1,385)
Actuarial (gain) loss
2,699 (18,156)(7,600)1,370 
Benefits paid(13,726)(11,093)(3,798)(3,776)
Foreign currency translation adjustment (loss) gain
 — 13,466 (6,733)
Benefit obligation at end of year$181,661 $175,194 $115,545 $104,196 
Domestic PlansForeign Plans
2025202420252024
Change in plan assets:
Fair value of plan assets at beginning of year$180,761 $173,735 $71,250 $72,434 
Actual return on plan assets24,437 17,624 942 3,605 
Employer contribution10,898 495 1,431 3,580 
Benefits paid(13,726)(11,093)(3,798)(3,776)
Foreign currency translation adjustment — 9,392 (4,593)
Fair value of plan assets at end of year$202,370 $180,761 $79,217 $71,250 
Funded status at end of year$20,709 $5,567 $(36,328)$(32,946)
The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Non-current assets$36,881 $19,739 $3,668 $3,648 
Current liabilities(670)(546)(111)(46)
Non-current liabilities(15,502)(13,626)(39,885)(36,548)
$20,709 $5,567 $(36,328)$(32,946)
The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Net actuarial (gain) loss
$(30,065)$(21,495)$8,462 $16,201 
Net prior service cost — (616)(531)
Tax effects8,797 6,713 (4,659)(6,413)
$(21,268)$(14,782)$3,187 $9,257 
Changes in benefit obligations and plan assets recognized in other comprehensive income in 2025, 2024 and 2023 are as follows:
Domestic Plans
202520242023
Current year actuarial gain (loss)
$9,058 $23,318 $(5,161)
Amortization of net (gain) loss
(488)— — 
$8,570 $23,318 $(5,161)
Foreign Plans
202520242023
Current year actuarial gain (loss)
$6,370 $(47)$(5,315)
Current year prior service cost 20 1,135 
Transfer Prior service Cost(16)— — 
Transfer actuarial gain (loss)
121 (694)124 
Amortization of net loss1,248 201 914 
Amortization of prior service cost101 349 177 
$7,824 $(171)$(2,966)
Components of net periodic benefit cost:
Domestic Plans
202520242023
Service cost$7,931 $9,462 $9,638 
Interest cost9,563 8,968 8,631 
Expected return on plan assets(12,743)(12,463)(12,378)
Amortization of net (gain) loss
(488)— — 
Net periodic benefit cost$4,263 $5,967 $5,891 
Foreign Plans
202520242023
Service cost$6,711 $6,492 $5,915 
Interest cost3,868 3,488 3,642 
Expected return on plan assets(2,440)(2,243)(2,340)
Amortization of net loss1,248 201 914 
Amortization of prior service cost101 349 177 
Net periodic benefit cost$9,488 $8,287 $8,308 
Curtailment(1,197)(2,205)(1)
Total Net periodic benefit cost$8,291 $6,082 $8,307 
During the years ended December 31, 2025 and 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $0.1 million and $1.9 million, respectively. The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Consolidated Statements of Income.
The accumulated benefit obligation (“ABO”) for our domestic defined benefit pension plans was $168.5 million and $163.4 million at 2025 and 2024, respectively. The ABO for our foreign defined benefit pension plans was $90.6 million and $80.2 million at December 31, 2025 and 2024, respectively.
The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Projected benefit obligation$16,173 $14,172 $87,278 $77,645 
Accumulated benefit obligation14,226 12,412 62,608 54,460 
Fair value of plan assets — 47,410 41,238 
The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Projected benefit obligation$16,173 $14,172 $87,278 $81,273 
Accumulated benefit obligation14,226 12,412 62,608 57,494 
Fair value of plan assets — 47,410 44,676 
Assumptions:
Domestic PlansForeign Plans
202520242023202520242023
Weighted-average assumptions used to determine benefit obligations at December 31:
Discount rate5.63 %5.60 %4.95 %3.90 %3.33 %3.20 %
Rate of compensation increase3.27 %3.24 %3.24 %3.20 %3.21 %3.20 %
Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31:
Discount rate5.60 %4.95 %5.15 %3.30 %3.32 %3.69 %
Expected long-term return on plan assets7.00 %7.00 %7.00 %3.23 %3.22 %3.23 %
Rate of compensation increase3.27 %3.24 %3.20 %3.20 %3.21 %3.20 %
We develop the expected long-term rate of return assumptions based on historical experience and by evaluating input from the plans’ asset managers, including the managers’ review of asset class return expectations and benchmarks, economic indicators and long-term inflation assumptions.
In order to determine the 2026 net periodic benefit cost, we expect to use the December 31, 2025 discount rates, December 31, 2025 rates of compensation increase assumptions and the same assumed long-term returns on domestic and foreign plan assets used for the 2025 net periodic benefit cost.
Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2025 and 2024 by asset category are as follows:
Plan Assets:
Domestic Plans Assets at December 31,Foreign Plans Assets at December 31,
2025202420252024
Equity securities50 %50 %2 %%
Fixed income securities25 %25 %1 %%
Corporate debt securities — 3 %%
Infrastructure7 %% — 
Hedge funds11 %11 % — 
Money market3 %% %— %
Investment Funds — 94 %94 %
Real estate4 %% — 
Total100 %100 %100 %100 %
Our investment strategy for our domestic and foreign pension plans is to maximize the long-term rate of return on plan assets within an acceptable level of risk. The investment policy strives to have assets sufficiently diversified so that adverse or unexpected results from one security type will not have an unduly detrimental impact on the entire portfolio and accordingly, establishes a target allocation for each asset category within the portfolio. The domestic plan asset allocation is reviewed on a quarterly basis and the foreign plan asset allocation is reviewed annually. Rebalancing occurs as needed to comply with the investment strategy. The domestic plan target allocation for 2026 is 64% equity securities and 36% fixed income securities and infrastructure. The foreign plan target allocation for 2026 is 100% investment funds.
Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.
Domestic Fair Value Measurement at December 31, 2025Foreign Fair Value Measurement at December 31, 2025
(In Thousands $)Total(Level 1)(Level 2)(Level 3)Total(Level 1)(Level 2)(Level 3)
Cash and Short-term Securities (a)$5,240 $5,240 $ $ $659 $659 $ $ 
USD— 5,240 — — — — — — 
EUR— — — — — 653 — — 
Others— — — — — — — 
Equity Securities (a)$91,509 $91,509 $ $ $1,205 $1,205 $ $ 
U.S. Large Cap Equities— 52,466 — — — — — — 
U.S. Small Cap Equities— 11,019 — — — — — — 
International Equities— 28,024 — — — 1,205 — — 
Fixed Income (a)(b)$33,029 $33,029 $ $ $586 $586 $ $ 
Corporate debts securities$ $ $ $ $2,029 $2,029 $ $ 
Euro Corporate Bonds (a)— — — — — 2,029 — — 
Investment Funds$ $ $ $ $74,738 $23,352 $51,386 $ 
Mutual Funds in Equities (a)— — — — — 4,718 — — 
Mutual Funds in Bonds (a)— — — — — 14,854 — — 
Mutual Funds Diversified (a)(b)— — — — — 3,780 51,386 — 
Total Investments in Fair Value Hierarchy$129,778 $129,778 $ $ $79,217 $27,831 $51,386 $ 
Investments at Net Asset Value per Share72,592 — — — — — — — 
Total Investments$202,370 $129,778 $ $ $79,217 $27,831 $51,386 $ 
Domestic Fair Value Measurement at December 31, 2024Foreign Fair Value Measurement at December 31, 2024
(In Thousands $)Total(Level 1)(Level 2)(Level 3)Total(Level 1)(Level 2)(Level 3)
Cash and Short-term Securities (a)$3,054 $3,054 $ $ $275 $275 $ $ 
USD— 3,054 — — — — — — 
EUR— — — — — 269 — — 
Others— — — — — — — 
Equity Securities (a)$78,234 $78,234 $ $ $1,873 $1,873 $ $ 
U.S. Large Cap Equities— 45,294 — — — — — — 
U.S. Small Cap Equities— 10,363 — — — — — — 
International Equities— 22,577 — — — 1,873 — — 
Fixed Income (a)(b)$28,526 $28,526 $ $ $562 $562 $ $ 
Corporate debts securities$ $ $ $ $1,213 $1,213 $ $ 
Euro Corporate Bonds (a)— — — — — 1,213 — — 
Investment Funds$ $ $ $ $67,327 $24,377 $42,950 $ 
Mutual Funds in Equities (a)— — — — — 5,781 — — 
Mutual Funds in Bonds (a)— — — — — 14,634 — — 
Mutual Funds Diversified (a)(b)— — — — — 3,962 42,950 — 
Total Investments in Fair Value Hierarchy$109,814 $109,814 $ $ $71,250 $28,300 $42,950 $ 
Investments at Net Asset Value per Share70,947 — — — — — — — 
Total Investments$180,761 $109,814 $ $ $71,250 $28,300 $42,950 $ 
(a)Based on third party quotation from financial institution.
(b)Based on observable market transactions.
Contributions
Although we have no minimum funding requirement, discretionary cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by ERISA. We contributed $10.0 million to our domestic defined benefit plan in 2025. We do not plan to contribute to our domestic defined benefit plans in 2026. For the supplemental executive retirement plan (SERP), $0.9 million company paid benefits were made in 2025, and an expected $0.7 million are to be made in 2026. Contributions to fund pension costs accrued under our foreign plans are made in accordance with local laws or at our discretion. We contributed approximately $1.4 million to our foreign defined benefit plan in 2025 and expect to contribute approximately $1.6 million in 2026.
Estimated Future Benefit Payments
As of December 31, 2025, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next 10 years:
Domestic PlansForeign Plans
2026$10,665 $5,803 
202711,753 4,259 
202812,151 5,015 
202913,488 6,601 
203013,802 6,663 
2031 - 203577,102 54,622 
Other Plans
We have a non-qualified supplemental pension plan for domestic employees which provides for pension amounts that would have been payable from our principal domestic pension plan if it were not for limitations imposed by income tax regulations. The liability for this plan, which is not funded, was $16.2 million and $14.2 million at December 31, 2025 and 2024, respectively. This amount is included in the liability for domestic plans shown above.
We have a defined contribution 401(k) employee savings plan ("401(k) plan") available to substantially all domestic employees. Company matching contributions are made in cash up to a maximum of 3% of the participating employee’s salary subject to income tax regulations. For each of the years ended December 31, 2025, 2024 and 2023, total contributions made to these plans were approximately $5.4 million, $5.0 million and $5.0 million, respectively. As discussed above, domestic employees hired after December 31, 2020 will no longer be eligible for the pension plans and will instead receive an annual Aptar Retirement Savings Account contribution of 5% of their eligible earnings in the 401(k) plan. For the years ended December 31, 2025, 2024 and 2023, total contributions for these eligible employees was approximately $4.2 million, $3.3 million and $2.7 million, respectively.
We have several foreign defined contribution plans, which require us to contribute a percentage of the participating employee’s salary according to local regulations. For each of the years ended December 31, 2025, 2024 and 2023, total contributions made to these plans were approximately $3.2 million, $3.0 million and $3.1 million, respectively.
We have no additional postretirement or postemployment benefit plans.
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)
12 Months Ended
Dec. 31, 2025
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS)
Changes in Accumulated Other Comprehensive Income/(Loss) by Component:
Foreign
Currency
Defined Benefit
Pension Plans
DerivativesTotal
Balance - December 31, 2022$(328,740)$(5,951)$(6,675)$(341,366)
Other comprehensive income (loss) before reclassifications48,658 (6,711)(10,086)31,861 
Amounts reclassified from accumulated other comprehensive income— 771 — 771 
Net current-period other comprehensive income (loss)48,658 (5,940)(10,086)32,632 
Balance - December 31, 2023$(280,082)$(11,891)$(16,761)$(308,734)
Other comprehensive (loss) income before reclassifications(145,967)17,043 7,813 (121,111)
Amounts reclassified from accumulated other comprehensive income— 370 — 370 
Net current-period other comprehensive (loss) income(145,967)17,413 7,813 (120,741)
Balance - December 31, 2024$(426,049)$5,522 $(8,948)$(429,475)
Other comprehensive income (loss) before reclassifications246,158 11,960 (15,621)242,497 
Amounts reclassified from accumulated other comprehensive income— 596 — 596 
Net current-period other comprehensive income (loss)246,158 12,556 (15,621)243,093 
Balance - December 31, 2025$(179,891)$18,078 $(24,569)$(186,382)
Reclassifications Out of Accumulated Other Comprehensive Income/(Loss):
Details about Accumulated Other
Comprehensive Income Components
Amount Reclassified from
Accumulated Other
Comprehensive Income
Affected Line in the Statement
Where Net Income is Presented
Year Ended December 31,202520242023
Defined Benefit Pension Plans
Amortization of net loss$760 $201 $914 (1)
Amortization of prior service cost101 349 177 (1)
861 550 1,091 Total before tax
(265)(180)(320)Tax benefit
$596 $370 $771 Net of tax
Total reclassifications for the period$596 $370 $771 
(1)These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
12 Months Ended
Dec. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.
For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Consolidated Balance Sheets (See Note 12 – Fair Value).
Cash Flow Hedge
For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Consolidated Statements of Cash Flows.
Net Investment Hedge
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar relative to foreign currencies has an additive effect on our financial statements. Conversely, a strengthening U.S. dollar has a dilutive effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.
On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203.0 million of the $400.0 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203.0 million of fixed-rate 3.60% USD debt to €200.0 million of fixed-rate 2.5224% EUR debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200.0 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive loss as the swaps are effective in hedging the designated risk. As of December 31, 2025, the fair value of the cross currency swap was a $32.5 million liability. The swap agreement will mature on September 15, 2029.
Other
As of December 31, 2025, we have recorded the fair value of foreign currency forward exchange contracts of $0.3 million in prepaid and other and $0.6 million in accounts payable, accrued and other liabilities in the Consolidated Balance Sheets. All forward exchange contracts outstanding as of December 31, 2025 had an aggregate notional contract amount of $91.8 million.
Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of
December 31, 2025 and December 31, 2024
December 31, 2025December 31, 2024
Balance Sheet
Location
Derivatives
Designated
as Hedging
Instruments
Derivatives
not
Designated
as Hedging
Instruments
Derivatives
Designated
as Hedging
Instruments
Derivatives
not
Designated
as Hedging
Instruments
Derivative Assets
Foreign Exchange ContractsPrepaid and other$— $298 $— $572 
$ $298 $— $572 
Derivative Liabilities
Foreign Exchange ContractsAccounts payable, accrued and other liabilities$ $632 $— $622 
Cross Currency Swap Contract (1)Deferred and other non-current liabilities32,542  11,851 — 
$32,542 $632 $11,851 $622 
(1)This cross currency swap contract is composed of both an interest component and a foreign exchange component.
The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the
Fiscal Years Ended December 31, 2025 and December 31, 2024
Derivatives in Cash
Flow Hedging
Relationships
Amount of Gain (Loss)
Recognized in
Other Comprehensive
Income on Derivative
Location of (Loss)
Gain Recognized
in Income on
Derivatives
Amount of Gain (Loss)
Reclassified from
Accumulated
Other Comprehensive
Income on Derivative
Total Amount
of Affected
Income
Statement
Line Item
2025202420252024
Cross currency swap contract:
Foreign exchange component$(15,621)$7,813 Miscellaneous, net$ $— $(2,027)
$(15,621)$7,813 $ $— 
The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2025 and December 31, 2024
Derivatives Not Designated
as Hedging Instruments
Location of (Loss) Gain Recognized
in Income on Derivatives
Amount of (Loss) Gain
Recognized in Income
on Derivatives
20252024
Foreign Exchange ContractsOther (Expense) Income:
Miscellaneous, net
$(314)$(190)
$(314)$(190)
Gross Amounts
Offset in the
Statement of
Financial Position
Net Amounts
Presented in
the Statement of
Financial Position
Gross Amounts not Offset
in the Statement of
Financial Position
Gross
Amount
Financial
Instruments
Cash Collateral
Received
Net
Amount
Description
December 31, 2025
Derivative Assets$298 $ $298 $ $ $298 
Total Assets$298 $ $298 $ $ $298 
Derivative Liabilities$33,174 $ $33,174 $ $ $33,174 
Total Liabilities$33,174 $ $33,174 $ $ $33,174 
December 31, 2024
Derivative Assets$572 $— $572 $— $— $572 
Total Assets$572 $— $572 $— $— $572 
Derivative Liabilities$12,473 $— $12,473 $— $— $12,473 
Total Liabilities$12,473 $— $12,473 $— $— $12,473 
v3.25.4
FAIR VALUE
12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.
As of December 31, 2025, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$2,503 $2,503 $ $ 
Foreign exchange contracts (2)
298  298  
Convertible notes (3)
5,650   5,650 
Total assets at fair value$8,451 $2,503 $298 $5,650 
Liabilities
Foreign exchange contracts (2)
$632 $ $632 $ 
Cross currency swap contract (2)
32,542  32,542  
Contingent consideration obligation3,983   3,983 
Total liabilities at fair value$37,157 $ $33,174 $3,983 
As of December 31, 2024, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$2,986 $2,986 $— $— 
Foreign exchange contracts (2)
572 — 572 — 
Convertible notes (3)
5,650 — — 5,650 
Total assets at fair value$9,208 $2,986 $572 $5,650 
Liabilities
Foreign exchange contracts (2)
$622 $— $622 $— 
Cross currency swap contract (2)
11,851 — 11,851 — 
Total liabilities at fair value$12,473 $— $12,473 $— 
(1)Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment.
(2)Market approach valuation technique based on observable market transactions of spot and forward rates.
(3)Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Consolidated Balance Sheets.
The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.09 billion and $624.7 million as of December 31, 2025 and December 31, 2024, respectively.
As discussed in Note 19 - Acquisitions, as part of the Sommaplast acquisition, we are also obligated to pay to the shareholders of Sommaplast certain contingent consideration based on 2025 and 2026 cumulative financial performance metrics as defined in the purchase agreement. We consider these obligations a Level 3 liability. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $4.0 million utilizing a Monte Carlo valuation model.
Changes in the fair value of these obligations are recorded within selling, research & development and administrative expenses in our Consolidated Statements of Income. Significant changes to the inputs, as noted above, can result in a significantly higher or lower fair value measurement. The following table provides a summary of changes in our Level 3 fair value measurements:
Balance, December 31, 2024$— 
Acquisition3,983 
Balance, December 31, 2025$3,983 
v3.25.4
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
We are subject to a number of lawsuits and claims both actual and potential in nature including those involving intellectual property and commercial disputes. For example, we are involved in legal proceedings in certain jurisdictions related to alleged infringement of intellectual property rights, alleged customer breach of confidentiality obligations, alleged customer misuse of proprietary information and alleged violations of competition and antitrust laws. We are actively litigating our interests in these matters and management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.
Purchase Commitments
We have various purchase commitments for raw materials, supplies, and property and equipment obtained in the normal course of business. As of December 31, 2025, we have unconditional purchase commitments of approximately $56.2 million of which the majority relate to open purchase orders for fixed assets over the next three years, for which no liabilities have been recorded.
Legal Proceedings
On March 25, 2025, AptarGroup, Inc. and its subsidiary, Aptar France SAS, filed a lawsuit in the United States District Court for the Southern District of New York against ARS Pharmaceuticals, Inc. and ARS Pharmaceuticals Operations, Inc. (together, “ARS”). The complaint alleges that ARS misappropriated Aptar’s trade secrets and breached multiple contractual confidentiality obligations. This matter is pending and no final determination has been made by the court. Aptar seeks injunctive relief and damages. Relatedly, on September 29, 2025, ARS filed a lawsuit in the United States District Court for the Southern District of California against Aptar. The complaint alleges that Aptar violated Sections 1 and 2 of the Sherman Act and Section 3 of the Clayton Act by refusing to sell certain components. ARS seeks injunctive relief and damages.
In May 2025, Nemera La Verpillière SAS ("Nemera") filed parallel patent infringement actions in Mannheim Regional Court, Germany and Paris Judicial Court, France against Aptar and certain subsidiaries alleging that Aptar's ophthalmic product infringes a Nemera patent, seeking an injunction and damages. Aptar is contesting the claims. Aptar filed oppositions before the European Patent Office ("EPO") challenging the validity of the European Patent (EP) asserted by Nemera. On October 2, 2025, an EPO hearing invalidated Nemera’s main patent claim while allowing an amended claim to continue. The infringement proceedings in Germany and France are continuing.
At this stage, each of the above matters is too preliminary to form a judgment as to whether an adverse outcome is probable, and we are unable to estimate the possible loss or range of loss, if any.
Other Contingencies
Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of December 31, 2025.
A fire caused damage to our facility in Annecy, France in June 2016. We were insured for the damages caused by the fire, including business interruption insurance. In 2022, we filed a lawsuit against the insurance company to recover a part of our claim. We reached a settlement with the insurance company during the fourth quarter of 2023 for $6.6 million, which is recorded in miscellaneous (expense) income, net in our Consolidated Statements of Income.
We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $11.0 million in principal and $22.0 million to $23.0 million for interest and penalties. We are currently defending our position with respect to these claims in the respective administrative procedures. Due to uncertainty in the probability of settlement and the timing of our appeal, no liability is recorded as of December 31, 2025.
We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.
v3.25.4
STOCK REPURCHASE PROGRAM
12 Months Ended
Dec. 31, 2025
Equity [Abstract]  
STOCK REPURCHASE PROGRAM STOCK REPURCHASE PROGRAM
On October 10, 2024, we announced a share repurchase authorization of up to $500.0 million of common stock. Subsequent to year end, the 2024 authorization was superseded on February 3, 2026, when the Board approved a new share repurchase authorization of up to $600.0 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
In 2025, 2024 and 2023, we repurchased approximately 2.7 million, 433 thousand and 399 thousand shares, respectively, of our outstanding common stock at a total cost of $365.0 million, $68.6 million and $47.6 million, respectively. As of December 31, 2025, there was $97.7 million of authorized share repurchases available to us.
v3.25.4
CAPITAL STOCK
12 Months Ended
Dec. 31, 2025
CAPITAL STOCK  
CAPITAL STOCK CAPITAL STOCK
We have 199 million authorized shares of common stock. The number of shares of common stock and treasury stock and the share activity were as follows:
Common SharesTreasury Shares
202520242023202520242023
Balance at the beginning of the year72,466,548 71,679,658 70,848,810 6,015,772 5,775,295 5,555,027 
Employee option exercises171,648 629,541 679,878 (144,288)(192,123)(178,326)
Director option exercises 6,500 —  — — 
Restricted stock vestings190,317 150,849 150,970  — — 
Common stock repurchases — — 2,744,260 432,600 398,594 
Balance at the end of the year72,828,513 72,466,548 71,679,658 8,615,744 6,015,772 5,775,295 
The cash dividends paid on the common stock for the years ended December 31, 2025, 2024 and 2023 aggregated $120.8 million, $114.1 million and $103.7 million, respectively.
v3.25.4
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company's 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met.
For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest based on our return on invested capital ("ROIC"). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return (“TSR”) modifier.
At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant.
The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.
Year Ended December 31,202520242023
Fair value per stock award$154.20 $145.79 $116.17 
Grant date stock price$147.84 $141.00 $111.38 
Assumptions:
Aptar's stock price expected volatility17.70 %18.80 %20.00 %
Expected average volatility of peer companies34.10 %34.80 %39.70 %
Correlation assumption31.00 %30.70 %33.30 %
Risk-free interest rate4.03 %4.51 %3.83 %
Dividend yield assumption1.22 %1.16 %1.36 %
A summary of RSU activity as of December 31, 2025, and changes during the period then ended is presented below:
Time-Based RSUsPerformance-Based RSUs
UnitsWeighted Average
Grant-Date Fair Value
UnitsWeighted Average
Grant-Date Fair Value
Nonvested at January 1, 2025
277,245$123.28 513,226$127.17 
Granted96,240144.48 207,167147.38 
Vested(145,504)117.97 (214,235)131.12 
Forfeited(12,548)129.24 (71,280)124.02 
Nonvested at December 31, 2025215,433$135.89 434,878$135.31 
Included in the December 31, 2025 time-based RSU activity are 9,805 units granted to non-employee directors and 10,208 units vested related to non-employee directors.
Year Ended December 31,202520242023
Compensation expense (included in SG&A)$33,259 $37,529 $34,454 
Compensation expense (included in Cost of sales)3,271 3,052 2,561 
Compensation expense$36,530 $40,581 $37,015 
Fair value of units vested43,605 36,313 29,100 
Intrinsic value of units vested54,076 40,083 33,914 
The actual tax benefit realized for the tax deduction from RSUs was approximately $9.9 million, $7.6 million and $5.9 million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, there was $42.2 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted average period of 1.7 years.
Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were reinstituted for employees in 2023 and valued based on the Black-Scholes model and generally vest ratably over three years and expire 10 years after grant.
The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $36.91 and $36.07 per share, respectively, for all employees during 2025 and 2024. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all other employees, respectively, during 2023. In 2023, Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. The exercise price of the options granted in 2024 was $141.00. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Stock Award Plans:
Year Ended December 31,202520242023
Dividend Yield1.17 %1.28 %1.41 %
Expected Stock Price Volatility17.66 %17.03 %16.55 %
Risk-free Interest Rate4.21 %4.51 %3.57 %
Expected Life of Option (years)7.07.07.0
A summary of option activity under our stock plans as of December 31, 2025, and changes during the period then ended is presented below:
Stock Awards Plans
OptionsWeighted Average
Exercise Price
Outstanding, January 1, 2025
1,663,307 $93.69 
Granted226,187 147.84 
Exercised(250,188)75.64 
Forfeited or expired(30,808)128.35 
Outstanding at December 31, 20251,608,498 $103.45 
Exercisable at December 31, 20251,140,413 $88.82 
Weighted-Average Remaining Contractual Term (Years):
Outstanding at December 31, 20254.3
Exercisable at December 31, 20252.6
Aggregate Intrinsic Value:
Outstanding at December 31, 2025$39,920 
Exercisable at December 31, 2025$39,351 
Intrinsic Value of Options Exercised During the Years Ended:
December 31, 2025$17,809 
December 31, 2024$57,259 
December 31, 2023$38,706 
Year Ended December 31,202520242023
Compensation expense (included in SG&A)$6,729 $6,381 $3,929 
Compensation expense (included in Cost of sales)682 688 349 
Compensation expense, Total$7,411 $7,069 $4,278 
Compensation expense, net of tax7,241 6,880 4,278 
Grant date fair value of options vested5,204 2,320 2,663 
The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises was approximately $18.9 million, $54.8 million and $54.0 million for the years ended December 31, 2025, 2024 and 2023, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $4.4 million, $13.2 million and $9.1 million in the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, there was $4.5 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 1.8 years.
v3.25.4
EARNINGS PER SHARE
12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2025, 2024 and 2023 are as follows:
Income
(Numerator)
Shares
(Denominator)
Per Share
Amount
For the Year Ended December 31, 2025
Basic EPS
Income available to common stockholders$392,789 65,740 $5.97 
Effect of Dilutive Securities
Stock options497 
Restricted stock488 
Diluted EPS
Income available to common stockholders$392,789 66,725 $5.89 
For the Year Ended December 31, 2024
Basic EPS
Income available to common stockholders$374,541 66,334 $5.65 
Effect of Dilutive Securities
Stock options765 
Restricted stock592 
Diluted EPS
Income available to common stockholders$374,541 67,691 $5.53 
For the Year Ended December 31, 2023
Basic EPS
Income available to common stockholders$284,487 65,616 $4.34 
Effect of Dilutive Securities
Stock options874 
Restricted stock415 
Diluted EPS
Income available to common stockholders$284,487 66,905 $4.25 
v3.25.4
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Pharma segment. Operations that sell dispensing systems and sealing solutions to the fragrance, facial skincare, color cosmetics, personal care and home care markets form our Beauty segment. Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and other markets form our Closures segment. The Pharma and Beauty segments are named for the markets they serve with multiple product platforms, while the Closures segment is named primarily for a single product platform that serves all available markets.
The accounting policies of the segments are the same as those described in Note 1 – Summary of Significant Accounting Policies. We adopted ASU 2023-07, Improvement to Reportable Segment Disclosures which requires enhanced segment disclosure. Our chief operating decision maker, ("CODM") is our President and Chief Executive Officer, Stephan Tanda. Our CODM is provided operating reports from each of our reportable segments which include or can easily derive significant segment expenses identified as selling, research & development and administrative expenses and cost of sales by segment. Additionally, the other segment items is primarily comprised of foreign currency gains or losses from operations and other non-operating activity. Our CODM evaluates performance of our reporting segments and allocates resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA provides useful information regarding performance of each segment as it reflects profitability and performance of each segment on a consistent and comparable basis, and our CODM considers budget-to-actual variances on a monthly basis when making decisions supporting capital resource allocation, including in connection with development, acquisition and disposition activities in each segment.
Financial information regarding our reporting segments is shown below:
In thousands
Year Ended December 31,202520242023
Total Sales:
Pharma$1,738,470 $1,644,012 $1,521,837 
Beauty1,338,138 1,252,904 1,297,477 
Closures736,943 721,564 706,847 
Total Sales$3,813,551 $3,618,480 $3,526,161 
Less: Intersegment Sales:
Pharma$989 $860 $844 
Beauty28,701 27,174 29,780 
Closures6,680 7,556 8,087 
Total Intersegment Sales$36,370 $35,590 $38,711 
Net Sales:
Pharma$1,737,481 $1,643,152 $1,520,993 
Beauty1,309,437 1,225,730 1,267,697 
Closures730,263 714,008 698,760 
Net Sales$3,777,181 $3,582,890 $3,487,450 
Less:
Cost of Sales (exclusive of depreciation and amortization):
Pharma885,928 834,595 797,542 
Beauty965,316 884,433 922,223 
Closures523,939 511,409 507,866 
Selling, Research & Development and Administrative:
Pharma252,946 241,357 221,808 
Beauty194,246 183,903 192,831 
Closures91,921 89,913 87,930 
Other Segment Items:
Pharma(9,039)(1,171)(990)
Beauty(8,896)(2,515)(11,073)
Closures(2,074)(1,456)(729)
Adjusted EBITDA (1):
Pharma$607,646 $568,371 $502,633 
Beauty158,771 159,909 163,716 
Closures116,477 114,142 103,693 
Adjusted EBITDA for Reportable Segments
$882,894 $842,422 $770,042 
Corporate & Other, unallocated
(67,792)(67,498)(62,320)
Acquisition-related costs (2)(3,253)(140)(480)
Restructuring Initiatives (3)(9,837)(13,002)(45,004)
Curtailment gain related to restructuring initiatives (4)115 1,851 — 
Net unrealized investment (loss) gain (5)(483)1,713 (2,775)
Gain from remeasurement of equity method investment (6)26,518 — — 
Other special items (7)(8,360)— — 
Depreciation and amortization(287,363)(263,784)(248,593)
Interest Expense(52,737)(43,898)(40,418)
Interest Income11,676 12,101 4,373 
Income before Income Taxes$491,378 $469,765 $374,825 
In thousands
Year Ended December 31,202520242023
Depreciation and Amortization:
Pharma$136,111 $120,429 $109,365 
Beauty91,066 82,931 83,399 
Closures56,716 57,326 52,095 
Depreciation and Amortization for Reportable Segments
283,893 260,686 244,859 
Corporate & Other3,470 3,098 3,734 
Depreciation and Amortization$287,363 $263,784 $248,593 
Capital Expenditures:
Pharma$143,068 $148,261 $196,083 
Beauty68,193 64,571 83,872 
Closures50,968 45,766 52,160 
Capital Expenditures for Reportable Segments
262,229 258,598 332,115 
Corporate & Other11,889 23,630 14,729 
Transfer of Corporate Expenditures (8)(3,699)(5,747)(34,502)
Capital Expenditures$270,419 $276,481 $312,342 
Total Assets:
Pharma$2,283,609 $2,057,586 $2,111,779 
Beauty1,691,850 1,392,491 1,412,203 
Closures799,403 746,127 765,930 
Total Assets for Reportable Segments
4,774,862 4,196,204 4,289,912 
Corporate & Other477,857 236,074 161,978 
Total Assets$5,252,719 $4,432,278 $4,451,890 
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 19 - Acquisitions and Note 20 – Investments in Equity Securities for further details).
(3)Restructuring Initiatives includes expense items for the years ended December 31, 2025, 2024 and 2023 as follows (see Note 21 – Restructuring Initiatives for further details):
In thousands
Year Ended December 31,202520242023
Restructuring Initiatives by Plan:
Optimization initiative$9,837 $13,019 $45,445 
Prior year initiatives (17)(441)
Total Restructuring Initiatives$9,837 $13,002 $45,004 
Restructuring Initiatives by Segment:
Pharma$1,080 $589 $4,852 
Beauty4,469 8,041 20,683 
Closures3,566 3,835 17,927 
Corporate & Other722 537 1,542 
Total Restructuring Initiatives$9,837 $13,002 $45,004 
(4)The curtailment gain is included in the line miscellaneous income (expense), net in the Consolidated Statements of Income (see Note 9 - Retirement and Deferred Compensation Plans).
(5)Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 20 – Investment in Equity Securities for further details).
(6)The gain on remeasurement of equity method investment represents the remeasurement of our previously held minority equity interest in BTY at fair value (see Note 19 – Acquisitions for further details).
(7)Other special items includes costs related to non-ordinary-course litigation regarding the matters disclosed under "Legal Proceedings" within Note 13 – Commitments and Contingencies, as these costs do not reflect our core operating performance.
(8)The transfer of corporate expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level. The increase in 2023 relates to a project build in Suzhou, China.
Geographic Information
The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2025, 2024 and 2023:
202520242023
Net Sales to Unaffiliated Customers (1):
United States$1,071,430 $1,037,968 $949,248 
Europe:
France513,281 499,795 541,333 
Germany163,913 169,891 160,812 
Italy201,895 180,101 200,817 
Spain195,405 171,779 175,101 
Other Europe788,065 748,302 727,662 
Total Europe1,862,559 1,769,868 1,805,725 
China194,406 155,502 146,026 
Other Foreign Countries648,786 619,552 586,451 
Total$3,777,181 $3,582,890 $3,487,450 
Property, Plant and Equipment, Net
United States$346,879 $349,255 $357,729 
Europe:
France590,775 527,570 550,738 
Germany266,695 229,637 225,860 
Italy51,178 44,087 42,240 
Other Europe96,765 66,546 63,864 
Total Europe1,005,413 867,840 882,702 
China165,598 105,613 112,017 
Other Foreign Countries158,589 124,442 125,615 
Total$1,676,479 $1,447,150 $1,478,063 
(1)Sales are attributed to countries based upon shipped to location.
No single customer or group of affiliated customers represents greater than 4%, 4% and 5% of our net sales in 2025, 2024 or 2023, respectively.
v3.25.4
ACQUISITIONS
12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
ACQUISITIONS ACQUISITIONS
Business Combinations
On December 1, 2025 we completed the acquisition of all the outstanding capital stock of Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as droppers, dispensers and dosing cups, based in Brazil. The aggregate purchase price was approximately $31.0 million (net of $0.7 million cash acquired), which includes $24.5 million in cash paid at closing, $2.5 million held in restricted cash and contingent consideration with a fair value of $4.0 million. The contingent consideration is payable upon achieving future financial performance milestones as defined in the purchase agreement. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement utilizing a Monte Carlo valuation model. The restricted cash is pending the finalization of indemnity escrows and will be released in annual installments of 25% each over the next four years. The results of Sommaplast have been included in the consolidated financial statements within our Pharma segment since the date of acquisition. We are working to complete the valuation of assets acquired and liabilities assumed and have recorded a preliminary purchase price allocation as of December 31, 2025. Net assets acquired totaled $31.0 million. Within definite-lived intangible assets, we allocated $3.7 million to customer relationships which have an estimated useful life of 15 years. The fair value of customer relationships at the acquisition date was determined using the multi-period excess earnings method under the income approach. The fair value measurements are based on significant unobservable inputs, and thus represent Level 3 inputs. Significant assumptions used in assessing the fair values of the intangible assets include discounted cash flows, customer attrition rates and discount rates.
On July 28, 2025, we executed our call option to purchase an additional 31% equity interest in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) increasing our beneficial ownership to 80%, in exchange for cash consideration of $29.2 million with additional $7.4 million consideration that was paid on October 28, 2025. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. We accounted for this acquisition as a business combination resulting in the consolidation of BTY within the Beauty segment in our financial statements. A redeemable non-controlling interest was recognized at fair value. Under the terms of the agreement, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula in three years. Additionally, the other shareholder of BTY has a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula.
As a result of this acquisition, we remeasured our previously held minority equity interest in BTY at fair value resulting in a pre-tax gain of $26.5 million recognized in Gain from remeasurement of equity method investment on our Consolidated Statements of Income. The acquisition date fair value of the previously held minority equity interest was calculated by multiplying the gross-up of the total consideration for the acquired ownership interest by the related effective previously held equity interest of 49%.
The following table summarizes the assets acquired and liabilities assumed from the BTY acquisition as of the acquisition date at the estimated fair value.
2025
Assets
Cash and equivalents$8,908 
Accounts and notes receivable15,525 
Inventories13,042 
Prepaid and other935 
Buildings and improvements28,566 
Machinery and equipment26,223 
Goodwill71,709 
Intangible assets21,468 
Operating lease right-of-use assets610 
Other miscellaneous assets3,401 
Liabilities
Current maturities of long-term obligations, net of unamortized debt issuance costs27,724 
Accounts payable, accrued and other liabilities27,894 
Deferred income taxes4,718 
Operating lease liabilities610 
Long-term obligations, net of unamortized debt issuance costs10,936 
Deferred and other non-current liabilities781 
Net assets acquired$117,724 
The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives for the BTY acquisition as of the acquisition date:
2025
Weighted-Average
Useful Life
(in years)
Estimated
Fair Value
of Asset
Acquired technology5.4$4,876 
Customer relationships14.411,145 
License agreements and other43.25,447 
Total$21,468 
The fair value of customer relationships at the acquisition date was determined using the multi-period excess earnings method under the income approach. The fair value measurements are based on significant unobservable inputs, and thus represent Level 3 inputs. Significant assumptions used in assessing the fair values of the intangible assets include the timing and amounts of cash flows projections, the revenue growth, the customer attrition rates, the EBITDA margins and the discount rate.
For the year ended December 31, 2025, we recognized $1.5 million in transaction costs related to the acquisitions of Sommaplast and BTY. These costs are reflected in the selling, research & development and administration section of the Consolidated Statements of Income and within acquisition-related costs as disclosed in Note 18 – Segment Information.
Goodwill in the amount of $81.1 million was recorded related to the 2025 acquisitions, of which $9.4 million is included in the Pharma segment and $71.7 million is included in the Beauty segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill acquired in our 2025 acquisitions has expanded our portfolio of pharma packaging solutions in the Brazilian market and expanded our market opportunities, including strengthening our presence in China and the Middle East beauty markets. Goodwill will not be amortized, but will be tested for impairment at least annually. For 2025 and 2024 acquisitions, no goodwill will be deductible for tax purposes.
Pro forma results of operations for the 2025 acquisitions are not presented because the acquisitions are not material to the Company's consolidated results of operations for the period ended December 31, 2025.
v3.25.4
INVESTMENT IN EQUITY SECURITIES
12 Months Ended
Dec. 31, 2025
Equity Method Investments and Joint Ventures [Abstract]  
INVESTMENT IN EQUITY SECURITIES INVESTMENT IN EQUITY SECURITIES
Our investment in equity securities consisted of the following:
December 31, 2025December 31, 2024
Equity Method Investments
Goldrain
$104,112 $96,667 
BTY 32,047 
Sonmol5,044 4,712 
Others5,392 948 
Other Investments
PureCycle2,503 2,986 
YAT5,433 5,206 
Others8,546 3,703 
$131,030 $146,269 
Equity Method Investments
BTY
On July 28, 2025, we increased our beneficial ownership in BTY from 49% to 80%, effectively moving from equity accounting to consolidation. For additional information, see Note 19 - Acquisitions and Note 22 - Redeemable Controlling Interests. For the year to date period through July 28, 2025, prior to consolidation upon our call exercise, Aptar had purchases of $7.4 million from BTY. For the year ended December 31, 2024, Aptar had purchases of $11.4 million from BTY. As of July 28, 2025 and December 31, 2024, approximately $2.1 million and $2.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Consolidated Balance Sheets.
Goldrain
On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99.0 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products. Additionally, we noted an initial basis difference between our investment in the business and the amount recorded in Goldrain's equity of $82.7 million including equity method goodwill that will not be amortized. The future amortizable basis difference of $14.7 million as of December 31, 2024 was comprised of intangible assets which are being amortized on a straight line basis over a weighted average useful life of 11.8 years.
Other Investments
In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker "PCT". At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Consolidated Statements of Income. Our remaining investment is subject to lockup conditions that will be released upon PCT's Ironton facility becoming operational and certified by Leidos, as such the duration of the lockup is unknown.
We have sold the following PCT shares related to the PureCycle investment for the year ended December 31, 2023:
Shares SoldProceedsRealized Gain
2023510,449$5,604 $4,188 
No shares were sold during 2024 or 2025 related to PCT. On April 26, 2024, we received $0.2 million of equity from PureCycle in exchange for our resource dedication for technological partnership and support.
For the years ended December 31, 2025, 2024 and 2023 we recorded the following net investment gain or loss on our investment in PureCycle:
202520242023
Net investment (loss) gain$(483)$1,713 $1,413 
There were no indications of impairment noted in the year ended December 31, 2025 related to these investments.
v3.25.4
RESTRUCTURING INITIATIVES
12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
RESTRUCTURING INITIATIVES RESTRUCTURING INITIATIVES
For the years ended December 31, 2025, 2024 and 2023, we recognized $9.8 million, $13.0 million and $45.4 million, respectively, of restructuring costs related to our initiative to better leverage our fixed cost base through growth and cost reduction measures. The cumulative expense incurred as of December 31, 2025 was $74.5 million.
As of December 31, 2025, we have recorded the following activity associated with our optimization initiative:
Beginning Reserve at December 31, 2024Net Charges for the Year Ended December 31, 2025Cash PaidInterest and
FX Impact
Ending Reserve at December 31, 2025
Employee severance$9,161 $2,350 $(7,830)$602 $4,283 
Professional fees and other costs796 7,487 (6,129)21 2,175 
Totals$9,957 $9,837 $(13,959)$623 $6,458 
As of December 31, 2024, we recorded the following activity associated with our optimization initiative:
Beginning Reserve at December 31, 2023Net Charges for the Year Ended December 31, 2024Cash PaidInterest and
FX Impact
Ending Reserve at December 31, 2024
Employee severance$27,078 $6,562 $(23,791)$(688)$9,161 
Professional fees and other costs2,810 6,457 (8,559)88 796 
Totals$29,888 $13,019 $(32,350)$(600)$9,957 
v3.25.4
REDEEMABLE NONCONTROLLING INTERESTS
12 Months Ended
Dec. 31, 2025
Temporary Equity Disclosure [Abstract]  
REDEEMABLE NONCONTROLLING INTERESTS REDEEMABLE NONCONTROLLING INTERESTS
The BTY purchase agreement includes a call option and a put option. The put option, held by the noncontrolling shareholder of BTY, provides the right to sell its remaining 20% interest in BTY to Aptar. The call option, held by Aptar, provides us the right to acquire from the noncontrolling shareholder the remaining 20% interest in BTY based on a predetermined formula subject to future negotiations. The call option and put option become exercisable in the third quarter of 2028 and remains outstanding indefinitely.
The noncontrolling interest is considered redeemable due to the existence of the put option as (i) the noncontrolling shareholder can put the BTY shares to Aptar, (ii) the put is outside Aptar's control; and (iii) it is probable of becoming redeemable solely based on the passage of time. The put and call options cannot be separated from the noncontrolling interest and did not require bifurcation from the noncontrolling interest under the guidance in ASC 815. Due to the redemption features, the noncontrolling interest is classified as redeemable noncontrolling interest within mezzanine equity on the Consolidated Balance Sheets. For additional information, see Note 19 - Acquisitions.
Redeemable noncontrolling interests are initially recorded at the issuance date fair value, as of the acquisition date of BTY. When redeemable noncontrolling interest becomes redeemable, or it is probable of becoming redeemable, its value is adjusted to the greater of current redemption value or carrying value. The redemption value is remeasured on a quarterly basis based on the predetermined formula set forth in the shareholder agreement. No adjustment was required to the redemption value as of December 31, 2025.
The following table presents a roll forward of the redeemable noncontrolling interests for the year ended December 31, 2025:
2025
Balance at January 1$— 
Acquisition of redeemable noncontrolling interests23,607 
Additional contributions703 
Net loss attributable to redeemable noncontrolling interests(86)
Foreign currency adjustments2,020 
Balance at December 31$26,244 
v3.25.4
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
12 Months Ended
Dec. 31, 2025
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
AptarGroup, Inc
SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS
For the years ended December 31, 2025, 2024 and 2023
Dollars in thousands
Balance at
Beginning
Of Period
Charged to
Costs and
Expenses
Charged
to Other
Accounts
Deductions
from
Reserve
Balance
at End of
Period
2025
CECL (a)
$15,785 $1,301 $1,485 $(839)$17,732 
Deferred tax valuation allowance61,134 890 8,368 (13,927)56,465 
2024
CECL (a)
$16,217 $1,016 $— $(1,448)$15,785 
Deferred tax valuation allowance (b)48,856 1,739 26,903 (16,364)61,134 
2023
CECL (a)
$9,519 $8,077 $12 $(1,391)$16,217 
Deferred tax valuation allowance46,239 1,498 2,495 (1,376)48,856 
(a)The deductions from reserve column represents the write-off of accounts considered uncollectible, net of recoveries and foreign currency impact adjustments.
(b)The 2024 increase to the deferred tax valuation allowance in the charged to other accounts column primarily relates to the establishment of a $29.5 million deferred tax valuation allowance for deferred tax assets established to reflect prior period tax losses not previously expected to be realized that were not recognized on the Balance Sheet. As of December 31, 2024, management expects $11.0 million of these losses to be realizable in future periods, which is reflected in the deductions from the reserve column.
v3.25.4
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.25.4
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.4
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Increased global cybersecurity threats and sophisticated, targeted computer crime could pose a risk to our operations. Aptar has strategically integrated cybersecurity risk management into a broader enterprise-wide risk management framework, which consists of administrative, operational, organizational, physical, and technical processes that we believe are appropriate to the scope and nature of our business. We believe this integrated approach allows cybersecurity considerations to be an integral part of our decision-making processes. Our risk management team works closely with our Information Security Department to continuously evaluate and address cybersecurity risks in alignment with our business and operational needs.
Our cybersecurity strategy focuses on continued strengthening of our security posture, improvement of security operational efficiencies, and preparedness for evolving business and technology needs including the detection, analysis, and response to known, anticipated or unexpected cybersecurity threats, management of material risks related to cybersecurity threats and resilience against cybersecurity incidents. We regularly assess potential threats and make investments seeking to reduce the risk of these threats against our critical information and assets by implementing a broad set of security measures, including comprehensive monitoring of our networks and systems, rapid detection and response, and threat management capabilities. For example, we scan our systems for vulnerabilities and annually engage external experts, including cybersecurity assessors, consultants, and auditors in evaluating and testing our cybersecurity systems. The results of such assessments and reviews are reported to our Information Security Department and Audit Committee of the Board of Directors (the "Audit Committee"), and then we consider adjustments to our cybersecurity processes and practices as appropriate based on the information provided by the third-party assessments and reviews.
Security and data privacy awareness and training is provided to new employees and annually for current Aptar employees, is designed to educate employees on recognizing information security and cybersecurity concerns, how they can help protect the organization and how to inform the cybersecurity team of potential incidents. In addition, Aptar implements stringent processes to oversee and manage risks associated with our third-party providers. As set forth in our Sustainable Purchasing Charter, third-party providers are expected to, among other things, protect personal data and implement security and protection measures in relation thereto. We conduct security assessments of third-party providers before engagement and monitor their compliance with our cybersecurity standards on an ongoing basis. The monitoring includes periodic and ongoing assessments by our Information Security Department. This approach is designed to mitigate risks related to data breaches or other security incidents originating from third parties. In addition, we maintain cybersecurity insurance as part of our overall insurance portfolio.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] Aptar has strategically integrated cybersecurity risk management into a broader enterprise-wide risk management framework, which consists of administrative, operational, organizational, physical, and technical processes that we believe are appropriate to the scope and nature of our business. We believe this integrated approach allows cybersecurity considerations to be an integral part of our decision-making processes.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
The Audit Committee is responsible for the oversight of risks from cybersecurity threats. The Audit Committee is composed of independent directors with diverse experiences, including relating to risk management, technology, and finance. Management briefs the Audit Committee on a quarterly basis, and on an as needed basis, regarding our information security program and related risks to Aptar. As part of its oversight responsibilities, the Audit Committee regularly discusses and reviews with management, among other items, Aptar’s risk management system, including cybersecurity programs. The Audit Committee receives regular updates on any significant developments relating to cybersecurity. Furthermore, significant cybersecurity matters and related strategic risk management decisions are escalated to the Board of Directors.
We also periodically test our systems for vulnerabilities and regularly engage third parties to conduct evaluations of our security controls whether through penetration testing, independent audit or consulting on best practices to address new challenges. An independent review of our cybersecurity program has been assessed against the National Institute of Standards and Technology (NIST) cybersecurity framework.
Our Information Security Department reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Incident Response
Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] The Audit Committee is responsible for the oversight of risks from cybersecurity threats.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Role of Management [Text Block]
The Audit Committee is responsible for the oversight of risks from cybersecurity threats. The Audit Committee is composed of independent directors with diverse experiences, including relating to risk management, technology, and finance. Management briefs the Audit Committee on a quarterly basis, and on an as needed basis, regarding our information security program and related risks to Aptar. As part of its oversight responsibilities, the Audit Committee regularly discusses and reviews with management, among other items, Aptar’s risk management system, including cybersecurity programs. The Audit Committee receives regular updates on any significant developments relating to cybersecurity. Furthermore, significant cybersecurity matters and related strategic risk management decisions are escalated to the Board of Directors.
We also periodically test our systems for vulnerabilities and regularly engage third parties to conduct evaluations of our security controls whether through penetration testing, independent audit or consulting on best practices to address new challenges. An independent review of our cybersecurity program has been assessed against the National Institute of Standards and Technology (NIST) cybersecurity framework.
Our Information Security Department reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Incident Response
Aptar has a detailed incident response plan that provides the process and workflow of communication for escalation of incidents to executive leadership to determine if there is a breach that would warrant further action. We also have a cyber incident materiality committee, which is a cross functional team that includes various departments across the Company including Finance, Public Relations, Accounting/Controller, Legal and the Chief Information Security Officer. Our Information Security Department, in conjunction with the cyber incident materiality committee, review each incident under our materiality framework to assess whether further escalation and reporting is required and if the incidents could constitute a material breach. Periodically, our incident response team participates in a tabletop exercise or cybersecurity preparedness led by a third-party incident response provider.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our Information Security Department reports to our Chief Information Security Officer who reports to the Chief Information Officer. This team is comprised of full-time information security professionals, is responsible for the implementation of our cybersecurity strategy, including assessing and managing material risks from cybersecurity threats. Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems. Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our Chief Information Officer is an experienced information technology professional with 35 years of experience in the industry, including oversight of our cybersecurity department and has a degree in Management Information Systems.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Our Chief Information Security Officer regularly informs our Chief Information Officer and Chief Financial Officer of any cybersecurity risks and incidents. Our Chief Financial Officer is responsible for oversight of our response to cybersecurity incidents, as appropriate. In addition, our executive management discusses cybersecurity issues quarterly.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
BASIS OF PRESENTATION
BASIS OF PRESENTATION
The accompanying consolidated financial statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.
AptarGroup’s organizational structure consists of three market-focused business segments which are Pharma, Beauty and Closures. This is a strategic structure which allows us to better serve our customers and position us for long-term profitable growth.
Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiary pursuant to U.S. GAAP. We have changed the functional currency from the Argentine peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. Our Argentinian operations contributed less than 0.4% and 1.1% of consolidated net assets and revenues, respectively, at and for the year ended December 31, 2025.
ACCOUNTING ESTIMATES
ACCOUNTING ESTIMATES
The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). This process requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS
We consider all investments that are readily convertible to known amounts of cash with an original maturity of three months or less when purchased to be cash equivalents.
ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES
ACCOUNTS RECEIVABLE AND CURRENT EXPECTED CREDIT LOSSES
The allowance is estimated using reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions.
INVENTORIES
INVENTORIES
Inventories are stated at lower of cost or net realizable value. Cost of our inventories is determined by costing methods that approximate a first-in, first-out ("FIFO") basis. Costs included in inventories are raw materials, direct labor and manufacturing overhead.
ACQUISITIONS
ACQUISITIONS
We account for business combinations using the acquisition method, which requires management to estimate the fair value of identifiable assets acquired and liabilities assumed, and to properly allocate purchase price consideration to the individual assets acquired and liabilities assumed. Goodwill is measured as the excess amount of consideration transferred, compared to fair value of the assets acquired and the liabilities assumed. The allocation of the purchase price utilizes estimates and significant assumptions in determining the fair values of identifiable assets acquired and liabilities assumed, especially with respect to intangible assets. These estimates are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset and are reviewed by consulting with outside valuation experts. The purchase price allocation for business acquisitions contains uncertainties because it requires management's judgment.
INVESTMENTS IN EQUITY SECURITIES
INVESTMENTS IN EQUITY SECURITIES
We account for our 20% to 50% owned investments using the equity method. Under the equity method, we initially record our investment at cost and our interest in the net assets of the investee is included in the equity method investment on the Consolidated Balance Sheets. We recognize our equity in earnings in our equity method affiliates on a one-month lag basis and record our proportionate share of each investee's net income or loss into earnings after the date of investment, the adjustment of basis difference initially recognized and the other comprehensive income allocated to us from the investee. We evaluate the equity method investments for impairment under ASC 323. An impairment loss on the equity method investments is recognized in earnings when the decline in value is determined to be other-than-temporary.
Equity investments that do not result in consolidation and are not accounted for under the equity method are measured at fair value. Any related changes in fair value are recognized in net income unless the investments qualify for a practicality exception.
REDEEMABLE NONCONTROLLING INTEREST
REDEEMABLE NONCONTROLLING INTEREST
During the third quarter of 2025, we entered into an agreement with the shareholder of three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”), which provides them with redemption rights (i.e., a put option) that could require Aptar to purchase the shareholder's remaining 20% noncontrolling interests in BTY upon the passage of time. As these redemption rights are not solely within the control of Aptar, such interests are classified as redeemable noncontrolling interest outside of permanent equity, in mezzanine equity, on the Consolidated Balance Sheets.
At initial recognition, redeemable noncontrolling interests are recorded at their issuance-date or acquisition date, fair value. The fair value is estimated by applying an income approach and is based on significant inputs that are not observable in the market and is therefore a Level 3 model. Key assumptions in the valuation of the redeemable noncontrolling interest include a discount rate, a terminal value based on a range of long-term sustainable growth rates and adjustments because of the lack of control that market participants would consider when measuring the fair value of the noncontrolling interests. Subsequently, redeemable noncontrolling interests that are currently redeemable, or probable of becoming redeemable, are adjusted to the greater of (i) current redemption value or (ii) carrying amount. Adjustments to redemption value are recorded through retained earnings. Upward adjustments are considered a deemed dividend, and would result in a reduction to earnings available to common shareholders for the calculation of earnings per common share.
PROPERTY AND DEPRECIATION
PROPERTY AND DEPRECIATION
Properties are stated at cost. Depreciation is determined on a straight-line basis over the estimated useful lives for financial reporting purposes and accelerated methods for income tax reporting. Generally, the estimated useful lives are 10 to 40 years for buildings and improvements and 3 to 15 years for machinery and equipment.
FINITE-LIVED INTANGIBLE ASSETS
FINITE-LIVED INTANGIBLE ASSETS
Finite-lived intangibles, consisting of patents, acquired technology, customer relationships, trademarks and trade names and license agreements acquired in purchase transactions, are capitalized and amortized over their useful lives which range from 1 to 50 years.
IMPAIRMENT OF LONG-LIVED ASSETS
IMPAIRMENT OF LONG-LIVED ASSETS
Long-lived assets, such as property, plant and equipment and finite-lived intangibles, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In those circumstances, we perform undiscounted operating cash flow analyses for asset groups at the lowest level for which cash flows are separately identifiable to determine if an impairment exists. Any impairment loss is calculated as the excess of the asset group’s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset group less costs of disposal.
GOODWILL
GOODWILL
The Company evaluates the excess of purchase price over the fair value of the net assets acquired (“goodwill”) for impairment annually as of October 1 or more frequently if impairment indicators arise in accordance with Accounting Standards Codification (“ASC”) Topic 350, “Intangibles - Goodwill and Other.” We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires judgment and the use of estimates and significant assumptions related to projected revenue growth rates, projected EBITDA margins, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted today. The estimates and assumptions for future cash flows and its impact on the impairment testing of goodwill is a critical accounting estimate.
Management believes goodwill in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. The annual goodwill impairment test may first consider qualitative factors to determine whether it is more likely than not (i.e., greater than 50 percent chance) that the fair value of a reporting unit is less than its book value. This is sometimes referred to as the “step zero” approach and is an optional step in the annual goodwill impairment analysis. Management performed this qualitative assessment as of October 1, 2025 over all reporting units with the exception of Beauty and October 1, 2024 over all reporting units with the exception of Injectables and Other Pharma. As we performed our annual goodwill impairment assessment, due to events or circumstances that were unfavorable for the Beauty segment, management determined it appropriate to calculate the Step 1 fair value of the Beauty reporting unit and compare with its associated carrying amount as of October 1, 2025.
Based on our qualitative and quantitative analysis performed over the reporting units, we determined that it was more likely than not that the fair value of these reporting units was greater than their carrying amounts and therefore no impairment of goodwill is required.
DERIVATIVES INSTRUMENTS AND HEDGING ACTIVITIES
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Derivative financial instruments are recorded in the Consolidated Balance Sheets at fair value as either assets or liabilities. Changes in the fair value of derivatives are recorded in each period in earnings or other comprehensive income, depending on whether a derivative is designated and effective as part of a hedge transaction.
We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.
For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Consolidated Balance Sheets (See Note 12 – Fair Value).
Cash Flow Hedge
For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Consolidated Statements of Cash Flows.
Net Investment Hedge
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar relative to foreign currencies has an additive effect on our financial statements. Conversely, a strengthening U.S. dollar has a dilutive effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.
PURCHASE OF TREASURY STOCK
PURCHASE OF TREASURY STOCK
We allocate the excess purchase price over par value between additional paid-in capital and retained earnings.
RESEARCH & DEVELOPMENT EXPENSES
RESEARCH & DEVELOPMENT EXPENSES
Research and development costs, net of any customer funded research and development or government research and development credits, are expensed as incurred.
INCOME TAXES
INCOME TAXES
We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and its reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made.
We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: $160.0 million of 2025 earnings in France, all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding tax, local income taxes, and U.S. federal and state income tax when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals.
We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 6 – Income Taxes for more information.
We are subject to taxation and file income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. We believe that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Consolidated Financial Statements.
We have elected to include amounts paid for transferable, non-refundable U.S. energy credits as income taxes paid in our table of income taxes paid. Refer to Note 6 - Income Taxes for further details.
TRANSLATION OF FOREIGN CURRENCIES
TRANSLATION OF FOREIGN CURRENCIES
The functional currencies of the majority of our foreign operations are their local currencies. Assets and liabilities of our foreign operations are translated into U.S. dollars at the rates of exchange on the balance sheet date. Sales and expenses are translated at the average rates of exchange prevailing during the year. The related translation adjustments are accumulated in a separate section of Stockholders’ Equity.
STOCK BASED COMPENSATION
STOCK-BASED COMPENSATION
Accounting standards require the application of the non-substantive vesting approach which means that an award is fully vested when the employee’s retention of the award is no longer contingent on providing future service. Under this approach, compensation costs are recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. As such, costs are recognized immediately if the employee is retirement eligible on the date of grant or over the period from the date of grant until retirement eligibility if retirement eligibility is reached before the end of the vesting period stated in the grant. Forfeitures are recognized as they occur.
REVENUE RECOGNITION
REVENUE RECOGNITION
At inception of customer contracts, we assess the goods and services promised in order to identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product, tooling and service contract sales; however, we also receive revenues from license, exclusivity and royalty arrangements, which collectively are not material to the results.
LEASES
LEASES
We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities are included in accounts payable, accrued and other liabilities in our Consolidated Balance Sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our Consolidated Balance Sheets.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.
We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize ROU assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise).
Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability.
GOVERNMENT GRANTS
GOVERNMENT GRANTS
We record non-reimbursable government grants when there is reasonable assurance that we will comply with the relevant conditions of the grant agreement and the grant funds will be received. When a grant is received toward the purchase or construction of an asset, the funds received are recorded as a contra-asset and deducted from the cost of the related asset. Additionally, we record expenses net of reimbursements for government grants from a reimbursement of cost.
SUPPLY CHAIN FINANCE PROGRAM
SUPPLY CHAIN FINANCE PROGRAM
We regularly renegotiate our supplier contracts and as a result have been successful in securing extended payment terms with many of our suppliers to be in line with local and regional trends. We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions.
All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Consolidated Balance Sheets, and associated payments are included in operating activities within our Consolidated Statements of Cash Flows.
To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. While we have offered third party alternatives for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS
ADOPTION OF RECENT ACCOUNTING PRONOUNCEMENTS
Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses ("DISE"), which requires the disaggregation of certain expenses in the notes to the financial statements, to provide enhanced transparency into the expense captions presented on the face of the income statement. In January 2025, the FASB issued ASU 2025-01 clarifying the effective date. This standard will be effective for fiscal years beginning after December 15, 2026 and interim reporting periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective adoption. We are evaluating the impact of the standard on our disclosures in the Consolidated Financial Statements.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and is required to be applied prospectively with the option of retrospective application. We adopted this guidance in the fourth quarter of 2025 on a prospective basis. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 6 - Income Taxes for further discussion.
In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We adopted this guidance in the fourth quarter of 2024. The adoption of this standard did not have a material impact on our Consolidated Financial Statements; however we have expanded disclosures. See Note 18 - Segment Information for further discussion.
In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. We adopted this guidance in the fourth quarter of 2024.
Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our consolidated financial statements.
v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Schedule of Supply Chain Finance Program
20252024
SCF obligations outstanding at the beginning of the year$34,401 $36,309 
Additions161,090 160,847 
Settlements(163,535)(162,755)
SCF obligations outstanding at the end of the year$31,956 $34,401 
v3.25.4
REVENUE (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Revenue by Segment by Geographic Area Revenue by segment and geography based on shipped to locations for the years ended December 31, 2025, 2024 and 2023 were as follows:
For the Year Ended December 31, 2025
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$833,146 $601,861 $48,752 $253,722 $1,737,481 
Beauty795,903 230,049 163,880 119,605 1,309,437 
Closures233,510 342,392 83,773 70,588 730,263 
Total$1,862,559 $1,174,302 $296,405 $443,915 $3,777,181 
For the Year Ended December 31, 2024
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$806,606 $556,642 $47,124 $232,780 $1,643,152 
Beauty745,198 241,115 155,692 83,725 1,225,730 
Closures218,064 347,733 83,376 64,835 714,008 
Total$1,769,868 $1,145,490 $286,192 $381,340 $3,582,890 
For the Year Ended December 31, 2023
SegmentEuropeDomesticLatin
America
AsiaTotal
Pharma$779,929 $495,057 $52,074 $193,933 $1,520,993 
Beauty806,963 219,760 152,963 88,011 1,267,697 
Closures218,833 336,315 84,146 59,466 698,760 
Total$1,805,725 $1,051,132 $289,183 $341,410 $3,487,450 
Schedule of Contract Assets and Contract Liabilities
The opening and closing balances of our contract asset and contract liabilities are as follows:
Balance as of December 31, 2025Balance as of December 31, 2024Increase/
(Decrease)
Contract asset (current)$11,600 $12,571 $(971)
Contract liability (current)74,827 64,425 10,402 
Contract liability (long-term)49,901 40,551 9,350 
v3.25.4
INVENTORIES (Tables)
12 Months Ended
Dec. 31, 2025
Inventory Disclosure [Abstract]  
Schedule of Inventories, by Component
Inventories, by component net of reserves, consisted of:
20252024
Raw materials$152,574 $133,885 
Work in process194,176 161,350 
Finished goods191,095 166,572 
Total$537,845 $461,807 
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
12 Months Ended
Dec. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in the Carrying Amount of Goodwill
The changes in the carrying amount of goodwill for the year ended December 31, 2025 by reporting segment are as follows:
PharmaBeautyClosuresTotal
Balance as of December 31, 2023$508,447 $287,097 $167,874 $963,418 
Foreign currency exchange effects(20,213)(5,811)(1,138)(27,162)
Balance as of December 31, 2024$488,234 $281,286 $166,736 $936,256 
Acquisitions9,397 76,183 — 85,580 
Foreign currency exchange effects41,072 13,379 1,611 56,062 
Balance as of December 31, 2025$538,703 $370,848 $168,347 $1,077,898 
Schedule of Intangible Assets
The table below shows a summary of intangible assets for the years ended December 31, 2025 and 2024.
20252024
Weighted Average
Amortization Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Net
Value
Gross
Carrying
Amount
Accumulated
Amortization
Net
Value
Amortized intangible assets:
Patents13.0$19,032 $(4,016)$15,016 $18,333 $(2,343)$15,990 
Acquired technology10.7157,350 (99,551)57,799 137,444 (80,171)57,273 
Customer relationships13.9332,088 (177,686)154,402 303,502 (145,772)157,730 
Trademarks and trade names7.146,885 (41,726)5,159 42,882 (36,450)6,432 
License agreements and other25.232,927 (9,964)22,963 26,318 (8,974)17,344 
Total intangible assets14.0$588,282 $(332,943)$255,339 $528,479 $(273,710)$254,769 
Schedule of Future Estimated Amortization Expense
Future estimated amortization expense for the years ending December 31 is as follows:
2026$45,384 
202738,615 
202833,964 
202933,018 
203029,568 
2031 and thereafter74,790 
v3.25.4
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2025
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
At December 31, 2025 and 2024, accounts payable, accrued and other liabilities consisted of the following:
20252024
Accounts payable, principally trade$340,563 $295,967 
Accrued employee compensation costs232,595 211,441 
Customer deposits and other unearned income74,827 64,425 
Other accrued liabilities174,928 158,163 
Total$822,913 $729,996 
v3.25.4
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of Income Before Income Taxes
Income before income taxes consists of:
Years Ended December 31,202520242023
United States$135,913 $99,573 $49,681 
International355,465 370,192 325,144 
Total$491,378 $469,765 $374,825 
Schedule of Provision (Benefit) for Income Taxes
The provision (benefit) for income taxes is composed of:
Years Ended December 31,202520242023
Current tax expense (benefit):
U.S. Federal$6,726 $10,933 $11,777 
U.S. State and Local3,735 2,744 1,300 
International100,109 103,316 97,455 
Total current tax expense (benefit)$110,570 $116,993 $110,532 
Deferred tax expense (benefit):
U.S. Federal$12,040 $(8,936)$(10,931)
U.S. State and Local889 (923)(675)
International(24,618)(11,547)(8,277)
Total deferred tax expense (benefit)$(11,689)$(21,406)$(19,883)
Total income tax expense (benefit):
U.S. Federal$18,766 $1,997 $846 
U.S. State and Local4,624 1,821 625 
International75,491 91,769 89,178 
Total income tax expense (benefit)$98,881 $95,587 $90,649 
Schedule of Reconciliation of Actual Income Tax Provision and the Tax Provision Computed by Applying Statutory Federal Income Tax Rate The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company’s effective tax rate for the year ended December 31, 2025 in accordance with the guidance in ASU No. 2023-09:
Years Ended December 31,2025
AmountPercent
Provision for Income taxes at U.S. federal statutory rate$103,189 21.0 %
Domestic Federal:
Tax credits(2,115)(0.4)%
Nontaxable and nondeductible items, net
Excess benefits from share-based compensation(2,804)(0.6)%
Other382 0.1 %
Cross border tax laws (1)(3,045)(0.6)%
Changes in valuation allowance(300)(0.1)%
Other313 0.1 %
Domestic state and local income taxes, net of federal effect (2)3,179 0.6 %
Foreign:
France
Rate differential8,114 1.7 %
Other2,256 0.5 %
Germany - Federal
Municipal taxes12,781 2.6 %
Other(7,380)(1.5)%
Brazil
Changes in valuation allowance(8,300)(1.7)%
Other262 0.1 %
China
Nontaxable and nondeductible items, net
Equity investment remeasurement gain(5,394)(1.1)%
Other(2,129)(0.4)%
Other Foreign Jurisdictions2,007 0.2 %
Worldwide changes in unrecognized tax benefits(2,135)(0.4)%
$98,881 20.1 %
(1)The Company has elected to include U.S. foreign tax credits in the Cross Border tax section.
(2)The states that contribute to the majority (greater than 50%) of the tax effect in this category include New Jersey, Illinois and California.
As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective tax rate differs from the statutory tax rate as follows:
Years Ended December 31,20242023
Income tax at statutory rate$98,651 $78,713 
State income taxes, net of federal tax effect1,439 362 
Excess tax benefits from share-based compensation(11,041)(5,935)
Deferred tax (benefits) charges, incl. tax rate changes2,691 (3,512)
Valuation allowance(14,625)158 
Legal entity reorganization— 3,630 
Rate differential on earnings of foreign operations21,357 18,917 
Other items, net(2,885)(1,684)
Actual income tax provision$95,587 $90,649 
Effective income tax rate20.3 %24.2 %
Schedule of Income Taxes Paid
The amount of income taxes paid were as follows:
Years Ended December 31,2025
U.S. Federal (1)
$28,166 
U.S. State and Local5,407 
Foreign
France55,539 
Germany - Federal32,445 
Germany - Muni27,943 
Other29,851 
Total Foreign$145,778 
Total income taxes paid
$179,351 
(1)The Company has elected to include amounts paid for transferable, non-refundable U.S. energy credits of $17.5 million, as income taxes paid.
Schedule of Significant Deferred Tax Assets and Liabilities
Significant deferred tax assets and liabilities as of December 31, 2025 and 2024 are composed of the following temporary differences:
20252024
Deferred Tax Assets:
Net operating loss carryforwards$82,593 $72,766 
Operating and finance leases22,077 21,712 
Share-based compensation11,061 3,747 
Vacation and bonus15,979 16,223 
U.S. capitalized research expenditures41,338 41,956 
Accrued liabilities and other reserves10,324 9,598 
Other35,589 33,931 
Total gross deferred tax assets$218,961 $199,933 
Less valuation allowance(56,465)(61,134)
Net deferred tax assets$162,496 $138,799 
Deferred Tax Liabilities:
Acquisition related intangibles$52,023 $51,155 
Depreciation and amortization26,489 21,325 
Operating and finance leases22,408 22,672 
Other7,169 8,059 
Total gross deferred tax liabilities$108,089 $103,211 
Net deferred tax assets
$54,407 $35,588 
Schedule of Reconciliation of the Beginning and Ending Amount of Income Tax Uncertainties A reconciliation of the beginning and ending amount of income tax uncertainties is as follows:
202520242023
Balance at January 1$5,792 $5,942 $6,919 
Increases based on tax positions for the current year400 300 985 
Increases (Decreases) based on tax positions of prior years3,759 107 (997)
Settlements(301)(127)(901)
Lapse of statute of limitations(720)(430)(64)
Balance at December 31$8,930 $5,792 $5,942 
Schedule of Major Tax Jurisdictions the Company Files in, with the Years Still Subject to Income Tax Examinations The major tax jurisdictions we file in, with the years still subject to income tax examinations, are listed below:
Major Tax
Jurisdiction
Tax Years
Subject to
Examination
United States — Federal2022-2025
United States — State2021-2025
France2022-2025
Germany2023-2025
Italy2019-2025
China2015-2025
v3.25.4
DEBT (Tables)
12 Months Ended
Dec. 31, 2025
Debt Disclosure [Abstract]  
Schedule of Short-term Debt Obligations
At December 31, 2025 and 2024, our short term obligations, revolving credit facility and overdrafts consisted of the following:
20252024
Short-term obligations 1.50% to 3.00%
$31,314 $— 
Revolving credit facility 2.96%
152,633 176,035 
$183,947 $176,035 
Schedule of Long-term Obligations
At December 31, 2025 and 2024, our long-term obligations consisted of the following:
December 31, 2025December 31, 2024
Notes payable 0.00% – 8.35%, due in monthly and annual installments through 2035
$17,051 $15,135 
Senior unsecured notes 3.6%, due in 2025
 125,000 
Senior unsecured notes 3.6%, due in 2026
125,000 125,000 
Term loan 4.9% floating, due in 2027
141,100 166,000 
Senior unsecured notes 4.8%, due in 2031, net of discount of $0.5 million
599,512 — 
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.6 million
399,361 399,258 
Finance Lease Liabilities25,339 23,753 
Unamortized debt issuance costs(8,346)(3,830)
$1,299,017 $850,316 
Current maturities of long-term obligations(159,584)(162,250)
Total long-term obligations$1,139,433 $688,066 
Schedule of Long-Term Maturities
The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 8, due annually for the next five years and thereafter are:
2026$156,528 
2027116,565 
2028959 
2029109 
203055 
Thereafter1,007,808 
Schedule of Covenants on Revolving Credit Facility and Corporate Long-term Obligations
Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:
RequirementLevel at December 31, 2025
Consolidated Leverage Ratio (1)
Maximum of 3.50 to 1.00
1.38 to 1.00
Consolidated Interest Coverage Ratio (1)
Minimum of 3.00 to 1.00
15.07 to 1.00
(1)Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.
v3.25.4
LEASE COMMITMENTS (Tables)
12 Months Ended
Dec. 31, 2025
Leases [Abstract]  
Schedule of Components of Lease Expense
The components of lease expense for the years ended December 31, 2025 and 2024 were as follows:
Year Ended December 31,20252024
Operating lease cost$22,714 $20,061 
Finance lease cost:
Amortization of right-of-use assets$7,778 $6,803 
Interest on lease liabilities1,226 1,192 
Total finance lease cost$9,004 $7,995 
Short-term lease and variable lease costs$21,938 $20,149 
Schedule of Supplemental Cash Flow Information Related to Leases
Supplemental cash flow information related to leases was as follows:
Year Ended December 31,20252024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$22,387 $20,376 
Operating cash flows from finance leases1,367 1,289 
Financing cash flows from finance leases3,706 3,054 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$12,135 $33,726 
Finance leases4,791 1,705 
Schedule of Supplemental Balance Sheet Information Related to Leases
Supplemental balance sheet information related to leases was as follows:
December 31,
2025
December 31,
2024
Operating Leases
Operating lease right-of-use assets$65,698 $64,213 
Accounts payable, accrued and other liabilities$17,745 $17,015 
Operating lease liabilities47,940 49,716 
Total operating lease liabilities$65,685 $66,731 
Finance Leases
Property, plant and equipment, gross$57,610 $50,319 
Accumulated depreciation(28,588)(20,103)
Property, plant and equipment, net$29,022 $30,216 
Current maturities of long-term obligations, net of unamortized debt issuance cost$3,303 $3,563 
Long-term obligations, net of unamortized debt issuance cost22,036 20,190 
Total finance lease liabilities$25,339 $23,753 
Weighted Average Remaining Lease Term (in years)
Operating leases5.14.7
Finance leases4.84.9
Weighted Average Discount Rate
Operating leases5.69 %5.77 %
Finance leases4.95 %5.12 %
Schedule of Maturities of Lease Liabilities
Maturities of lease liabilities as of December 31, 2025, were as follows:
Operating
Leases
Finance
Leases
Year 1$20,903 $4,532 
Year 217,176 7,727 
Year 311,020 2,994 
Year 47,750 8,015 
Year 55,510 1,098 
Thereafter17,000 4,532 
Total lease payments79,359 28,898 
Less imputed interest(13,674)(3,559)
Total$65,685 $25,339 
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)
12 Months Ended
Dec. 31, 2025
Retirement Benefits [Abstract]  
Schedule Of Change In The Projected Benefit Obligation, Plan Assets At Fair Value And Funded Status
The following table presents the changes in the benefit obligations and plan assets for the most recent two years for our domestic and foreign plans.
Domestic PlansForeign Plans
2025202420252024
Change in benefit obligation:
Benefit obligation at beginning of year$175,194 $186,013 $104,196 $104,757 
Service cost7,931 9,462 6,711 6,492 
Interest cost9,563 8,968 3,868 3,488 
Plan Amendment —  (17)
Curtailment/Settlement — (1,298)(1,385)
Actuarial (gain) loss
2,699 (18,156)(7,600)1,370 
Benefits paid(13,726)(11,093)(3,798)(3,776)
Foreign currency translation adjustment (loss) gain
 — 13,466 (6,733)
Benefit obligation at end of year$181,661 $175,194 $115,545 $104,196 
Domestic PlansForeign Plans
2025202420252024
Change in plan assets:
Fair value of plan assets at beginning of year$180,761 $173,735 $71,250 $72,434 
Actual return on plan assets24,437 17,624 942 3,605 
Employer contribution10,898 495 1,431 3,580 
Benefits paid(13,726)(11,093)(3,798)(3,776)
Foreign currency translation adjustment — 9,392 (4,593)
Fair value of plan assets at end of year$202,370 $180,761 $79,217 $71,250 
Funded status at end of year$20,709 $5,567 $(36,328)$(32,946)
Schedule Of Funded Status Amounts Recognized In The Consolidated Balance Sheet
The following table presents the funded status amounts recognized in our Consolidated Balance Sheets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Non-current assets$36,881 $19,739 $3,668 $3,648 
Current liabilities(670)(546)(111)(46)
Non-current liabilities(15,502)(13,626)(39,885)(36,548)
$20,709 $5,567 $(36,328)$(32,946)
Schedule Of Amounts Not Recognized As Components Of Periodic Benefit Cost That Are Recognized In Accumulated Other Comprehensive Loss
The following table presents the amounts not recognized as components of periodic benefit cost that are recognized in accumulated other comprehensive (gain) loss as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Net actuarial (gain) loss
$(30,065)$(21,495)$8,462 $16,201 
Net prior service cost — (616)(531)
Tax effects8,797 6,713 (4,659)(6,413)
$(21,268)$(14,782)$3,187 $9,257 
Schedule Of Changes In Benefit Obligations And Plan Assets Recognized In Other Comprehensive Income
Changes in benefit obligations and plan assets recognized in other comprehensive income in 2025, 2024 and 2023 are as follows:
Domestic Plans
202520242023
Current year actuarial gain (loss)
$9,058 $23,318 $(5,161)
Amortization of net (gain) loss
(488)— — 
$8,570 $23,318 $(5,161)
Foreign Plans
202520242023
Current year actuarial gain (loss)
$6,370 $(47)$(5,315)
Current year prior service cost 20 1,135 
Transfer Prior service Cost(16)— — 
Transfer actuarial gain (loss)
121 (694)124 
Amortization of net loss1,248 201 914 
Amortization of prior service cost101 349 177 
$7,824 $(171)$(2,966)
Schedule Of Components Of Net Periodic Benefit Cost
Components of net periodic benefit cost:
Domestic Plans
202520242023
Service cost$7,931 $9,462 $9,638 
Interest cost9,563 8,968 8,631 
Expected return on plan assets(12,743)(12,463)(12,378)
Amortization of net (gain) loss
(488)— — 
Net periodic benefit cost$4,263 $5,967 $5,891 
Foreign Plans
202520242023
Service cost$6,711 $6,492 $5,915 
Interest cost3,868 3,488 3,642 
Expected return on plan assets(2,440)(2,243)(2,340)
Amortization of net loss1,248 201 914 
Amortization of prior service cost101 349 177 
Net periodic benefit cost$9,488 $8,287 $8,308 
Curtailment(1,197)(2,205)(1)
Total Net periodic benefit cost$8,291 $6,082 $8,307 
Schedule Of Projected Benefit Obligation ("PBO"), ABO, And Fair Value Of Plan Assets For All Pension Plans With An ABO In Excess Of Plan Assets
The following table provides the projected benefit obligation (“PBO”), ABO, and fair value of plan assets for all pension plans with an ABO in excess of plan assets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Projected benefit obligation$16,173 $14,172 $87,278 $77,645 
Accumulated benefit obligation14,226 12,412 62,608 54,460 
Fair value of plan assets — 47,410 41,238 
Schedule of PBO, ABO, And Fair Value Of Plan Assets For All Pension Plans With A Pbo In Excess Of Plan Assets
The following table provides the PBO, ABO and fair value of plan assets for all pension plans with a PBO in excess of plan assets as of December 31, 2025 and 2024.
Domestic PlansForeign Plans
2025202420252024
Projected benefit obligation$16,173 $14,172 $87,278 $81,273 
Accumulated benefit obligation14,226 12,412 62,608 57,494 
Fair value of plan assets — 47,410 44,676 
Schedule Of Weighted-average Assumptions Used To Determine Benefit Obligations And Net Periodic Benefit Cost
Assumptions:
Domestic PlansForeign Plans
202520242023202520242023
Weighted-average assumptions used to determine benefit obligations at December 31:
Discount rate5.63 %5.60 %4.95 %3.90 %3.33 %3.20 %
Rate of compensation increase3.27 %3.24 %3.24 %3.20 %3.21 %3.20 %
Weighted-average assumptions used to determine net periodic benefit cost for years ended December 31:
Discount rate5.60 %4.95 %5.15 %3.30 %3.32 %3.69 %
Expected long-term return on plan assets7.00 %7.00 %7.00 %3.23 %3.22 %3.23 %
Rate of compensation increase3.27 %3.24 %3.20 %3.20 %3.21 %3.20 %
Schedule Of Domestic And Foreign Pension Plan Weighted-average Asset Allocations By Asset Category
Our domestic and foreign pension plan weighted-average asset allocations at December 31, 2025 and 2024 by asset category are as follows:
Plan Assets:
Domestic Plans Assets at December 31,Foreign Plans Assets at December 31,
2025202420252024
Equity securities50 %50 %2 %%
Fixed income securities25 %25 %1 %%
Corporate debt securities — 3 %%
Infrastructure7 %% — 
Hedge funds11 %11 % — 
Money market3 %% %— %
Investment Funds — 94 %94 %
Real estate4 %% — 
Total100 %100 %100 %100 %
Summary Of Fair Value Of Pension Plan Assets
Domestic Fair Value Measurement at December 31, 2025Foreign Fair Value Measurement at December 31, 2025
(In Thousands $)Total(Level 1)(Level 2)(Level 3)Total(Level 1)(Level 2)(Level 3)
Cash and Short-term Securities (a)$5,240 $5,240 $ $ $659 $659 $ $ 
USD— 5,240 — — — — — — 
EUR— — — — — 653 — — 
Others— — — — — — — 
Equity Securities (a)$91,509 $91,509 $ $ $1,205 $1,205 $ $ 
U.S. Large Cap Equities— 52,466 — — — — — — 
U.S. Small Cap Equities— 11,019 — — — — — — 
International Equities— 28,024 — — — 1,205 — — 
Fixed Income (a)(b)$33,029 $33,029 $ $ $586 $586 $ $ 
Corporate debts securities$ $ $ $ $2,029 $2,029 $ $ 
Euro Corporate Bonds (a)— — — — — 2,029 — — 
Investment Funds$ $ $ $ $74,738 $23,352 $51,386 $ 
Mutual Funds in Equities (a)— — — — — 4,718 — — 
Mutual Funds in Bonds (a)— — — — — 14,854 — — 
Mutual Funds Diversified (a)(b)— — — — — 3,780 51,386 — 
Total Investments in Fair Value Hierarchy$129,778 $129,778 $ $ $79,217 $27,831 $51,386 $ 
Investments at Net Asset Value per Share72,592 — — — — — — — 
Total Investments$202,370 $129,778 $ $ $79,217 $27,831 $51,386 $ 
Domestic Fair Value Measurement at December 31, 2024Foreign Fair Value Measurement at December 31, 2024
(In Thousands $)Total(Level 1)(Level 2)(Level 3)Total(Level 1)(Level 2)(Level 3)
Cash and Short-term Securities (a)$3,054 $3,054 $ $ $275 $275 $ $ 
USD— 3,054 — — — — — — 
EUR— — — — — 269 — — 
Others— — — — — — — 
Equity Securities (a)$78,234 $78,234 $ $ $1,873 $1,873 $ $ 
U.S. Large Cap Equities— 45,294 — — — — — — 
U.S. Small Cap Equities— 10,363 — — — — — — 
International Equities— 22,577 — — — 1,873 — — 
Fixed Income (a)(b)$28,526 $28,526 $ $ $562 $562 $ $ 
Corporate debts securities$ $ $ $ $1,213 $1,213 $ $ 
Euro Corporate Bonds (a)— — — — — 1,213 — — 
Investment Funds$ $ $ $ $67,327 $24,377 $42,950 $ 
Mutual Funds in Equities (a)— — — — — 5,781 — — 
Mutual Funds in Bonds (a)— — — — — 14,634 — — 
Mutual Funds Diversified (a)(b)— — — — — 3,962 42,950 — 
Total Investments in Fair Value Hierarchy$109,814 $109,814 $ $ $71,250 $28,300 $42,950 $ 
Investments at Net Asset Value per Share70,947 — — — — — — — 
Total Investments$180,761 $109,814 $ $ $71,250 $28,300 $42,950 $ 
(a)Based on third party quotation from financial institution.
(b)Based on observable market transactions.
Schedule Of Estimated Benefit Payments Relating To Defined Benefit Plans Over The Next Ten Years
As of December 31, 2025, we expect the plans to make the following estimated benefit payments relating to our defined benefit plans over the next 10 years:
Domestic PlansForeign Plans
2026$10,665 $5,803 
202711,753 4,259 
202812,151 5,015 
202913,488 6,601 
203013,802 6,663 
2031 - 203577,102 54,622 
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) (Tables)
12 Months Ended
Dec. 31, 2025
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]  
Schedule of Changes in Accumulated Other Comprehensive (loss) Income by Component
Changes in Accumulated Other Comprehensive Income/(Loss) by Component:
Foreign
Currency
Defined Benefit
Pension Plans
DerivativesTotal
Balance - December 31, 2022$(328,740)$(5,951)$(6,675)$(341,366)
Other comprehensive income (loss) before reclassifications48,658 (6,711)(10,086)31,861 
Amounts reclassified from accumulated other comprehensive income— 771 — 771 
Net current-period other comprehensive income (loss)48,658 (5,940)(10,086)32,632 
Balance - December 31, 2023$(280,082)$(11,891)$(16,761)$(308,734)
Other comprehensive (loss) income before reclassifications(145,967)17,043 7,813 (121,111)
Amounts reclassified from accumulated other comprehensive income— 370 — 370 
Net current-period other comprehensive (loss) income(145,967)17,413 7,813 (120,741)
Balance - December 31, 2024$(426,049)$5,522 $(8,948)$(429,475)
Other comprehensive income (loss) before reclassifications246,158 11,960 (15,621)242,497 
Amounts reclassified from accumulated other comprehensive income— 596 — 596 
Net current-period other comprehensive income (loss)246,158 12,556 (15,621)243,093 
Balance - December 31, 2025$(179,891)$18,078 $(24,569)$(186,382)
Schedule of Reclassifications Out of Accumulated Other Comprehensive (loss) Income
Reclassifications Out of Accumulated Other Comprehensive Income/(Loss):
Details about Accumulated Other
Comprehensive Income Components
Amount Reclassified from
Accumulated Other
Comprehensive Income
Affected Line in the Statement
Where Net Income is Presented
Year Ended December 31,202520242023
Defined Benefit Pension Plans
Amortization of net loss$760 $201 $914 (1)
Amortization of prior service cost101 349 177 (1)
861 550 1,091 Total before tax
(265)(180)(320)Tax benefit
$596 $370 $771 Net of tax
Total reclassifications for the period$596 $370 $771 
(1)These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax (see Note 9 - Retirement and Deferred Compensation Plans for additional details).
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)
12 Months Ended
Dec. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments in The Consolidated Balance Sheets
Fair Value of Derivative Instruments in the Consolidated Balance Sheets as of
December 31, 2025 and December 31, 2024
December 31, 2025December 31, 2024
Balance Sheet
Location
Derivatives
Designated
as Hedging
Instruments
Derivatives
not
Designated
as Hedging
Instruments
Derivatives
Designated
as Hedging
Instruments
Derivatives
not
Designated
as Hedging
Instruments
Derivative Assets
Foreign Exchange ContractsPrepaid and other$— $298 $— $572 
$ $298 $— $572 
Derivative Liabilities
Foreign Exchange ContractsAccounts payable, accrued and other liabilities$ $632 $— $622 
Cross Currency Swap Contract (1)Deferred and other non-current liabilities32,542  11,851 — 
$32,542 $632 $11,851 $622 
(1)This cross currency swap contract is composed of both an interest component and a foreign exchange component.
Schedule of Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (loss)
The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the
Fiscal Years Ended December 31, 2025 and December 31, 2024
Derivatives in Cash
Flow Hedging
Relationships
Amount of Gain (Loss)
Recognized in
Other Comprehensive
Income on Derivative
Location of (Loss)
Gain Recognized
in Income on
Derivatives
Amount of Gain (Loss)
Reclassified from
Accumulated
Other Comprehensive
Income on Derivative
Total Amount
of Affected
Income
Statement
Line Item
2025202420252024
Cross currency swap contract:
Foreign exchange component$(15,621)$7,813 Miscellaneous, net$ $— $(2,027)
$(15,621)$7,813 $ $— 
Schedule of Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income
The Effect of Derivatives Not Designated as Hedging Instruments on the Consolidated Statements of Income for the Fiscal Years Ended December 31, 2025 and December 31, 2024
Derivatives Not Designated
as Hedging Instruments
Location of (Loss) Gain Recognized
in Income on Derivatives
Amount of (Loss) Gain
Recognized in Income
on Derivatives
20252024
Foreign Exchange ContractsOther (Expense) Income:
Miscellaneous, net
$(314)$(190)
$(314)$(190)
Schedule of Offsetting Derivative Assets and Liabilities
Gross Amounts
Offset in the
Statement of
Financial Position
Net Amounts
Presented in
the Statement of
Financial Position
Gross Amounts not Offset
in the Statement of
Financial Position
Gross
Amount
Financial
Instruments
Cash Collateral
Received
Net
Amount
Description
December 31, 2025
Derivative Assets$298 $ $298 $ $ $298 
Total Assets$298 $ $298 $ $ $298 
Derivative Liabilities$33,174 $ $33,174 $ $ $33,174 
Total Liabilities$33,174 $ $33,174 $ $ $33,174 
December 31, 2024
Derivative Assets$572 $— $572 $— $— $572 
Total Assets$572 $— $572 $— $— $572 
Derivative Liabilities$12,473 $— $12,473 $— $— $12,473 
Total Liabilities$12,473 $— $12,473 $— $— $12,473 
v3.25.4
FAIR VALUE (Tables)
12 Months Ended
Dec. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Fair Values of Financial Assets and Liabilities
As of December 31, 2025, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$2,503 $2,503 $ $ 
Foreign exchange contracts (2)
298  298  
Convertible notes (3)
5,650   5,650 
Total assets at fair value$8,451 $2,503 $298 $5,650 
Liabilities
Foreign exchange contracts (2)
$632 $ $632 $ 
Cross currency swap contract (2)
32,542  32,542  
Contingent consideration obligation3,983   3,983 
Total liabilities at fair value$37,157 $ $33,174 $3,983 
As of December 31, 2024, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$2,986 $2,986 $— $— 
Foreign exchange contracts (2)
572 — 572 — 
Convertible notes (3)
5,650 — — 5,650 
Total assets at fair value$9,208 $2,986 $572 $5,650 
Liabilities
Foreign exchange contracts (2)
$622 $— $622 $— 
Cross currency swap contract (2)
11,851 — 11,851 — 
Total liabilities at fair value$12,473 $— $12,473 $— 
(1)Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 20 - Investment in Equity Securities for discussion of this investment.
(2)Market approach valuation technique based on observable market transactions of spot and forward rates.
(3)Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Consolidated Balance Sheets.
Summary of Changes in Level 3 Fair Value Measurements The following table provides a summary of changes in our Level 3 fair value measurements:
Balance, December 31, 2024$— 
Acquisition3,983 
Balance, December 31, 2025$3,983 
v3.25.4
CAPITAL STOCK (Tables)
12 Months Ended
Dec. 31, 2025
CAPITAL STOCK  
Schedule of Number of Shares of Common Stock and Treasury Stock and the Share Activity The number of shares of common stock and treasury stock and the share activity were as follows:
Common SharesTreasury Shares
202520242023202520242023
Balance at the beginning of the year72,466,548 71,679,658 70,848,810 6,015,772 5,775,295 5,555,027 
Employee option exercises171,648 629,541 679,878 (144,288)(192,123)(178,326)
Director option exercises 6,500 —  — — 
Restricted stock vestings190,317 150,849 150,970  — — 
Common stock repurchases — — 2,744,260 432,600 398,594 
Balance at the end of the year72,828,513 72,466,548 71,679,658 8,615,744 6,015,772 5,775,295 
v3.25.4
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Restricted Stock Units Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.
Year Ended December 31,202520242023
Fair value per stock award$154.20 $145.79 $116.17 
Grant date stock price$147.84 $141.00 $111.38 
Assumptions:
Aptar's stock price expected volatility17.70 %18.80 %20.00 %
Expected average volatility of peer companies34.10 %34.80 %39.70 %
Correlation assumption31.00 %30.70 %33.30 %
Risk-free interest rate4.03 %4.51 %3.83 %
Dividend yield assumption1.22 %1.16 %1.36 %
Schedule of Restricted Stock Unit Activity
A summary of RSU activity as of December 31, 2025, and changes during the period then ended is presented below:
Time-Based RSUsPerformance-Based RSUs
UnitsWeighted Average
Grant-Date Fair Value
UnitsWeighted Average
Grant-Date Fair Value
Nonvested at January 1, 2025
277,245$123.28 513,226$127.17 
Granted96,240144.48 207,167147.38 
Vested(145,504)117.97 (214,235)131.12 
Forfeited(12,548)129.24 (71,280)124.02 
Nonvested at December 31, 2025215,433$135.89 434,878$135.31 
Schedule of Compensation Expense, Fair Value, and Intrinsic Value Related to Rsu's
Year Ended December 31,202520242023
Compensation expense (included in SG&A)$33,259 $37,529 $34,454 
Compensation expense (included in Cost of sales)3,271 3,052 2,561 
Compensation expense$36,530 $40,581 $37,015 
Fair value of units vested43,605 36,313 29,100 
Intrinsic value of units vested54,076 40,083 33,914 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Stock Award Plans:
Year Ended December 31,202520242023
Dividend Yield1.17 %1.28 %1.41 %
Expected Stock Price Volatility17.66 %17.03 %16.55 %
Risk-free Interest Rate4.21 %4.51 %3.57 %
Expected Life of Option (years)7.07.07.0
Schedule of Option Activity
A summary of option activity under our stock plans as of December 31, 2025, and changes during the period then ended is presented below:
Stock Awards Plans
OptionsWeighted Average
Exercise Price
Outstanding, January 1, 2025
1,663,307 $93.69 
Granted226,187 147.84 
Exercised(250,188)75.64 
Forfeited or expired(30,808)128.35 
Outstanding at December 31, 20251,608,498 $103.45 
Exercisable at December 31, 20251,140,413 $88.82 
Weighted-Average Remaining Contractual Term (Years):
Outstanding at December 31, 20254.3
Exercisable at December 31, 20252.6
Aggregate Intrinsic Value:
Outstanding at December 31, 2025$39,920 
Exercisable at December 31, 2025$39,351 
Intrinsic Value of Options Exercised During the Years Ended:
December 31, 2025$17,809 
December 31, 2024$57,259 
December 31, 2023$38,706 
Schedule of Compensation Expense, and Fair Value Related to Options
Year Ended December 31,202520242023
Compensation expense (included in SG&A)$6,729 $6,381 $3,929 
Compensation expense (included in Cost of sales)682 688 349 
Compensation expense, Total$7,411 $7,069 $4,278 
Compensation expense, net of tax7,241 6,880 4,278 
Grant date fair value of options vested5,204 2,320 2,663 
v3.25.4
EARNINGS PER SHARE (Tables)
12 Months Ended
Dec. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic and Diluted Earnings Per Share The reconciliation of basic and diluted earnings per share (“EPS”) for the years ended December 31, 2025, 2024 and 2023 are as follows:
Income
(Numerator)
Shares
(Denominator)
Per Share
Amount
For the Year Ended December 31, 2025
Basic EPS
Income available to common stockholders$392,789 65,740 $5.97 
Effect of Dilutive Securities
Stock options497 
Restricted stock488 
Diluted EPS
Income available to common stockholders$392,789 66,725 $5.89 
For the Year Ended December 31, 2024
Basic EPS
Income available to common stockholders$374,541 66,334 $5.65 
Effect of Dilutive Securities
Stock options765 
Restricted stock592 
Diluted EPS
Income available to common stockholders$374,541 67,691 $5.53 
For the Year Ended December 31, 2023
Basic EPS
Income available to common stockholders$284,487 65,616 $4.34 
Effect of Dilutive Securities
Stock options874 
Restricted stock415 
Diluted EPS
Income available to common stockholders$284,487 66,905 $4.25 
v3.25.4
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Financial Information Regarding the Company's Reportable Segments
Financial information regarding our reporting segments is shown below:
In thousands
Year Ended December 31,202520242023
Total Sales:
Pharma$1,738,470 $1,644,012 $1,521,837 
Beauty1,338,138 1,252,904 1,297,477 
Closures736,943 721,564 706,847 
Total Sales$3,813,551 $3,618,480 $3,526,161 
Less: Intersegment Sales:
Pharma$989 $860 $844 
Beauty28,701 27,174 29,780 
Closures6,680 7,556 8,087 
Total Intersegment Sales$36,370 $35,590 $38,711 
Net Sales:
Pharma$1,737,481 $1,643,152 $1,520,993 
Beauty1,309,437 1,225,730 1,267,697 
Closures730,263 714,008 698,760 
Net Sales$3,777,181 $3,582,890 $3,487,450 
Less:
Cost of Sales (exclusive of depreciation and amortization):
Pharma885,928 834,595 797,542 
Beauty965,316 884,433 922,223 
Closures523,939 511,409 507,866 
Selling, Research & Development and Administrative:
Pharma252,946 241,357 221,808 
Beauty194,246 183,903 192,831 
Closures91,921 89,913 87,930 
Other Segment Items:
Pharma(9,039)(1,171)(990)
Beauty(8,896)(2,515)(11,073)
Closures(2,074)(1,456)(729)
Adjusted EBITDA (1):
Pharma$607,646 $568,371 $502,633 
Beauty158,771 159,909 163,716 
Closures116,477 114,142 103,693 
Adjusted EBITDA for Reportable Segments
$882,894 $842,422 $770,042 
Corporate & Other, unallocated
(67,792)(67,498)(62,320)
Acquisition-related costs (2)(3,253)(140)(480)
Restructuring Initiatives (3)(9,837)(13,002)(45,004)
Curtailment gain related to restructuring initiatives (4)115 1,851 — 
Net unrealized investment (loss) gain (5)(483)1,713 (2,775)
Gain from remeasurement of equity method investment (6)26,518 — — 
Other special items (7)(8,360)— — 
Depreciation and amortization(287,363)(263,784)(248,593)
Interest Expense(52,737)(43,898)(40,418)
Interest Income11,676 12,101 4,373 
Income before Income Taxes$491,378 $469,765 $374,825 
In thousands
Year Ended December 31,202520242023
Depreciation and Amortization:
Pharma$136,111 $120,429 $109,365 
Beauty91,066 82,931 83,399 
Closures56,716 57,326 52,095 
Depreciation and Amortization for Reportable Segments
283,893 260,686 244,859 
Corporate & Other3,470 3,098 3,734 
Depreciation and Amortization$287,363 $263,784 $248,593 
Capital Expenditures:
Pharma$143,068 $148,261 $196,083 
Beauty68,193 64,571 83,872 
Closures50,968 45,766 52,160 
Capital Expenditures for Reportable Segments
262,229 258,598 332,115 
Corporate & Other11,889 23,630 14,729 
Transfer of Corporate Expenditures (8)(3,699)(5,747)(34,502)
Capital Expenditures$270,419 $276,481 $312,342 
Total Assets:
Pharma$2,283,609 $2,057,586 $2,111,779 
Beauty1,691,850 1,392,491 1,412,203 
Closures799,403 746,127 765,930 
Total Assets for Reportable Segments
4,774,862 4,196,204 4,289,912 
Corporate & Other477,857 236,074 161,978 
Total Assets$5,252,719 $4,432,278 $4,451,890 
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 19 - Acquisitions and Note 20 – Investments in Equity Securities for further details).
(3)Restructuring Initiatives includes expense items for the years ended December 31, 2025, 2024 and 2023 as follows (see Note 21 – Restructuring Initiatives for further details):
In thousands
Year Ended December 31,202520242023
Restructuring Initiatives by Plan:
Optimization initiative$9,837 $13,019 $45,445 
Prior year initiatives (17)(441)
Total Restructuring Initiatives$9,837 $13,002 $45,004 
Restructuring Initiatives by Segment:
Pharma$1,080 $589 $4,852 
Beauty4,469 8,041 20,683 
Closures3,566 3,835 17,927 
Corporate & Other722 537 1,542 
Total Restructuring Initiatives$9,837 $13,002 $45,004 
(4)The curtailment gain is included in the line miscellaneous income (expense), net in the Consolidated Statements of Income (see Note 9 - Retirement and Deferred Compensation Plans).
(5)Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 20 – Investment in Equity Securities for further details).
(6)The gain on remeasurement of equity method investment represents the remeasurement of our previously held minority equity interest in BTY at fair value (see Note 19 – Acquisitions for further details).
(7)Other special items includes costs related to non-ordinary-course litigation regarding the matters disclosed under "Legal Proceedings" within Note 13 – Commitments and Contingencies, as these costs do not reflect our core operating performance.
(8)The transfer of corporate expenditures represents amounts of projects managed by corporate for the benefit of specific entities within each segment. Once the projects are complete, all related costs are allocated from corporate to and paid by the appropriate entity and the associated assets are then depreciated at the entity level. The increase in 2023 relates to a project build in Suzhou, China.
Schedule of Restructuring Initiatives Restructuring Initiatives includes expense items for the years ended December 31, 2025, 2024 and 2023 as follows (see Note 21 – Restructuring Initiatives for further details):
In thousands
Year Ended December 31,202520242023
Restructuring Initiatives by Plan:
Optimization initiative$9,837 $13,019 $45,445 
Prior year initiatives (17)(441)
Total Restructuring Initiatives$9,837 $13,002 $45,004 
Restructuring Initiatives by Segment:
Pharma$1,080 $589 $4,852 
Beauty4,469 8,041 20,683 
Closures3,566 3,835 17,927 
Corporate & Other722 537 1,542 
Total Restructuring Initiatives$9,837 $13,002 $45,004 
Schedule of Net Sales and Long-Lived Asset Information by Geographic Area
The following are net sales and long-lived asset information by geographic area and product information for the years ended December 31, 2025, 2024 and 2023:
202520242023
Net Sales to Unaffiliated Customers (1):
United States$1,071,430 $1,037,968 $949,248 
Europe:
France513,281 499,795 541,333 
Germany163,913 169,891 160,812 
Italy201,895 180,101 200,817 
Spain195,405 171,779 175,101 
Other Europe788,065 748,302 727,662 
Total Europe1,862,559 1,769,868 1,805,725 
China194,406 155,502 146,026 
Other Foreign Countries648,786 619,552 586,451 
Total$3,777,181 $3,582,890 $3,487,450 
Property, Plant and Equipment, Net
United States$346,879 $349,255 $357,729 
Europe:
France590,775 527,570 550,738 
Germany266,695 229,637 225,860 
Italy51,178 44,087 42,240 
Other Europe96,765 66,546 63,864 
Total Europe1,005,413 867,840 882,702 
China165,598 105,613 112,017 
Other Foreign Countries158,589 124,442 125,615 
Total$1,676,479 $1,447,150 $1,478,063 
(1)Sales are attributed to countries based upon shipped to location.
v3.25.4
ACQUISITIONS (Tables)
12 Months Ended
Dec. 31, 2025
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Assets Acquired and Liabilities Assumed at Estimated Fair Value
The following table summarizes the assets acquired and liabilities assumed from the BTY acquisition as of the acquisition date at the estimated fair value.
2025
Assets
Cash and equivalents$8,908 
Accounts and notes receivable15,525 
Inventories13,042 
Prepaid and other935 
Buildings and improvements28,566 
Machinery and equipment26,223 
Goodwill71,709 
Intangible assets21,468 
Operating lease right-of-use assets610 
Other miscellaneous assets3,401 
Liabilities
Current maturities of long-term obligations, net of unamortized debt issuance costs27,724 
Accounts payable, accrued and other liabilities27,894 
Deferred income taxes4,718 
Operating lease liabilities610 
Long-term obligations, net of unamortized debt issuance costs10,936 
Deferred and other non-current liabilities781 
Net assets acquired$117,724 
Schedule of the Fair Value Estimates of the Acquired Identifiable Intangible Assets and Weighted-average Useful Lives as of the Acquisition Date
The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives for the BTY acquisition as of the acquisition date:
2025
Weighted-Average
Useful Life
(in years)
Estimated
Fair Value
of Asset
Acquired technology5.4$4,876 
Customer relationships14.411,145 
License agreements and other43.25,447 
Total$21,468 
v3.25.4
INVESTMENT IN EQUITY SECURITIES (Tables)
12 Months Ended
Dec. 31, 2025
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of Investments in Equity Securities
Our investment in equity securities consisted of the following:
December 31, 2025December 31, 2024
Equity Method Investments
Goldrain
$104,112 $96,667 
BTY 32,047 
Sonmol5,044 4,712 
Others5,392 948 
Other Investments
PureCycle2,503 2,986 
YAT5,433 5,206 
Others8,546 3,703 
$131,030 $146,269 
Schedule of Investment Company, Financial Highlights
We have sold the following PCT shares related to the PureCycle investment for the year ended December 31, 2023:
Shares SoldProceedsRealized Gain
2023510,449$5,604 $4,188 
Schedule of Net Investment Gain/Loss
For the years ended December 31, 2025, 2024 and 2023 we recorded the following net investment gain or loss on our investment in PureCycle:
202520242023
Net investment (loss) gain$(483)$1,713 $1,413 
v3.25.4
RESTRUCTURING INITIATIVES (Tables)
12 Months Ended
Dec. 31, 2025
Restructuring and Related Activities [Abstract]  
Schedule of Activity Associated with Optimization Initiative
As of December 31, 2025, we have recorded the following activity associated with our optimization initiative:
Beginning Reserve at December 31, 2024Net Charges for the Year Ended December 31, 2025Cash PaidInterest and
FX Impact
Ending Reserve at December 31, 2025
Employee severance$9,161 $2,350 $(7,830)$602 $4,283 
Professional fees and other costs796 7,487 (6,129)21 2,175 
Totals$9,957 $9,837 $(13,959)$623 $6,458 
As of December 31, 2024, we recorded the following activity associated with our optimization initiative:
Beginning Reserve at December 31, 2023Net Charges for the Year Ended December 31, 2024Cash PaidInterest and
FX Impact
Ending Reserve at December 31, 2024
Employee severance$27,078 $6,562 $(23,791)$(688)$9,161 
Professional fees and other costs2,810 6,457 (8,559)88 796 
Totals$29,888 $13,019 $(32,350)$(600)$9,957 
v3.25.4
REDEEMABLE NONCONTROLLING INTERESTS (Tables)
12 Months Ended
Dec. 31, 2025
Temporary Equity Disclosure [Abstract]  
Schedule of Rollforward Redeemable Noncontrolling Interest
The following table presents a roll forward of the redeemable noncontrolling interests for the year ended December 31, 2025:
2025
Balance at January 1$— 
Acquisition of redeemable noncontrolling interests23,607 
Additional contributions703 
Net loss attributable to redeemable noncontrolling interests(86)
Foreign currency adjustments2,020 
Balance at December 31$26,244 
v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ / shares in Units, shares in Thousands
3 Months Ended 12 Months Ended
Jul. 28, 2025
company
Sep. 30, 2025
company
Dec. 31, 2025
USD ($)
segment
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2023
USD ($)
shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Number of reportable segments | segment     3    
Accounts and note receivable     $ 803,830,000 $ 658,057,000  
Accounts and notes receivable, less current expected credit loss     17,732,000 15,785,000  
Dividends received from affiliates     $ 0 $ 0 $ 0
Common stock repurchased (retired and held in treasury) (in shares) | shares     2,700 433 399
Common stock, par value (in dollars per share) | $ / shares     $ 0.01 $ 0.01  
Research and development expenses incurred net of customer funded research and development or government research and development credits     $ 105,100,000 $ 96,100,000 $ 92,800,000
Foreign currency transaction loss     (2,900,000) (2,000,000.0) (7,300,000)
Supplier chain finance program, obligation     $ 31,956,000 $ 34,401,000 $ 36,309,000
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]     Accounts payable, accrued and other liabilities    
Foreign Tax Jurisdiction          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Foreign earnings to be repatriated     $ 160,000,000    
BTY          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Ownership percentage 20.00% 20.00%      
BTY Acquisition          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Number of related companies | company 3 3      
Maximum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Supplier finance program payment terms     120 days    
Maximum | Finite-Lived Intangible Assets          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Finite-lived intangible asset, useful life (in years)     50 years    
Maximum | Buildings and improvements          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Estimated useful lives (in years)     40 years    
Maximum | Machinery and equipment          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Estimated useful lives (in years)     15 years    
Minimum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Supplier finance program payment terms     60 days    
Minimum | Finite-Lived Intangible Assets          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Finite-lived intangible asset, useful life (in years)     1 year    
Minimum | Buildings and improvements          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Estimated useful lives (in years)     10 years    
Minimum | Machinery and equipment          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Estimated useful lives (in years)     3 years    
Argentina | Consolidated net revenues | Geographic concentration risk | Maximum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Concentration risk     1.10%    
Argentina | Consolidated net assets | Geographic concentration risk | Maximum          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Concentration risk     0.40%    
v3.25.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supply Chain Finance (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
SCF [Roll Forward]    
SCF obligations outstanding at the beginning of the year $ 34,401 $ 36,309
Additions 161,090 160,847
Settlements (163,535) (162,755)
SCF obligations outstanding at the end of the year $ 31,956 $ 34,401
v3.25.4
REVENUE - Schedule of Revenue by Segment by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
REVENUE      
Net Sales $ 3,777,181 $ 3,582,890 $ 3,487,450
Pharma      
REVENUE      
Net Sales 1,737,481 1,643,152 1,520,993
Beauty      
REVENUE      
Net Sales 1,309,437 1,225,730 1,267,697
Closures      
REVENUE      
Net Sales 730,263 714,008 698,760
Europe      
REVENUE      
Net Sales 1,862,559 1,769,868 1,805,725
Europe | Pharma      
REVENUE      
Net Sales 833,146 806,606 779,929
Europe | Beauty      
REVENUE      
Net Sales 795,903 745,198 806,963
Europe | Closures      
REVENUE      
Net Sales 233,510 218,064 218,833
Domestic      
REVENUE      
Net Sales 1,174,302 1,145,490 1,051,132
Domestic | Pharma      
REVENUE      
Net Sales 601,861 556,642 495,057
Domestic | Beauty      
REVENUE      
Net Sales 230,049 241,115 219,760
Domestic | Closures      
REVENUE      
Net Sales 342,392 347,733 336,315
Latin America      
REVENUE      
Net Sales 296,405 286,192 289,183
Latin America | Pharma      
REVENUE      
Net Sales 48,752 47,124 52,074
Latin America | Beauty      
REVENUE      
Net Sales 163,880 155,692 152,963
Latin America | Closures      
REVENUE      
Net Sales 83,773 83,376 84,146
Asia      
REVENUE      
Net Sales 443,915 381,340 341,410
Asia | Pharma      
REVENUE      
Net Sales 253,722 232,780 193,933
Asia | Beauty      
REVENUE      
Net Sales 119,605 83,725 88,011
Asia | Closures      
REVENUE      
Net Sales $ 70,588 $ 64,835 $ 59,466
v3.25.4
REVENUE - Schedule of Contract Assets and Contract Liabilities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]    
Contract asset (current) $ 11,600 $ 12,571
Increase / (decrease) in contract asset (current) (971)  
Contract liability (current) 74,827 64,425
Increase / (decrease) in contract liability (current) 10,402  
Contract liability (long-term) 49,901 $ 40,551
Increase / (decrease) in contract liability (long-term) 9,350  
Revenue recognized previously included in current contract liabilities 162,100  
Revenue recognized previously included in current contract liabilities at the beginning of the year $ 60,900  
v3.25.4
INVENTORIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Inventories, by component    
Raw materials $ 152,574 $ 133,885
Work in process 194,176 161,350
Finished goods 191,095 166,572
Total $ 537,845 $ 461,807
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Changes in the carrying amount of goodwill    
Goodwill beginning balance $ 936,256 $ 963,418
Acquisition 85,580  
Foreign currency exchange effects 56,062 (27,162)
Goodwill ending balance 1,077,898 936,256
Operating Segments | Pharma    
Changes in the carrying amount of goodwill    
Goodwill beginning balance 488,234 508,447
Acquisition 9,397  
Foreign currency exchange effects 41,072 (20,213)
Goodwill ending balance 538,703 488,234
Operating Segments | Beauty    
Changes in the carrying amount of goodwill    
Goodwill beginning balance 281,286 287,097
Acquisition 76,183  
Foreign currency exchange effects 13,379 (5,811)
Goodwill ending balance 370,848 281,286
Operating Segments | Closures    
Changes in the carrying amount of goodwill    
Goodwill beginning balance 166,736 167,874
Acquisition 0  
Foreign currency exchange effects 1,611 (1,138)
Goodwill ending balance $ 168,347 $ 166,736
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Amortized intangible assets:      
Impairment of goodwill $ 0 $ 0 $ 0
Payments to acquire intangible assets 5,020,000 17,709,000 6,061,000
Aggregate amortization expense 45,051,000 $ 44,117,000 $ 44,720,000
Business Combination, Series of Individually Immaterial Business Combinations      
Amortized intangible assets:      
Payments to acquire intangible assets 31,200,000    
Customer relationships | Business Combination, Series of Individually Immaterial Business Combinations      
Amortized intangible assets:      
Payments to acquire intangible assets 17,400,000    
Acquired technology | Business Combination, Series of Individually Immaterial Business Combinations      
Amortized intangible assets:      
Payments to acquire intangible assets 7,200,000    
Other Intangible Assets | Business Combination, Series of Individually Immaterial Business Combinations      
Amortized intangible assets:      
Payments to acquire intangible assets $ 6,600,000    
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Amortized intangible assets:    
Gross Carrying Amount $ 588,282 $ 528,479
Accumulated Amortization (332,943) (273,710)
Net Value $ 255,339 254,769
Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 14 years  
Patents    
Amortized intangible assets:    
Gross Carrying Amount $ 19,032 18,333
Accumulated Amortization (4,016) (2,343)
Net Value $ 15,016 15,990
Patents | Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 13 years  
Acquired technology    
Amortized intangible assets:    
Gross Carrying Amount $ 157,350 137,444
Accumulated Amortization (99,551) (80,171)
Net Value $ 57,799 57,273
Acquired technology | Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 10 years 8 months 12 days  
Customer relationships    
Amortized intangible assets:    
Gross Carrying Amount $ 332,088 303,502
Accumulated Amortization (177,686) (145,772)
Net Value $ 154,402 157,730
Customer relationships | Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 13 years 10 months 24 days  
Trademarks and trade names    
Amortized intangible assets:    
Gross Carrying Amount $ 46,885 42,882
Accumulated Amortization (41,726) (36,450)
Net Value $ 5,159 6,432
Trademarks and trade names | Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 7 years 1 month 6 days  
License agreements and other    
Amortized intangible assets:    
Gross Carrying Amount $ 32,927 26,318
Accumulated Amortization (9,964) (8,974)
Net Value $ 22,963 $ 17,344
License agreements and other | Weighted Average    
Amortized intangible assets:    
Weighted Average Amortization Period (Years) 25 years 2 months 12 days  
v3.25.4
GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Future Estimated Amortization Expense (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2026 $ 45,384
2027 38,615
2028 33,964
2029 33,018
2030 29,568
2031 and thereafter $ 74,790
v3.25.4
ACCOUNTS PAYABLE, ACCRUED AND OTHER LIABILITIES (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Accounts payable, principally trade $ 340,563 $ 295,967
Accrued employee compensation costs 232,595 211,441
Customer deposits and other unearned income 74,827 64,425
Other accrued liabilities 174,928 158,163
Total $ 822,913 $ 729,996
v3.25.4
INCOME TAXES - Provision (Benefit) for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income before income taxes:      
United States $ 135,913 $ 99,573 $ 49,681
International 355,465 370,192 325,144
Income before Income Taxes 491,378 469,765 374,825
Current tax expense (benefit):      
U.S. Federal 6,726 10,933 11,777
U.S. State and Local 3,735 2,744 1,300
International 100,109 103,316 97,455
Total current tax expense (benefit) 110,570 116,993 110,532
Deferred tax expense (benefit):      
U.S. Federal 12,040 (8,936) (10,931)
U.S. State and Local 889 (923) (675)
International (24,618) (11,547) (8,277)
Total deferred tax expense (benefit) (11,689) (21,406) (19,883)
Total income tax expense (benefit):      
U.S. Federal 18,766 1,997 846
U.S. State and Local 4,624 1,821 625
International 75,491 91,769 89,178
Actual income tax provision $ 98,881 $ 95,587 $ 90,649
v3.25.4
INCOME TAXES - Effective Income Tax Reconciliation - Current Year (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Amount      
Provision for Income taxes at U.S. federal statutory rate $ 103,189 $ 98,651 $ 78,713
Tax credits (2,115)    
Excess benefits from share-based compensation (2,804) (11,041) (5,935)
Other 382    
Cross border tax laws (3,045)    
Changes in valuation allowance   (14,625) 158
Other   (2,885) (1,684)
Domestic state and local income taxes, net of federal effect, and municipal taxes   1,439 362
Rate differential   21,357 18,917
Worldwide changes in unrecognized tax benefits (2,135)    
Actual income tax provision $ 98,881 $ 95,587 $ 90,649
Percent      
Provision for Income taxes at U.S. federal statutory rate 21.00%    
Excess benefits from share-based compensation (0.60%)    
Tax credits (0.40%)    
Other 0.10%    
Cross border tax laws (0.60%)    
Worldwide changes in unrecognized tax benefits (0.40%)    
Effective income tax rate 20.10% 20.30% 24.20%
United States      
Amount      
Changes in valuation allowance $ (300)    
Other 313    
Domestic state and local income taxes, net of federal effect, and municipal taxes $ 3,179    
Percent      
Changes in valuation allowance (0.10%)    
Other 0.10%    
Domestic state and local income taxes, net of federal effect, and municipal taxes 0.60%    
France      
Amount      
Other $ 2,256    
Rate differential $ 8,114    
Percent      
Other 0.50%    
Rate differential 1.70%    
Germany      
Amount      
Other $ (7,380)    
Domestic state and local income taxes, net of federal effect, and municipal taxes $ 12,781    
Percent      
Other (1.50%)    
Domestic state and local income taxes, net of federal effect, and municipal taxes 2.60%    
Brazil      
Amount      
Changes in valuation allowance $ (8,300)    
Other $ 262    
Percent      
Changes in valuation allowance (1.70%)    
Other 0.10%    
China      
Amount      
Other $ (2,129)    
Equity investment remeasurement gain $ (5,394)    
Percent      
Other (0.40%)    
Equity investment remeasurement gain (1.10%)    
Other Foreign Jurisdictions      
Amount      
Rate differential $ 2,007    
Percent      
Rate differential 0.20%    
v3.25.4
INCOME TAXES - Effective Income Tax Reconciliation - Prior Years (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]      
Income tax at statutory rate $ 103,189 $ 98,651 $ 78,713
State income taxes, net of federal tax effect   1,439 362
Excess benefits from share-based compensation (2,804) (11,041) (5,935)
Deferred tax (benefits) charges, incl. tax rate changes   2,691 (3,512)
Valuation allowance   (14,625) 158
Legal entity reorganization   0 3,630
Rate differential on earnings of foreign operations   21,357 18,917
Other   (2,885) (1,684)
Actual income tax provision $ 98,881 $ 95,587 $ 90,649
Effective income tax rate 20.10% 20.30% 24.20%
v3.25.4
INCOME TAXES - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Valuation Allowance [Line Items]        
Effective income tax rate 20.10% 20.30% 24.20%  
Legal entity reorganization   $ 0 $ 3,630  
Excess benefits from share-based compensation $ (2,804) (11,041) (5,935)  
Income taxes paid 179,351 89,400 112,000  
Deferred tax assets, valuation allowance 56,465 61,134    
Net operating loss carryforwards 82,593 72,766    
Tax-effected net operating loss subject to expiration 9,800      
Tax-effected net operating loss carryforwards not subject to expiration 72,800      
Unrecognized tax benefits 8,930 5,792 5,942 $ 6,919
Unrecognized tax benefits, income tax penalties and interest accrued 4,000 3,600 3,400  
Unrecognized tax benefits, income tax penalties and interest expense 400 200 $ 200  
State and Local Jurisdiction        
Valuation Allowance [Line Items]        
Tax-effected net operating loss subject to expiration 7,000      
Foreign Tax Jurisdiction        
Valuation Allowance [Line Items]        
Foreign earnings to be repatriated 160,000      
Foreign Tax Jurisdiction | Minimum        
Valuation Allowance [Line Items]        
Estimated additional tax payable on previously unremitted earnings 20,000      
Foreign Tax Jurisdiction | Maximum        
Valuation Allowance [Line Items]        
Estimated additional tax payable on previously unremitted earnings 25,000      
Deferred tax assets for specified locations        
Valuation Allowance [Line Items]        
Deferred tax assets, valuation allowance 51,200      
Deferred tax assets related to tax credit carryforwards, U.S. state        
Valuation Allowance [Line Items]        
Deferred tax assets, valuation allowance $ 5,000      
Luxembourg        
Valuation Allowance [Line Items]        
Tax benefit from revised assessment of tax losses   $ (11,000)    
v3.25.4
INCOME TAXES - Schedule of Income Taxes Paid (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Valuation Allowance [Line Items]      
U.S. Federal $ 28,166    
U.S. State and Local 5,407    
Total Foreign 145,778    
Total income taxes paid 179,351 $ 89,400 $ 112,000
France      
Valuation Allowance [Line Items]      
Total Foreign 55,539    
Germany - Federal      
Valuation Allowance [Line Items]      
Total Foreign 32,445    
Germany - Muni      
Valuation Allowance [Line Items]      
Total Foreign 27,943    
Other      
Valuation Allowance [Line Items]      
Total Foreign 29,851    
U.S | Transferable, Non-Refundable U.S. Energy Credits      
Valuation Allowance [Line Items]      
Total income taxes paid $ 17,500    
v3.25.4
INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Deferred Tax Assets:    
Net operating loss carryforwards $ 82,593 $ 72,766
Operating and finance leases 22,077 21,712
Share-based compensation 11,061 3,747
Vacation and bonus 15,979 16,223
U.S. capitalized research expenditures 41,338 41,956
Accrued liabilities and other reserves 10,324 9,598
Other 35,589 33,931
Total gross deferred tax assets 218,961 199,933
Less valuation allowance (56,465) (61,134)
Net deferred tax assets 162,496 138,799
Deferred Tax Liabilities:    
Acquisition related intangibles 52,023 51,155
Depreciation and amortization 26,489 21,325
Operating and finance leases 22,408 22,672
Other 7,169 8,059
Total gross deferred tax liabilities 108,089 103,211
Net deferred tax assets $ 54,407 $ 35,588
v3.25.4
INCOME TAXES - Reconciliation of Income Tax Uncertainties (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Reconciliation of the beginning and ending amount of income tax uncertainties      
Balance at the beginning of period $ 5,792 $ 5,942 $ 6,919
Increases based on tax positions for the current year 400 300 985
Increases based on tax positions of prior years 3,759 107  
Decreases based on tax positions of prior years     (997)
Settlements (301) (127) (901)
Lapse of statute of limitations (720) (430) (64)
Balance at the end of period $ 8,930 $ 5,792 $ 5,942
v3.25.4
DEBT - Schedule of Short-term Debt Obligations (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Short-term Debt [Line Items]    
Short-term obligations $ 183,947 $ 176,035
Short-term obligations 1.50% to 3.00%    
Short-term Debt [Line Items]    
Short-term obligations $ 31,314 0
Short-term obligations 1.50% to 3.00% | Minimum    
Short-term Debt [Line Items]    
Interest rate 1.50%  
Short-term obligations 1.50% to 3.00% | Maximum    
Short-term Debt [Line Items]    
Interest rate 3.00%  
Revolving credit facility 2.96%    
Short-term Debt [Line Items]    
Interest rate 2.96%  
Short-term obligations $ 152,633 $ 176,035
v3.25.4
DEBT - Narrative (Details)
€ in Millions
12 Months Ended
Dec. 16, 2025
USD ($)
Sep. 05, 2024
USD ($)
Jul. 19, 2024
EUR (€)
Jul. 02, 2024
USD ($)
extension
Feb. 26, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2025
EUR (€)
Nov. 20, 2025
USD ($)
Dec. 31, 2024
EUR (€)
Debt Instrument [Line Items]                    
Short-term borrowing           $ 183,947,000 $ 176,035,000      
Money Market Borrowing Arrangement                    
Debt Instrument [Line Items]                    
Short-term borrowing           0 0      
Short-term borrowing, maximum borrowing capacity           30,000,000        
Short-term obligations 1.50% to 3.00%                    
Debt Instrument [Line Items]                    
Short-term borrowing           $ 31,314,000 0      
Short-term obligations 1.50% to 3.00% | Minimum                    
Debt Instrument [Line Items]                    
Interest rate           1.50%        
Short-term obligations 1.50% to 3.00% | Maximum                    
Debt Instrument [Line Items]                    
Interest rate           3.00%        
Amended Revolving Credit Facility Maturing In July 2029                    
Debt Instrument [Line Items]                    
Line of credit facility, maximum borrowing capacity       $ 600,000,000.0            
Line of credit facility, increase limit       $ 300,000,000.0            
Line of credit facility, number of extensions | extension       2            
Line of credit facility, duration of extension (in years)       1 year            
Compensating balance, amount           $ 0        
Amended Revolving Credit Facility Maturing In July 2029 | Subsidiaries                    
Debt Instrument [Line Items]                    
Long-term line of credit           0 0      
Amended Revolving Credit Facility Maturing In July 2029 | Revolving Credit Facility                    
Debt Instrument [Line Items]                    
Long-term line of credit           152,600,000 176,000,000.0 € 130.0   € 170.0
Unsecured Lines Of Credit                    
Debt Instrument [Line Items]                    
Interest and fees           10,100,000 9,500,000      
Line of credit facility, average outstanding amount           $ 237,700,000 $ 170,600,000      
Short-term debt, weighted average interest rate, over time           3.90% 5.10%      
Senior Unsecured Notes 4.75 Percent Due 2031                    
Debt Instrument [Line Items]                    
Debt instrument, face amount                 $ 600,000,000  
Interest rate on notes (as a percent)           4.80%   4.80% 4.75%  
Long-term debt, gross           $ 599,512,000 $ 0      
Senior unsecured notes 3.6%, due in 2025                    
Debt Instrument [Line Items]                    
Interest rate on notes (as a percent)           3.60%   3.60%    
Debt instrument, repaid $ 125,000,000                  
Long-term debt, gross           $ 0 125,000,000      
Senior Unsecured Notes 3.49 Percent Due In 2024                    
Debt Instrument [Line Items]                    
Interest rate on notes (as a percent)         3.49%          
Debt instrument, repaid         $ 100,000,000          
Senior Unsecured Notes 1.17 Percent Due In 2024                    
Debt Instrument [Line Items]                    
Interest rate on notes (as a percent)     1.17%              
Debt instrument, repaid | €     € 200.0              
Senior Unsecured Notes 3.4 Percent Due In September 2024                    
Debt Instrument [Line Items]                    
Interest rate on notes (as a percent)   3.40%                
Debt instrument, repaid   $ 50,000,000                
Term loan 4.9% floating, due in 2027                    
Debt Instrument [Line Items]                    
Interest rate on notes (as a percent)           4.90%   4.90%    
Long-term debt, gross           $ 141,100,000 $ 166,000,000      
v3.25.4
DEBT - Schedule of Long-Term Obligations (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Nov. 20, 2025
Dec. 31, 2024
Jul. 06, 2022
Debt Instrument [Line Items]        
Finance Lease Liabilities $ 25,339   $ 23,753  
Unamortized debt issuance costs (8,346)   (3,830)  
Long-term debt and lease obligation, including current maturities 1,299,017   850,316  
Current maturities of long-term obligations (159,584)   (162,250)  
Total long-term obligations 1,139,433   688,066  
Notes payable 0.00% – 8.35%, due in monthly and annual installments through 2035        
Debt Instrument [Line Items]        
Long-term debt, gross $ 17,051   15,135  
Notes payable 0.00% – 8.35%, due in monthly and annual installments through 2035 | Minimum        
Debt Instrument [Line Items]        
Interest rate on notes 0.00%      
Notes payable 0.00% – 8.35%, due in monthly and annual installments through 2035 | Maximum        
Debt Instrument [Line Items]        
Interest rate on notes 8.35%      
Senior unsecured notes 3.6%, due in 2025        
Debt Instrument [Line Items]        
Long-term debt, gross $ 0   125,000  
Interest rate on notes 3.60%      
Senior unsecured notes 3.6%, due in 2026        
Debt Instrument [Line Items]        
Long-term debt, gross $ 125,000   125,000  
Interest rate on notes 3.60%      
Term loan 4.9% floating, due in 2027        
Debt Instrument [Line Items]        
Long-term debt, gross $ 141,100   166,000  
Interest rate on notes 4.90%      
Senior unsecured notes 4.8%, due in 2031, net of discount of $0.5 million        
Debt Instrument [Line Items]        
Long-term debt, gross $ 599,512   0  
Interest rate on notes 4.80% 4.75%    
Debt instrument, discount $ 500      
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.6 million        
Debt Instrument [Line Items]        
Long-term debt, gross $ 399,361   $ 399,258  
Interest rate on notes 3.60%     3.60%
Debt instrument, discount $ 600      
v3.25.4
DEBT - Schedule of Long-Term Maturities (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
Debt Disclosure [Abstract]  
2026 $ 156,528
2027 116,565
2028 959
2029 109
2030 55
Thereafter $ 1,007,808
v3.25.4
DEBT - Schedule of Covenants on Revolving Credit Facility and Corporate Long-term Obligations (Details)
Dec. 31, 2025
Line of Credit Facility [Line Items]  
Consolidated Leverage Ratio 1.38
Consolidated Interest Coverage Ratio 15.07
Maximum  
Line of Credit Facility [Line Items]  
Consolidated Leverage Ratio 3.50
Minimum  
Line of Credit Facility [Line Items]  
Consolidated Interest Coverage Ratio 3.00
v3.25.4
LEASE COMMITMENTS - Schedule of Components of Lease Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Components of lease expense:    
Operating lease cost $ 22,714 $ 20,061
Finance lease cost:    
Amortization of right-of-use assets 7,778 6,803
Interest on lease liabilities 1,226 1,192
Total finance lease cost 9,004 7,995
Short-term lease and variable lease costs $ 21,938 $ 20,149
v3.25.4
LEASE COMMITMENTS - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 22,387 $ 20,376
Operating cash flows from finance leases 1,367 1,289
Financing cash flows from finance leases 3,706 3,054
Right-of-use assets obtained in exchange for lease obligations:    
Operating leases 12,135 33,726
Finance leases $ 4,791 $ 1,705
v3.25.4
LEASE COMMITMENTS - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Operating Leases    
Operating lease right-of-use assets $ 65,698 $ 64,213
Accounts payable, accrued and other liabilities 17,745 17,015
Operating lease liabilities 47,940 49,716
Total operating lease liabilities $ 65,685 $ 66,731
Operating lease, liability, current, Statement of Financial Position [Extensible List] Accounts payable, accrued and other liabilities Accounts payable, accrued and other liabilities
Finance Leases    
Property, plant and equipment, gross $ 57,610 $ 50,319
Accumulated depreciation (28,588) (20,103)
Property, plant and equipment, net 29,022 30,216
Current maturities of long-term obligations, net of unamortized debt issuance cost 3,303 3,563
Long-term obligations, net of unamortized debt issuance cost 22,036 20,190
Total finance lease liabilities $ 25,339 $ 23,753
Finance lease, right-of-use asset, Statement of Financial Position [Extensible List] Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization
Finance lease, liability, current, Statement of Financial Position [Extensible List] Long-Term Debt and Lease Obligation, Current Long-Term Debt and Lease Obligation, Current
Finance lease, liability, noncurrent, Statement of Financial Position [Extensible List] Long-Term Obligations, net of unamortized debt issuance costs Long-Term Obligations, net of unamortized debt issuance costs
Weighted Average Remaining Lease Term (in years)    
Operating leases 5 years 1 month 6 days 4 years 8 months 12 days
Finance leases 4 years 9 months 18 days 4 years 10 months 24 days
Weighted Average Discount Rate    
Operating leases 5.69% 5.77%
Finance leases 4.95% 5.12%
v3.25.4
LEASE COMMITMENTS - Schedule of Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Operating Leases    
Year 1 $ 20,903  
Year 2 17,176  
Year 3 11,020  
Year 4 7,750  
Year 5 5,510  
Thereafter 17,000  
Total lease payments 79,359  
Less imputed interest (13,674)  
Total operating lease liabilities 65,685 $ 66,731
Finance Leases    
Year 1 4,532  
Year 2 7,727  
Year 3 2,994  
Year 4 8,015  
Year 5 1,098  
Thereafter 4,532  
Total lease payments 28,898  
Less imputed interest (3,559)  
Total finance lease liabilities $ 25,339 $ 23,753
v3.25.4
LEASE COMMITMENTS - Narrative (Details)
Dec. 31, 2025
USD ($)
Operating Leased Assets [Line Items]  
Unconditional purchase commitment $ 56,200,000
Minimum  
Operating Leased Assets [Line Items]  
Lessee, operating lease, lease not yet commenced, term of contract 3 years
Maximum  
Operating Leased Assets [Line Items]  
Lessee, operating lease, lease not yet commenced, term of contract 4 years
Operating Lease, Lease Not yet Commenced  
Operating Leased Assets [Line Items]  
Unconditional purchase commitment $ 300,000
Financing Lease, Lease Not yet Commenced  
Operating Leased Assets [Line Items]  
Unconditional purchase commitment $ 0
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Changes in the Benefit Obligations and Plan Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
United States      
Change in benefit obligation:      
Benefit obligation at beginning of year $ 175,194 $ 186,013  
Service cost 7,931 9,462 $ 9,638
Interest cost 9,563 8,968 8,631
Plan Amendment 0 0  
Curtailment/Settlement 0 0  
Actuarial (gain) loss 2,699 (18,156)  
Benefits paid (13,726) (11,093)  
Foreign currency translation adjustment (loss) gain 0 0  
Benefit obligation at end of year 181,661 175,194 186,013
Change in plan assets:      
Fair value of plan assets at beginning of year 180,761 173,735  
Actual return on plan assets 24,437 17,624  
Employer contribution 10,898 495  
Benefits paid (13,726) (11,093)  
Foreign currency translation adjustment 0 0  
Fair value of plan assets at end of year 202,370 180,761 173,735
Funded status at end of year 20,709 5,567  
Foreign Plans      
Change in benefit obligation:      
Benefit obligation at beginning of year 104,196 104,757  
Service cost 6,711 6,492 5,915
Interest cost 3,868 3,488 3,642
Plan Amendment 0 (17)  
Curtailment/Settlement (1,298) (1,385)  
Actuarial (gain) loss (7,600) 1,370  
Benefits paid (3,798) (3,776)  
Foreign currency translation adjustment (loss) gain 13,466 (6,733)  
Benefit obligation at end of year 115,545 104,196 104,757
Change in plan assets:      
Fair value of plan assets at beginning of year 71,250 72,434  
Actual return on plan assets 942 3,605  
Employer contribution 1,431 3,580  
Benefits paid (3,798) (3,776)  
Foreign currency translation adjustment 9,392 (4,593)  
Fair value of plan assets at end of year 79,217 71,250 $ 72,434
Funded status at end of year $ (36,328) $ (32,946)  
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Funded Status Amounts (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
United States    
Changes in the benefit obligations and plan assets    
Non-current assets $ 36,881 $ 19,739
Current liabilities (670) (546)
Non-current liabilities (15,502) (13,626)
Funded status amount 20,709 5,567
Foreign Plans    
Changes in the benefit obligations and plan assets    
Non-current assets 3,668 3,648
Current liabilities (111) (46)
Non-current liabilities (39,885) (36,548)
Funded status amount $ (36,328) $ (32,946)
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Components of Periodic Benefit Cost (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
United States    
Changes in the benefit obligations and plan assets    
Net actuarial (gain) loss $ (30,065) $ (21,495)
Net prior service cost 0 0
Tax effects 8,797 6,713
Net amount recognized (21,268) (14,782)
Foreign Plans    
Changes in the benefit obligations and plan assets    
Net actuarial (gain) loss 8,462 16,201
Net prior service cost (616) (531)
Tax effects (4,659) (6,413)
Net amount recognized $ 3,187 $ 9,257
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Changes in Benefit Obligations and Plan Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
United States      
Changes in the benefit obligations and plan assets      
Current year actuarial gain (loss) $ 9,058 $ 23,318 $ (5,161)
Amortization of net loss (488) 0 0
Net amount recognized 8,570 23,318 (5,161)
Foreign Plans      
Changes in the benefit obligations and plan assets      
Current year actuarial gain (loss) 6,370 (47) (5,315)
Current year prior service cost 0 20 1,135
Transfer Prior service Cost (16) 0 0
Transfer actuarial gain (loss) 121 (694) 124
Amortization of net loss 1,248 201 914
Amortization of prior service cost 101 349 177
Net amount recognized $ 7,824 $ (171) $ (2,966)
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Changes in the benefit obligations and plan assets      
Curtailment $ (115) $ (1,851) $ 0
United States      
Changes in the benefit obligations and plan assets      
Service cost 7,931 9,462 9,638
Interest cost 9,563 8,968 8,631
Expected return on plan assets (12,743) (12,463) (12,378)
Amortization of net (gain) loss (488) 0 0
Net periodic benefit cost 4,263 5,967 5,891
Foreign Plans      
Changes in the benefit obligations and plan assets      
Service cost 6,711 6,492 5,915
Interest cost 3,868 3,488 3,642
Expected return on plan assets (2,440) (2,243) (2,340)
Amortization of net (gain) loss 1,248 201 914
Amortization of prior service cost 101 349 177
Net periodic benefit cost 9,488 8,287 8,308
Curtailment (1,197) (2,205) (1)
Total Net periodic benefit cost $ 8,291 $ 6,082 $ 8,307
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Changes in the benefit obligations and plan assets      
Curtailment gain related to restructuring initiatives $ 115 $ 1,851 $ 0
United States      
Changes in the benefit obligations and plan assets      
Accumulated benefit obligation 168,500 163,400  
Employer contribution 10,898 495  
Total contributions by company $ 5,400 5,000 5,000
United States | Aptar Retirement Savings Account      
Changes in the benefit obligations and plan assets      
Employer matching contribution as a percentage of salary 5.00%    
Total contributions by company $ 4,200 3,300 2,700
United States | Maximum      
Changes in the benefit obligations and plan assets      
Employer matching contribution as a percentage of salary 3.00%    
United States | Pension Plan      
Changes in the benefit obligations and plan assets      
Employer contribution $ 10,000    
United States | Supplemental Employee Retirement Plan      
Changes in the benefit obligations and plan assets      
Contribution for SERP plan 900    
Expected contribution to SERP plans in next fiscal year 700    
United States | Other Plans      
Changes in the benefit obligations and plan assets      
Liability, defined benefit plan $ 16,200 14,200  
United States | Equity securities      
Changes in the benefit obligations and plan assets      
Target allocation percentage 64.00%    
United States | Fixed income securities and infrastructure      
Changes in the benefit obligations and plan assets      
Target allocation percentage 36.00%    
Foreign Plans      
Changes in the benefit obligations and plan assets      
Curtailment gain related to restructuring initiatives $ 1,197 2,205 1
Accumulated benefit obligation 90,600 80,200  
Employer contribution 1,431 3,580  
Expected contribution to defined benefit plan in next fiscal year 1,600    
Total contributions by company $ 3,200 $ 3,000 $ 3,100
Foreign Plans | Investment Funds      
Changes in the benefit obligations and plan assets      
Target allocation percentage 100.00%    
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Benefit Obligation (“PBO”), ABO, and Fair Value of Plan Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
United States    
Changes in the benefit obligations and plan assets    
Projected benefit obligation $ 16,173 $ 14,172
Accumulated benefit obligation 14,226 12,412
Fair value of plan assets 0 0
Foreign Plans    
Changes in the benefit obligations and plan assets    
Projected benefit obligation 87,278 77,645
Accumulated benefit obligation 62,608 54,460
Fair value of plan assets $ 47,410 $ 41,238
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of PBO, ABO and Fair Value of Plan Assets for All Pension Plans with a PBO in Excess of Plan Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
United States    
Changes in the benefit obligations and plan assets    
Projected benefit obligation $ 16,173 $ 14,172
Accumulated benefit obligation 14,226 12,412
Fair value of plan assets 0 0
Foreign Plans    
Changes in the benefit obligations and plan assets    
Projected benefit obligation 87,278 81,273
Accumulated benefit obligation 62,608 57,494
Fair value of plan assets $ 47,410 $ 44,676
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Weighted-Average Assumptions (Details)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
United States      
Weighted-average assumptions used to determine benefit obligations      
Discount rate 5.63% 5.60% 4.95%
Rate of compensation increase 3.27% 3.24% 3.24%
Weighted-average assumptions used to determine net periodic benefit cost      
Discount rate 5.60% 4.95% 5.15%
Expected long-term return on plan assets 7.00% 7.00% 7.00%
Rate of compensation increase 3.27% 3.24% 3.20%
Foreign Plans      
Weighted-average assumptions used to determine benefit obligations      
Discount rate 3.90% 3.33% 3.20%
Rate of compensation increase 3.20% 3.21% 3.20%
Weighted-average assumptions used to determine net periodic benefit cost      
Discount rate 3.30% 3.32% 3.69%
Expected long-term return on plan assets 3.23% 3.22% 3.23%
Rate of compensation increase 3.20% 3.21% 3.20%
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Pension Plan Weighted-Average Asset Allocations (Details)
Dec. 31, 2025
Dec. 31, 2024
United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 100.00% 100.00%
Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 100.00% 100.00%
Equity securities | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 50.00% 50.00%
Equity securities | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 2.00% 3.00%
Fixed income securities | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 25.00% 25.00%
Fixed income securities | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 1.00% 1.00%
Corporate debt securities | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
Corporate debt securities | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 3.00% 2.00%
Infrastructure | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 7.00% 8.00%
Infrastructure | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
Hedge funds | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 11.00% 11.00%
Hedge funds | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
Money market | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 3.00% 2.00%
Money market | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
Investment Funds | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
Investment Funds | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 94.00% 94.00%
Real estate | United States    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 4.00% 4.00%
Real estate | Foreign Plans    
Changes in the benefit obligations and plan assets    
Plan assets, actual allocation percentage 0.00% 0.00%
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Fair Value Measurement (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
United States      
Changes in the benefit obligations and plan assets      
Total investments $ 202,370 $ 180,761 $ 173,735
Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 79,217 71,250 $ 72,434
Fair Value, Inputs, Level 1, 2 and 3 | United States      
Changes in the benefit obligations and plan assets      
Total investments 129,778 109,814  
Fair Value, Inputs, Level 1, 2 and 3 | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 79,217 71,250  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 5,240 3,054  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | United States | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | United States | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | United States | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 659 275  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Foreign Plans | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Foreign Plans | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Cash and Short Term Securities | Foreign Plans | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 91,509 78,234  
Fair Value, Inputs, Level 1, 2 and 3 | Equity securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 1,205 1,873  
Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | U.S. Large Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | U.S. Small Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | International Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | International Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 33,029 28,526  
Fair Value, Inputs, Level 1, 2 and 3 | Fixed income securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 586 562  
Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Corporate debt securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 2,029 1,213  
Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Euro Corporate Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Investment Funds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 74,738 67,327  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds in Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Fair Value, Inputs, Level 1, 2 and 3 | Mutual Funds Diversified | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | United States      
Changes in the benefit obligations and plan assets      
Total investments 129,778 109,814  
Level 1 | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 27,831 28,300  
Level 1 | Cash and Short Term Securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 5,240 3,054  
Level 1 | Cash and Short Term Securities | United States | USD      
Changes in the benefit obligations and plan assets      
Total investments 5,240 3,054  
Level 1 | Cash and Short Term Securities | United States | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Cash and Short Term Securities | United States | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Cash and Short Term Securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 659 275  
Level 1 | Cash and Short Term Securities | Foreign Plans | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Cash and Short Term Securities | Foreign Plans | EUR      
Changes in the benefit obligations and plan assets      
Total investments 653 269  
Level 1 | Cash and Short Term Securities | Foreign Plans | Others      
Changes in the benefit obligations and plan assets      
Total investments 6 6  
Level 1 | Equity securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 91,509 78,234  
Level 1 | Equity securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 1,205 1,873  
Level 1 | U.S. Large Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 52,466 45,294  
Level 1 | U.S. Large Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | U.S. Small Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 11,019 10,363  
Level 1 | U.S. Small Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | International Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 28,024 22,577  
Level 1 | International Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 1,205 1,873  
Level 1 | Fixed income securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 33,029 28,526  
Level 1 | Fixed income securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 586 562  
Level 1 | Corporate debt securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Corporate debt securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 2,029 1,213  
Level 1 | Euro Corporate Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Euro Corporate Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 2,029 1,213  
Level 1 | Investment Funds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Investment Funds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 23,352 24,377  
Level 1 | Mutual Funds in Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Mutual Funds in Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 4,718 5,781  
Level 1 | Mutual Funds in Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Mutual Funds in Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 14,854 14,634  
Level 1 | Mutual Funds Diversified | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 1 | Mutual Funds Diversified | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 3,780 3,962  
Level 2 | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 51,386 42,950  
Level 2 | Cash and Short Term Securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | United States | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | United States | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | United States | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | Foreign Plans | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | Foreign Plans | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Cash and Short Term Securities | Foreign Plans | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Equity securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Equity securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | U.S. Large Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | U.S. Large Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | U.S. Small Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | U.S. Small Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | International Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | International Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Fixed income securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Fixed income securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Corporate debt securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Corporate debt securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Euro Corporate Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Euro Corporate Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Investment Funds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Investment Funds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 51,386 42,950  
Level 2 | Mutual Funds in Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Mutual Funds in Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Mutual Funds in Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Mutual Funds in Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Mutual Funds Diversified | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 2 | Mutual Funds Diversified | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 51,386 42,950  
Level 3 | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | United States | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | United States | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | United States | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | Foreign Plans | USD      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | Foreign Plans | EUR      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Cash and Short Term Securities | Foreign Plans | Others      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Equity securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Equity securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | U.S. Large Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | U.S. Large Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | U.S. Small Cap Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | U.S. Small Cap Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | International Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | International Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Fixed income securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Fixed income securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Corporate debt securities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Corporate debt securities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Euro Corporate Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Euro Corporate Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Investment Funds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Investment Funds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds in Equities | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds in Equities | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds in Bonds | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds in Bonds | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds Diversified | United States      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Level 3 | Mutual Funds Diversified | Foreign Plans      
Changes in the benefit obligations and plan assets      
Total investments 0 0  
Net Asset Value per Share | United States      
Changes in the benefit obligations and plan assets      
Total investments $ 72,592 $ 70,947  
v3.25.4
RETIREMENT AND DEFERRED COMPENSATION PLANS - Schedule of Estimated Benefit Payments to Defined Benefit Plans (Details)
$ in Thousands
Dec. 31, 2025
USD ($)
United States  
Changes in the benefit obligations and plan assets  
2026 $ 10,665
2027 11,753
2028 12,151
2029 13,488
2030 13,802
2031 - 2035 77,102
Foreign Plans  
Changes in the benefit obligations and plan assets  
2026 5,803
2027 4,259
2028 5,015
2029 6,601
2030 6,663
2031 - 2035 $ 54,622
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE INCOME/(LOSS) - Schedule of Changes in Accumulated Other Comprehensive Income/(Loss) by Component (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Accumulated other comprehensive income activity      
Balance at beginning of period $ 2,485,924 $ 2,321,298 $ 2,068,204
Total other comprehensive income (loss) 243,645 (120,581) 32,920
Balance at end of period 2,685,981 2,485,924 2,321,298
Accumulated Other Comprehensive (Loss)Income      
Accumulated other comprehensive income activity      
Balance at beginning of period (429,475) (308,734) (341,366)
Other comprehensive income (loss) before reclassifications 242,497 (121,111) 31,861
Amounts reclassified from accumulated other comprehensive income 596 370 771
Total other comprehensive income (loss) 243,093 (120,741) 32,632
Balance at end of period (186,382) (429,475) (308,734)
Foreign Currency      
Accumulated other comprehensive income activity      
Balance at beginning of period (426,049) (280,082) (328,740)
Other comprehensive income (loss) before reclassifications 246,158 (145,967) 48,658
Amounts reclassified from accumulated other comprehensive income 0 0 0
Total other comprehensive income (loss) 246,158 (145,967) 48,658
Balance at end of period (179,891) (426,049) (280,082)
Defined Benefit Pension Plans      
Accumulated other comprehensive income activity      
Balance at beginning of period 5,522 (11,891) (5,951)
Other comprehensive income (loss) before reclassifications 11,960 17,043 (6,711)
Amounts reclassified from accumulated other comprehensive income 596 370 771
Total other comprehensive income (loss) 12,556 17,413 (5,940)
Balance at end of period 18,078 5,522 (11,891)
Derivatives      
Accumulated other comprehensive income activity      
Balance at beginning of period (8,948) (16,761) (6,675)
Other comprehensive income (loss) before reclassifications (15,621) 7,813 (10,086)
Amounts reclassified from accumulated other comprehensive income 0 0 0
Total other comprehensive income (loss) (15,621) 7,813 (10,086)
Balance at end of period $ (24,569) $ (8,948) $ (16,761)
v3.25.4
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Schedule of Reclassifications From Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Amount Reclassified from Accumulated Other Comprehensive Income      
Total before tax $ (491,378) $ (469,765) $ (374,825)
Tax benefit 98,881 95,587 90,649
Net Income (392,497) (374,178) (284,176)
Amount Reclassified from Accumulated Other Comprehensive Income      
Amount Reclassified from Accumulated Other Comprehensive Income      
Net Income 596 370 771
Defined Benefit Pension Plans | Amount Reclassified from Accumulated Other Comprehensive Income      
Amount Reclassified from Accumulated Other Comprehensive Income      
Total before tax 861 550 1,091
Tax benefit (265) (180) (320)
Net Income 596 370 771
Amortization of net loss | Amount Reclassified from Accumulated Other Comprehensive Income      
Amount Reclassified from Accumulated Other Comprehensive Income      
Total before tax 760 201 914
Amortization of prior service cost | Amount Reclassified from Accumulated Other Comprehensive Income      
Amount Reclassified from Accumulated Other Comprehensive Income      
Total before tax $ 101 $ 349 $ 177
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details)
$ in Thousands, € in Millions
Jul. 06, 2022
EUR (€)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Jul. 06, 2022
USD ($)
Jul. 06, 2022
EUR (€)
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative asset   $ 298 $ 572    
Derivative liability   33,174 12,473    
Derivatives not Designated as Hedging Instruments          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative asset   298 572    
Derivative liability   632 622    
Cross Currency Swap Contract | Net Investment Hedging          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative, term of contract 7 years        
Amount hedged       $ 203,000 € 200.0
Derivative, fixed interest rate       2.5224% 2.5224%
Derivative, annual fixed interest payments receivable       $ 3,700  
Cash flow hedge derivative instrument liability at fair value   32,500      
Foreign Exchange Contracts          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative, notional amount   91,800      
Foreign Exchange Contracts | Prepaid and other | Derivatives not Designated as Hedging Instruments          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative asset   298 572    
Foreign Exchange Contracts | Accounts payable, accrued and other liabilities | Derivatives not Designated as Hedging Instruments          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Derivative liability   $ 632 $ 622    
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.6 million          
Derivative Instruments and Hedging Activities Disclosures [Line Items]          
Debt instrument, face amount       $ 400,000  
Interest rate on notes (as a percent)   3.60%   3.60% 3.60%
Debt instrument, periodic payment | € € 2.5        
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments in The Consolidated Balance Sheets (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Fair Value of Derivative Instruments    
Derivative Assets $ 298 $ 572
Derivative Liabilities 33,174 12,473
Derivatives Designated as Hedging Instruments    
Fair Value of Derivative Instruments    
Derivative Assets 0 0
Derivative Liabilities 32,542 11,851
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other    
Fair Value of Derivative Instruments    
Derivative Assets 0 0
Derivatives Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable, accrued and other liabilities    
Fair Value of Derivative Instruments    
Derivative Liabilities 0 0
Derivatives Designated as Hedging Instruments | Cross Currency Swap Contract | Deferred and other non-current liabilities    
Fair Value of Derivative Instruments    
Derivative Liabilities 32,542 11,851
Derivatives not Designated as Hedging Instruments    
Fair Value of Derivative Instruments    
Derivative Assets 298 572
Derivative Liabilities 632 622
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Prepaid and other    
Fair Value of Derivative Instruments    
Derivative Assets 298 572
Derivatives not Designated as Hedging Instruments | Foreign Exchange Contracts | Accounts payable, accrued and other liabilities    
Fair Value of Derivative Instruments    
Derivative Liabilities 632 622
Derivatives not Designated as Hedging Instruments | Cross Currency Swap Contract | Deferred and other non-current liabilities    
Fair Value of Derivative Instruments    
Derivative Liabilities $ 0 $ 0
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (loss) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Derivative instruments, gain or (loss)      
Miscellaneous (expense) income, net $ (2,027) $ 3,265 $ 3,212
Amount of (Loss) Gain Recognized in Income on Derivatives (314) (190)  
Derivatives in Cash Flow Hedging Relationships      
Derivative instruments, gain or (loss)      
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative (15,621) 7,813  
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative 0 0  
Changes in cross currency swap: foreign exchange component | Derivatives in Cash Flow Hedging Relationships      
Derivative instruments, gain or (loss)      
Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative (15,621) 7,813  
Miscellaneous (expense) income, net (2,027)    
Changes in cross currency swap: foreign exchange component | Miscellaneous, net | Derivatives in Cash Flow Hedging Relationships      
Derivative instruments, gain or (loss)      
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative 0 0  
Foreign Exchange Contracts      
Derivative instruments, gain or (loss)      
Amount of (Loss) Gain Recognized in Income on Derivatives $ (314) $ (190)  
v3.25.4
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Derivative Assets    
Gross Amount $ 298 $ 572
Gross Amounts Offset in the Statement of Financial Position 0 0
Net Amounts Presented in the Statement of Financial Position 298 572
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments 0 0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received 0 0
Net Amount $ 298 $ 572
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Prepaid and other Prepaid and other
Derivative Liabilities    
Gross Amount $ 33,174 $ 12,473
Gross Amounts Offset in the Statement of Financial Position 0 0
Net Amounts Presented in the Statement of Financial Position 33,174 12,473
Gross Amounts not Offset in the Statement of Financial Position, Financial Instruments 0 0
Gross Amounts not Offset in the Statement of Financial Position, Cash Collateral Received 0 0
Net Amount $ 33,174 $ 12,473
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accounts payable, accrued and other liabilities Accounts payable, accrued and other liabilities
v3.25.4
FAIR VALUE - Schedule of Fair Values of Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Assets    
Investment in equity securities $ 2,503 $ 2,986
Foreign exchange contracts 298 572
Convertible notes 5,650 5,650
Total assets at fair value 8,451 9,208
Liabilities    
Foreign exchange contracts 632 622
Cross currency swap contract 32,542 11,851
Contingent consideration obligation 3,983  
Total liabilities at fair value 37,157 12,473
Level 1    
Assets    
Investment in equity securities 2,503 2,986
Foreign exchange contracts 0 0
Convertible notes 0 0
Total assets at fair value 2,503 2,986
Liabilities    
Foreign exchange contracts 0 0
Cross currency swap contract 0 0
Contingent consideration obligation 0  
Total liabilities at fair value 0 0
Level 2    
Assets    
Investment in equity securities 0 0
Foreign exchange contracts 298 572
Convertible notes 0 0
Total assets at fair value 298 572
Liabilities    
Foreign exchange contracts 632 622
Cross currency swap contract 32,542 11,851
Contingent consideration obligation 0  
Total liabilities at fair value 33,174 12,473
Level 3    
Assets    
Investment in equity securities 0 0
Foreign exchange contracts 0 0
Convertible notes 5,650 5,650
Total assets at fair value 5,650 5,650
Liabilities    
Foreign exchange contracts 0 0
Cross currency swap contract 0 0
Contingent consideration obligation 3,983  
Total liabilities at fair value $ 3,983 $ 0
v3.25.4
FAIR VALUE - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 01, 2025
Dec. 31, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Fair value of long-term obligations $ 1,090,000   $ 624,700
Contingent consideration obligation 3,983    
Level 3      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration obligation $ 3,983    
Sommaplast      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration obligation   $ 4,000  
Sommaplast | Level 3      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]      
Contingent consideration obligation   $ 4,000  
v3.25.4
FAIR VALUE - Summary of Changes in Level 3 Fair Value Measurements (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2025
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance at beginning of period $ 0
Acquisition 3,983
Balance at end of period $ 3,983
v3.25.4
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2025
Commitments and contingencies    
Unconditional purchase commitment   $ 56,200,000
Purchase commitment, term   3 years
Liabilities recorded under indemnification agreements   $ 0
Gain related to litigation settlement $ 6,600,000  
Indemnification agreements    
Commitments and contingencies    
Liabilities recorded under indemnification agreements   0
Tax Assessment    
Commitments and contingencies    
Liabilities recorded under indemnification agreements   0
Estimated loss contingency   11,000,000.0
Tax Assessment Interest and Penalties | Minimum    
Commitments and contingencies    
Estimated loss contingency   22,000,000.0
Tax Assessment Interest and Penalties | Maximum    
Commitments and contingencies    
Estimated loss contingency   $ 23,000,000.0
v3.25.4
STOCK REPURCHASE PROGRAM (Details) - USD ($)
shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Feb. 03, 2026
Oct. 10, 2024
Stock repurchase program          
Common stock repurchased (retired and held in treasury) (in shares) 2,700 433 399    
Common stock repurchased (retired and held in treasury) $ 365.0 $ 68.6 $ 47.6    
Remaining authorized repurchase amount $ 97.7        
Subsequent Event          
Stock repurchase program          
Share repurchases authorized amount       $ 600.0  
Stock Repurchase Program October 10, 2024          
Stock repurchase program          
Share repurchases authorized amount         $ 500.0
v3.25.4
CAPITAL STOCK - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
CAPITAL STOCK      
Common stock, shares authorized (in shares) 199,000,000 199,000,000  
Cash dividends paid on the common stock $ 120,784 $ 114,055 $ 103,683
v3.25.4
CAPITAL STOCK - Schedule of Number of Shares of Common Stock and Treasury Stock and the Share Activity (Details) - shares
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Common stock and treasury stock and the share activity      
Balance at the beginning of the year (in shares) 72,500,000    
Balance at the beginning of the year (in shares) 6,000,000.0    
Balance at the end of the year (in shares) 72,800,000 72,500,000  
Balance at the end of the year (in shares) 8,600,000 6,000,000.0  
Common Shares      
Common stock and treasury stock and the share activity      
Balance at the beginning of the year (in shares) 72,466,548 71,679,658 70,848,810
Restricted stock vestings (in shares) 190,317 150,849 150,970
Balance at the end of the year (in shares) 72,828,513 72,466,548 71,679,658
Common Shares | Employee option exercises      
Common stock and treasury stock and the share activity      
Stock option exercises (in shares) 171,648 629,541 679,878
Common Shares | Director option exercises      
Common stock and treasury stock and the share activity      
Stock option exercises (in shares) 0 6,500 0
Treasury Shares      
Common stock and treasury stock and the share activity      
Balance at the beginning of the year (in shares) 6,015,772 5,775,295 5,555,027
Common stock repurchased (in shares) 2,744,260 432,600 398,594
Balance at the end of the year (in shares) 8,615,744 6,015,772 5,775,295
Treasury Shares | Employee option exercises      
Common stock and treasury stock and the share activity      
Stock option exercises (in shares) 144,288 192,123 178,326
v3.25.4
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Tax benefit $ 4,400 $ 13,200 $ 9,100
Weighted-average fair value of stock options granted (in dollars per share) $ 36.91 $ 36.07  
Options granted, Weighted average exercise price per share (in dollars per share)   $ 141.00  
Proceeds from stock option exercises $ 18,891 $ 54,809 $ 53,983
Executive Officer      
Share-based Compensation Arrangement by Share-based Payment Award      
Weighted-average fair value of stock options granted (in dollars per share)     $ 19.84
Received stock options exercise price percentage     110.00%
Non Executive Officer Employees      
Share-based Compensation Arrangement by Share-based Payment Award      
Weighted-average fair value of stock options granted (in dollars per share)     $ 24.23
Time-Based RSUs      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
RSUs granted (in shares) 96,240    
Restricted stock vestings (in shares) 145,504    
Time-Based RSUs | Director option exercises      
Share-based Compensation Arrangement by Share-based Payment Award      
RSUs granted (in shares) 9,805    
Restricted stock vestings (in shares) 10,208    
Performance-Based RSUs      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
RSUs granted (in shares) 207,167    
Restricted stock vestings (in shares) 214,235    
Restricted Stock Units      
Share-based Compensation Arrangement by Share-based Payment Award      
Tax benefit $ 9,900 $ 7,600 $ 5,900
Unrecognized compensation expense $ 42,200    
Weighted-average period cost will be recognized over 1 year 8 months 12 days    
Options      
Share-based Compensation Arrangement by Share-based Payment Award      
Vesting period (in years) 3 years    
Unrecognized compensation expense $ 4,500    
Weighted-average period cost will be recognized over 1 year 9 months 18 days    
Expiration period (in years) 10 years    
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Restricted Stock Units (Details) - Performance-Based RSUs - $ / shares
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Fair value per stock award (in dollars per share) $ 154.20 $ 145.79 $ 116.17
Grant date stock price (in dollars per share) $ 147.84 $ 141.00 $ 111.38
Assumptions:      
Aptar's stock price expected volatility 17.70% 18.80% 20.00%
Expected average volatility of peer companies 34.10% 34.80% 39.70%
Correlation assumption 31.00% 30.70% 33.30%
Risk-free interest rate 4.03% 4.51% 3.83%
Dividend yield assumption 1.22% 1.16% 1.36%
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)
12 Months Ended
Dec. 31, 2025
$ / shares
shares
Time-Based RSUs  
Units  
Nonvested outstanding beginning balance (in shares) | shares 277,245
RSUs granted (in shares) | shares 96,240
RSUs vested (in shares) | shares (145,504)
RSUs forfeited (in shares) | shares (12,548)
Nonvested outstanding ending balance (in shares) | shares 215,433
Weighted Average Grant-Date Fair Value  
Outstanding, beginning balance (in dollars per share) | $ / shares $ 123.28
Granted (in dollars per share) | $ / shares 144.48
Vested (in dollars per share) | $ / shares 117.97
Forfeited (in dollars per share) | $ / shares 129.24
Outstanding, ending balance (in dollars per share) | $ / shares $ 135.89
Performance-Based RSUs  
Units  
Nonvested outstanding beginning balance (in shares) | shares 513,226
RSUs granted (in shares) | shares 207,167
RSUs vested (in shares) | shares (214,235)
RSUs forfeited (in shares) | shares (71,280)
Nonvested outstanding ending balance (in shares) | shares 434,878
Weighted Average Grant-Date Fair Value  
Outstanding, beginning balance (in dollars per share) | $ / shares $ 127.17
Granted (in dollars per share) | $ / shares 147.38
Vested (in dollars per share) | $ / shares 131.12
Forfeited (in dollars per share) | $ / shares 124.02
Outstanding, ending balance (in dollars per share) | $ / shares $ 135.31
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Compensation Expense, Fair Value, and Intrinsic Value Related to Rsu's (Details) - Restricted Stock Units - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense $ 36,530 $ 40,581 $ 37,015
Fair value of units vested 43,605 36,313 29,100
Intrinsic value of units vested 54,076 40,083 33,914
Compensation expense (included in SG&A)      
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense 33,259 37,529 34,454
Compensation expense (included in Cost of sales)      
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense $ 3,271 $ 3,052 $ 2,561
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Weighted-Average Assumptions (Details) - Options - Employee option exercises
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Dividend yield assumption 1.17% 1.28% 1.41%
Aptar's stock price expected volatility 17.66% 17.03% 16.55%
Risk-free interest rate 4.21% 4.51% 3.57%
Expected Life of Option (years) 7 years 7 years 7 years
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Stock option weighted average exercise price      
Options granted, Weighted average exercise price per share (in dollars per share)   $ 141.00  
Options | Stock Awards Plans      
Stock options activity      
Outstanding at the beginning of the period (in shares) 1,663,307    
Granted (in shares) 226,187    
Exercised (in shares) (250,188)    
Forfeited or expired (in shares) (30,808)    
Outstanding at the end of the period (in shares) 1,608,498 1,663,307  
Stock option weighted average exercise price      
Outstanding at the beginning of the period (in dollars per share) $ 93.69    
Options granted, Weighted average exercise price per share (in dollars per share) 147.84    
Options exercised, Weighted average exercise price per share (in dollars per share) 75.64    
Options forfeited or expired, Weighted average exercise price per share (in dollars per share) 128.35    
Outstanding at the end of the period (in dollars per share) $ 103.45 $ 93.69  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Options exercisable, Number of options (in shares) 1,140,413    
Options exercisable, Weighted average exercise price per share (in dollars per share) $ 88.82    
Options outstanding, Weighted average remaining contractual term (in years) 4 years 3 months 18 days    
Options exercisable, Weighted average remaining contractual term (in years) 2 years 7 months 6 days    
Options outstanding, Aggregate intrinsic value (in USD) $ 39,920    
Options exercisable, Aggregate intrinsic value (in USD) 39,351    
Options exercised, Intrinsic value, at end of period $ 17,809 $ 57,259 $ 38,706
v3.25.4
STOCK-BASED COMPENSATION - Schedule of Compensation Expense, Fair Value, and Intrinsic Value Related to Option Activity (Details) - Options - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense $ 7,411 $ 7,069 $ 4,278
Compensation expense, net of tax 7,241 6,880 4,278
Grant date fair value of options vested 5,204 2,320 2,663
Compensation expense (included in SG&A)      
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense 6,729 6,381 3,929
Compensation expense (included in Cost of sales)      
Share-based Compensation Arrangement by Share-based Payment Award      
Compensation expense $ 682 $ 688 $ 349
v3.25.4
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Income (Numerator)      
Income available to common stockholders, basic $ 392,789 $ 374,541 $ 284,487
Income available to common stockholders, diluted $ 392,789 $ 374,541 $ 284,487
Shares (Denominator)      
Basic (in shares) 65,740 66,334 65,616
Total average equivalent shares (in shares) 66,725 67,691 66,905
Per Share Amount      
Net income per share, basic (in dollars per share) $ 5.97 $ 5.65 $ 4.34
Net income per share, diluted (in dollars per share) $ 5.89 $ 5.53 $ 4.25
Stock options      
Shares (Denominator)      
Effect of dilutive stock based compensation (in shares) 497 765 874
Restricted stock      
Shares (Denominator)      
Effect of dilutive stock based compensation (in shares) 488 592 415
v3.25.4
SEGMENT INFORMATION - Narrative (Details)
12 Months Ended
Dec. 31, 2025
segment
Segment Reporting [Abstract]  
Number of reportable segments 3
v3.25.4
SEGMENT INFORMATION - Schedule of Income Before Income Taxes Regarding the Company's Reportable Segments (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Financial information regarding the Company's reportable segments      
Net Sales $ 3,777,181 $ 3,582,890 $ 3,487,450
Cost of Sales (exclusive of depreciation and amortization): 2,372,446 2,227,381 2,224,051
Selling, Research & Development and Administrative: 606,497 582,226 565,783
Acquisition-related costs (3,253) (140) (480)
Restructuring initiatives (9,837) (13,002) (45,004)
Curtailment gain related to restructuring initiatives 115 1,851 0
Net unrealized investment (loss) gain (483) 1,713 (2,775)
Gain on remeasurement of equity method investment 26,518 0 0
Other special items (8,360) 0 0
Depreciation and amortization (287,363) (263,784) (248,593)
Interest Expense (52,737) (43,898) (40,418)
Interest income 11,676 12,101 4,373
Income before Income Taxes 491,378 469,765 374,825
Pharma      
Financial information regarding the Company's reportable segments      
Net Sales 1,737,481 1,643,152 1,520,993
Beauty      
Financial information regarding the Company's reportable segments      
Net Sales 1,309,437 1,225,730 1,267,697
Closures      
Financial information regarding the Company's reportable segments      
Net Sales 730,263 714,008 698,760
Operating Segments      
Financial information regarding the Company's reportable segments      
Net Sales 3,813,551 3,618,480 3,526,161
Adjusted EBITDA 882,894 842,422 770,042
Depreciation and amortization (283,893) (260,686) (244,859)
Operating Segments | Pharma      
Financial information regarding the Company's reportable segments      
Net Sales 1,738,470 1,644,012 1,521,837
Cost of Sales (exclusive of depreciation and amortization): 885,928 834,595 797,542
Selling, Research & Development and Administrative: 252,946 241,357 221,808
Other Segment Items: (9,039) (1,171) (990)
Adjusted EBITDA 607,646 568,371 502,633
Restructuring initiatives (1,080) (589) (4,852)
Depreciation and amortization (136,111) (120,429) (109,365)
Operating Segments | Beauty      
Financial information regarding the Company's reportable segments      
Net Sales 1,338,138 1,252,904 1,297,477
Cost of Sales (exclusive of depreciation and amortization): 965,316 884,433 922,223
Selling, Research & Development and Administrative: 194,246 183,903 192,831
Other Segment Items: (8,896) (2,515) (11,073)
Adjusted EBITDA 158,771 159,909 163,716
Restructuring initiatives (4,469) (8,041) (20,683)
Depreciation and amortization (91,066) (82,931) (83,399)
Operating Segments | Closures      
Financial information regarding the Company's reportable segments      
Net Sales 736,943 721,564 706,847
Cost of Sales (exclusive of depreciation and amortization): 523,939 511,409 507,866
Selling, Research & Development and Administrative: 91,921 89,913 87,930
Other Segment Items: (2,074) (1,456) (729)
Adjusted EBITDA 116,477 114,142 103,693
Restructuring initiatives (3,566) (3,835) (17,927)
Depreciation and amortization (56,716) (57,326) (52,095)
Intersegment      
Financial information regarding the Company's reportable segments      
Net Sales (36,370) (35,590) (38,711)
Intersegment | Pharma      
Financial information regarding the Company's reportable segments      
Net Sales (989) (860) (844)
Intersegment | Beauty      
Financial information regarding the Company's reportable segments      
Net Sales (28,701) (27,174) (29,780)
Intersegment | Closures      
Financial information regarding the Company's reportable segments      
Net Sales (6,680) (7,556) (8,087)
Corporate & Other      
Financial information regarding the Company's reportable segments      
Adjusted EBITDA (67,792) (67,498) (62,320)
Restructuring initiatives (722) (537) (1,542)
Depreciation and amortization $ (3,470) $ (3,098) $ (3,734)
v3.25.4
SEGMENT INFORMATION - Schedule of Segment Assets (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization $ 287,363 $ 263,784 $ 248,593
Capital Expenditures 270,419 276,481 312,342
Total Assets 5,252,719 4,432,278 4,451,890
Operating Segments      
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization 283,893 260,686 244,859
Capital Expenditures 262,229 258,598 332,115
Total Assets 4,774,862 4,196,204 4,289,912
Operating Segments | Pharma      
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization 136,111 120,429 109,365
Capital Expenditures 143,068 148,261 196,083
Total Assets 2,283,609 2,057,586 2,111,779
Operating Segments | Beauty      
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization 91,066 82,931 83,399
Capital Expenditures 68,193 64,571 83,872
Total Assets 1,691,850 1,392,491 1,412,203
Operating Segments | Closures      
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization 56,716 57,326 52,095
Capital Expenditures 50,968 45,766 52,160
Total Assets 799,403 746,127 765,930
Corporate & Other      
Segment Reporting, Asset Reconciling Item [Line Items]      
Depreciation and Amortization 3,470 3,098 3,734
Capital Expenditures 11,889 23,630 14,729
Total Assets 477,857 236,074 161,978
Transfer of Corporate Expenditures      
Segment Reporting, Asset Reconciling Item [Line Items]      
Capital Expenditures $ (3,699) $ (5,747) $ (34,502)
v3.25.4
SEGMENT INFORMATION - Schedule of Restructuring Initiatives (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Financial information regarding the Company's reportable segments      
Restructuring initiatives $ 9,837 $ 13,002 $ 45,004
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Curtailment Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Miscellaneous (expense) income, net Miscellaneous (expense) income, net Miscellaneous (expense) income, net
Operating Segments | Pharma      
Financial information regarding the Company's reportable segments      
Restructuring initiatives $ 1,080 $ 589 $ 4,852
Operating Segments | Beauty      
Financial information regarding the Company's reportable segments      
Restructuring initiatives 4,469 8,041 20,683
Operating Segments | Closures      
Financial information regarding the Company's reportable segments      
Restructuring initiatives 3,566 3,835 17,927
Corporate & Other      
Financial information regarding the Company's reportable segments      
Restructuring initiatives 722 537 1,542
Optimization initiative      
Financial information regarding the Company's reportable segments      
Restructuring initiatives 9,837 13,019 45,445
Prior year initiatives      
Financial information regarding the Company's reportable segments      
Restructuring initiatives $ 0 $ (17) $ (441)
v3.25.4
SEGMENT INFORMATION - Schedule of Net Sales and Long-Lived Asset Information by Geographic Area (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Net sales and long-lived asset information by geographic area      
Net Sales $ 3,777,181 $ 3,582,890 $ 3,487,450
Property, Plant and Equipment, Net 1,676,479 1,447,150 1,478,063
United States      
Net sales and long-lived asset information by geographic area      
Net Sales 1,071,430 1,037,968 949,248
Property, Plant and Equipment, Net 346,879 349,255 357,729
Europe      
Net sales and long-lived asset information by geographic area      
Net Sales 1,862,559 1,769,868 1,805,725
Property, Plant and Equipment, Net 1,005,413 867,840 882,702
France      
Net sales and long-lived asset information by geographic area      
Net Sales 513,281 499,795 541,333
Property, Plant and Equipment, Net 590,775 527,570 550,738
Germany      
Net sales and long-lived asset information by geographic area      
Net Sales 163,913 169,891 160,812
Property, Plant and Equipment, Net 266,695 229,637 225,860
Italy      
Net sales and long-lived asset information by geographic area      
Net Sales 201,895 180,101 200,817
Property, Plant and Equipment, Net 51,178 44,087 42,240
Spain      
Net sales and long-lived asset information by geographic area      
Net Sales 195,405 171,779 175,101
Other Europe      
Net sales and long-lived asset information by geographic area      
Net Sales 788,065 748,302 727,662
Property, Plant and Equipment, Net 96,765 66,546 63,864
China      
Net sales and long-lived asset information by geographic area      
Net Sales 194,406 155,502 146,026
Property, Plant and Equipment, Net 165,598 105,613 112,017
Other Foreign Countries      
Net sales and long-lived asset information by geographic area      
Net Sales 648,786 619,552 586,451
Property, Plant and Equipment, Net $ 158,589 $ 124,442 $ 125,615
v3.25.4
ACQUISITIONS - Narrative (Details)
3 Months Ended 12 Months Ended
Dec. 01, 2025
USD ($)
Jul. 28, 2025
USD ($)
company
Sep. 30, 2025
company
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Acquisitions            
Contingent consideration obligation       $ 3,983,000    
Gain on remeasurement of equity method investment       26,518,000 $ 0 $ 0
Acquisition-related costs       3,253,000 140,000 480,000
Goodwill       1,077,898,000 936,256,000 $ 963,418,000
Goodwill deductible for tax purposes       0 $ 0  
Sommaplast            
Acquisitions            
Purchase price $ 31,000,000          
Cash acquired 700,000          
Cash consideration transferred 24,500,000          
Restricted cash included in prepaid and other 2,500,000          
Contingent consideration obligation $ 4,000,000          
Contingent consideration annual installments percentage 25.00%          
Contingent consideration annual installments period 4 years          
Net assets acquired $ 31,000,000          
Sommaplast | Customer relationships            
Acquisitions            
Intangible assets acquired $ 3,700,000          
Useful life (in years) 15 years          
BTY Acquisition            
Acquisitions            
Cash consideration transferred   $ 29,200,000        
Intangible assets acquired   $ 21,468,000        
Percentage of interest acquired   31.00%        
Number of related companies | company   3 3      
Total ownership percentage   80.00%        
Consideration to be paid   $ 7,400,000        
Gain on remeasurement of equity method investment   $ 26,500,000        
Beneficial ownership percentage   49.00%        
Goodwill   $ 71,709,000        
BTY Acquisition | Customer relationships            
Acquisitions            
Useful life (in years)   14 years 4 months 24 days        
Sommaplast and BTY            
Acquisitions            
Acquisition-related costs       1,500,000    
Goodwill       81,100,000    
Sommaplast and BTY | Pharma            
Acquisitions            
Goodwill       9,400,000    
Sommaplast and BTY | Beauty            
Acquisitions            
Goodwill       $ 71,700,000    
v3.25.4
ACQUISITIONS - Schedule of Assets Acquired and Liabilities Assumed at Estimated Fair Value (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Jul. 28, 2025
Dec. 31, 2024
Dec. 31, 2023
Assets        
Goodwill $ 1,077,898   $ 936,256 $ 963,418
BTY Acquisition        
Assets        
Cash and equivalents   $ 8,908    
Accounts and notes receivable   15,525    
Inventories   13,042    
Prepaid and other   935    
Buildings and improvements   28,566    
Machinery and equipment   26,223    
Goodwill   71,709    
Intangible assets   21,468    
Operating lease right-of-use assets   610    
Other miscellaneous assets   3,401    
Liabilities        
Current maturities of long-term obligations, net of unamortized debt issuance costs   27,724    
Accounts payable, accrued and other liabilities   27,894    
Deferred income taxes   4,718    
Operating lease liabilities   610    
Long-term obligations, net of unamortized debt issuance costs   10,936    
Deferred and other non-current liabilities   781    
Net assets acquired   $ 117,724    
v3.25.4
ACQUISITIONS - Schedule of the Fair Value Estimates of the Acquired Identifiable Intangible Assets and Weighted-average Useful Lives as of the Acquisition Date (Details) - BTY Acquisition
$ in Thousands
Jul. 28, 2025
USD ($)
Acquired finite-lived intangible assets  
Estimated Fair Value of Asset $ 21,468
Acquired technology  
Acquired finite-lived intangible assets  
Weighted-Average Useful Life (in years) 5 years 4 months 24 days
Estimated Fair Value of Asset $ 4,876
Customer relationships  
Acquired finite-lived intangible assets  
Weighted-Average Useful Life (in years) 14 years 4 months 24 days
Estimated Fair Value of Asset $ 11,145
License agreements and other  
Acquired finite-lived intangible assets  
Weighted-Average Useful Life (in years) 43 years 2 months 12 days
Estimated Fair Value of Asset $ 5,447
v3.25.4
INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Schedule of Equity Method Investments [Line Items]    
Total equity method investments and other investments $ 131,030 $ 146,269
Goldrain    
Schedule of Equity Method Investments [Line Items]    
Equity Method Investments 104,112 96,667
BTY    
Schedule of Equity Method Investments [Line Items]    
Equity Method Investments 0 32,047
Sonmol    
Schedule of Equity Method Investments [Line Items]    
Equity Method Investments 5,044 4,712
Others    
Schedule of Equity Method Investments [Line Items]    
Equity Method Investments 5,392 948
Other Investments 8,546 3,703
PureCycle    
Schedule of Equity Method Investments [Line Items]    
Other Investments 2,503 2,986
YAT    
Schedule of Equity Method Investments [Line Items]    
Other Investments $ 5,433 $ 5,206
v3.25.4
INVESTMENT IN EQUITY SECURITIES - Narrative (Details)
7 Months Ended 12 Months Ended 72 Months Ended
Oct. 22, 2024
USD ($)
Apr. 26, 2024
USD ($)
Jul. 28, 2025
USD ($)
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
shares
Dec. 31, 2024
USD ($)
Mar. 31, 2021
Schedule of Equity Method Investments [Line Items]                
Investment impairment       $ 0        
BTY                
Schedule of Equity Method Investments [Line Items]                
Purchases from related party     $ 7,400,000   $ 11,400,000      
Accounts payable, accrued and other liabilities     $ 2,100,000   2,500,000   $ 2,500,000  
Goldrain                
Schedule of Equity Method Investments [Line Items]                
Ownership percentage of equity method investment 40.00%              
Investment in unconsolidated affiliate $ 99,000,000              
Equity method investment, underlying equity in net assets $ 82,700,000              
Equity method investment, difference between carrying amount and underlying equity         $ 14,700,000   14,700,000  
Weighted-Average Useful Life (in years)         11 years 9 months 18 days      
PureCycle                
Schedule of Equity Method Investments [Line Items]                
Investment ownership percentage               0.01
PureCycle | Preferred equity stocks                
Schedule of Equity Method Investments [Line Items]                
Investment in unconsolidated affiliate             3,000,000  
Equity received in exchange for services   $ 200,000         $ 700,000  
Number of shares sold (in shares) | shares       0 0 510,449    
BTY Acquisition                
Schedule of Equity Method Investments [Line Items]                
Beneficial ownership percentage     49.00%          
Total ownership percentage     80.00%          
v3.25.4
INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]      
Proceeds $ 2,401 $ 0 $ 5,604
PureCycle | Preferred stock      
Schedule of Equity Method Investments [Line Items]      
Shares Sold (in shares) 0 0 510,449
Proceeds     $ 5,604
Realized Gain     $ 4,188
v3.25.4
INVESTMENT IN EQUITY SECURITIES - Schedule of Net Investment Gain/Loss (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]      
Net investment (loss) gain $ (483) $ 1,713 $ 1,413
PureCycle | Preferred stock      
Schedule of Equity Method Investments [Line Items]      
Net investment (loss) gain $ (483) $ 1,713 $ 1,413
v3.25.4
RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Restructuring initiatives      
Restructuring charges $ 9,837 $ 13,002 $ 45,004
Optimization Plan      
Restructuring initiatives      
Restructuring charges 9,800 $ 13,000 $ 45,400
Cumulative expense incurred $ 74,500    
v3.25.4
RESTRUCTURING INITIATIVES - Schedule of Activity Associated with Optimization Initiative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Restructuring reserve      
Net Charges $ 9,837 $ 13,002 $ 45,004
Business Optimization Plan      
Restructuring reserve      
Beginning Reserve 9,957 29,888  
Net Charges 9,837 13,019  
Cash Paid (13,959) (32,350)  
Interest and FX Impact 623 (600)  
Ending Reserve 6,458 9,957 29,888
Business Optimization Plan | Employee severance      
Restructuring reserve      
Beginning Reserve 9,161 27,078  
Net Charges 2,350 6,562  
Cash Paid (7,830) (23,791)  
Interest and FX Impact 602 (688)  
Ending Reserve 4,283 9,161 27,078
Business Optimization Plan | Professional fees and other costs      
Restructuring reserve      
Beginning Reserve 796 2,810  
Net Charges 7,487 6,457  
Cash Paid (6,129) (8,559)  
Interest and FX Impact 21 88  
Ending Reserve $ 2,175 $ 796 $ 2,810
v3.25.4
REDEEMABLE NONCONTROLLING INTERESTS - Narrative (Details)
Sep. 30, 2025
Jul. 28, 2025
BTY    
Redeemable Noncontrolling Interest [Line Items]    
Ownership percentage 20.00% 20.00%
v3.25.4
REDEEMABLE NONCONTROLLING INTERESTS - Schedule of Rollforward Redeemable Noncontrolling Interest (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Increase (Decrease) in Temporary Equity [Roll Forward]      
Beginning balance $ 0    
Acquisition of redeemable noncontrolling interests 23,607    
Additional contributions 703    
Net loss attributable to redeemable noncontrolling interests (86) $ 0 $ 0
Foreign currency adjustments 2,020    
Ending balance $ 26,244 $ 0  
v3.25.4
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
VALUATION AND QUALIFYING ACCOUNTS      
Valuation allowance for deferred tax asset, tax losses not previously expected to be realized   $ 29,500  
Increase in unrecognized tax benefits is reasonably possible   11,000  
CECL      
VALUATION AND QUALIFYING ACCOUNTS      
Balance at Beginning Of Period $ 15,785 16,217 $ 9,519
Charged to Costs and Expenses 1,301 1,016 8,077
Charged to Other Accounts 1,485 0 12
Deductions from Reserve (839) (1,448) (1,391)
Balance at End of Period 17,732 15,785 16,217
Deferred tax valuation allowance      
VALUATION AND QUALIFYING ACCOUNTS      
Balance at Beginning Of Period 61,134 48,856 46,239
Charged to Costs and Expenses 890 1,739 1,498
Charged to Other Accounts 8,368 26,903 2,495
Deductions from Reserve (13,927) (16,364) (1,376)
Balance at End of Period $ 56,465 $ 61,134 $ 48,856